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The application of preferential crystallization as an effective and cheap technology 
for the production of pure enantiomers has become increasingly important. Synthetic 
organic chemists have put much attention on the chemistry aspects and thermodynamic 
behaviours, but the understanding of the factors that govern the chiral crystallization 
process itself is very limited. Particularly, the existence of unstable metastable zone in 
chiral nucleation has been documented in several cases. It indicates that supersaturation 
degree should play a crucial role in the optical purity during preferential crystallization. 
Furthermore, the importance of supersaturation control has been widely recognized in the 
aspects of crystal habits and purity. Therefore, it is necessary to systematically investigate 
the preferential crystallization process from thermodynamics and kinetics, and apply them 
in supersaturation control. Such efforts have been rather rare until now. 
In this dissertation, a systematic approach has been developed and applied to the 
preferential crystallization of 4-hydroxy-2-pyrrolidone in isopropanol by integration of 
system thermodynamics, crystallization kinetics, optimal operation and in-situ monitoring.  
Three types of racemate crystals, namely racemic conglomerates (4-hydroxy-2-
pyrrolidone and N-methylephedrine), racemic compounds (propranolol hydrochloride) 
and pseudoracemates (atenolol) were characterized using thermal analysis and structural 
characterizations. The two conglomerates and the racemic compound showed similar 
solubility characteristics. The metastable zone widths (MSZWs) of both conglomerates 
were independent of enantiomeric excess, while the MSZWs of the racemic compound 
were different with racemate and pure enantiomer. Their crystal lattice properties were 
attributed to this difference and three MSZW possibilities were discussed for racemic 
 X
compound. Furthermore, for the conglomerate 4-hydroxy-2-pyrrolidone, different orders 
of primary nucleation rate at different enantiomeric excess were observed, which suggests 
a critical supersaturation beyond which the nucleation of opposite isomer could occur. 
This appears to be the first detailed experimental investigation of metastable zone widths 
of different types of racemates in solution.  
S-plane analysis was developed and applied to the crystallization kinetics 
estimation of (R)- and (S)-4-hydroxy-2-pyrrolidone in isopropanol and similar kinetics 
were obtained.  With combination of thermodynamics properties and crystallization 
kinetics, a process modelling for batch crystallization was developed to predict the cooling 
profiles for the preferential crystallization of 4-hydroxy-2-pyrrolidone in isopropanol. The 
in-situ monitoring showed that relatively high supersaturation of the target enantiomer 
induced spontaneous nucleation of the undesired enantiomer, which accordingly resulted 
in low optical purity and poor crystal size distribution. The proposed optimal temperature 
trajectory to control the critical supersaturation successfully inhibited the induced 
nucleation of the undesired enantiomer, and hence produced almost pure crystals with 
good habits. Further investigations under various supersaturations indicated that there 
could be an optimal supersaturation which would not sacrifice optical purity. The 
supersaturation control was extended to the application of direct crystallization to racemic 
compound  propranolol hydrochloride coupling with chromatography. 
The metastable zone analysis and the optimal operation and monitoring results 
strongly suggest that it is important to control supersaturation degree in preferential 
crystallization and it is essential and helpful to integrate thermodynamics, crystallization 
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 CHAPTER 1   INTRODUCTION 
 
With the increasing demand of enantiomerically pure compounds, particularly in 
the industries of pharmaceuticals and fine chemicals, efficient strategies for preparation of 
enantiomers are required (Sheldon, 1993; Collins et al., 1997; Collet, 1999; Wibowo and 
Ng, 2000; Schroer, et al. 2001; Coquerel, 2003). There are different ways proposed to 
obtain pure enantiomers, such as biological resolution, asymmetric synthesis, 
chromatography, classical diastereomer crystallization, and immobilization and membrane 
technologies.  From the low cost and advantages of solid product standpoints, preferential 
crystallization, which is also called resolution by entrainment, is very attractive and 
promising. It consists of alternate selective nucleation/ crystallizations (O’Dell et al., 1978) 
of each antipode from a supersaturated mother liquor containing a slight excess of one 
enantiomer, by seeding with crystals of the enantiomer that is in excess (Collet et al, 1980; 
Jacques et al., 1994; Lim et al., 1995; Ndzié et al., 1997; Schroer et al., 2001, 2003; 
Coquerel, 2003; Elsner et al., 2005).  
Considerable academic efforts have been put to study the potential of preferential 
crystallization as an effective and cheap technology for the production of pure 
enantiomers in past years. Most of these emphases are often given to the chemistry aspects, 
conglomerate screening, and the knowledge of equilibrium phase diagrams with the 
purpose of identifying the concentration and temperature regions of thermodynamic 
stability of solid phases (Collet et al., 1980; Coquerel and Petit, 1993; Jacques et al, 1994; 
Miyazaki et al., 1994; Shiraiwa et al., 1994, 1997, 2003, 2005 ; Collet, 1999; Myerson, 
1999; Beilles et al., 2001; Dufour et al, 2001; Gervais et al., 2002; Pallavicini et al., 2004). 
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 From the process engineering viewpoint, the application of preferential 
crystallization requires the mastery of the factors that control the rate difference of 
crystallization between the two enantiomers (Collet et al., 1980; Jacques et al., 1994). It is 
therefore important to obtain the information on preferential crystallization process itself 
by combining studies of thermodynamic properties with kinetic measurements and 
therefore apply them in the control of preferential crystallization process. What is 
surprising, however, very few attempts have been directed towards this effort. Indeed, 
only several other experimental studies have been conducted on the process itself of 
preferential crystallization. Most of the studied preferential crystallization was conducted 
under   isothermal conditions - cooling the solution to a certain temperature, seeding and 
crystallization induced with the seeds (Collet et al., 1980). Coquerel et al. found that the 
classical Seeded Isothermal Preferential Crystallization (SIPC) programme was not 
suitable for the systems where the solubility ratio of racemate to enantiomer was bigger 
than 2 (Collect et al., 1980; Coquerel et al., 1990). Accordingly, an Auto Seeded 
Programmed Polythermic Preferential Crystallization (AS3PC) was proposed and applied 
to the preferential crystallization (Coquerel et al., 1995; Ndzie et al., 1997; Beilles et al., 
2001; Courvoisier et al., 2001, 2002; Dufour et al. 2001).  AS3PC method did not require 
inoculation of solid to initiate the crystallization and the temperature could be 
programmed, but the considerations of metastable zone and crystallization kinetics were 
not emphasized. Other efforts include simplified mathematical description and optimal 
initial conditions for isothermal preferential crystallization (Elsner et al. 2005; Angelov et 
al., 2006). Some preliminarily satisfying agreement was shown but further model 
improvement and more detailed experimental works are necessary. Ng and co-workers 
(Berry and Ng., 1997; Berry et al., 1997; Wibowo and Ng, 2000; Schroer,et al. 2001) had 
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studied the synthesis of chiral crystallization processes by considering the separation steps 
in the flowsheet as movements on phase diagrams.  
In view of thermodynamic aspects, supersaturation control is very important in 
preferential crystallization. It is crucial to keep the freedom of supersaturation of the 
undesired enantiomer in its metastable zone. On the other hand, the supersaturation of the 
target enantiomer should be also kept within its metastable zone.  Otherwise, the 
spontaneous nucleation of the target enantiomer will happen, which will easily initiate the 
spontaneous nucleation of its isomer. Indeed, in most of the preferential crystallization 
processes, there is only a slight excess of the target enantiomer and the concentrations of 
the two enantiomers are quite close. Under this circumstance and considering the identical 
physical properties of the two isomers in solutions, the spontaneous nucleation is expected 
to occur simultaneously for both enantiomers. This is the most important issue that should 
be avoided in the chiral resolution by direct crystallization (Jacques et al., 1994; Collet, 
1999).  Although metastable zone width is very useful in understanding the crystallization 
process in chiral resolution, it has been rarely reported on its measurement and 
interpretation in enantiomeric systems.  
Furthermore, it appears that the supersaturation of the target enantiomer should be 
controlled even lower than its spontaneous nucleation metastable zone. The effect of 
supersaturation degree on the optical purity was reported as early as 1950 in the system of 
β-phenylglyceric acid (Furberg and Hassel, 1950). In the synthesis of the agrochemical 
paclobutrazol where resolution of a racemic chiral ketone was involved, a similar 
phenomenon was observed (Black et al., 1989; Collins et al., 1997). Very low 
supersaturation (1 oC undercooling) was required to give the product with a high optical 
purity. It was suggested that if high supersaturations which are still within the metastable 
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zone are used, some conglomerates will form crystals that contain domains of both lattices 
in a single crystal, which means that the enantiomerically pure seed could nucleate the 
other enantiomer at its surface. In studies of the stability of the supersaturation state of 
DL-serine m-xylene-4-sulfonate dehydrate (Hongo et al., 1981), two metastable regions 
were identified. The first region was the one where the supersaturation degree was lower 
than a constant value and no spontaneous crystallization of the unseeded isomer was 
observed, while the supersaturation was stable for only a certain time in the second 
metastable region and spontaneous crystallization was ready to take place. 
Investigations of chiral nucleation also support the existence of a critical 
supersaturation within the metastable zone during the preferential crystallization process. 
In studies of nuclei breeding from a chiral crystal seed of NaClO3 (Denk and Botsaris, 
1972; Kondepudi et al., 1990, 1993, 1995; McBride and Carter, 1991;Yokota and 
Toyokura, 1992; Qian and Botsaris, 1997, 1998), it was found that at low supersaturation 
all nuclei were of the same chirality. At relatively high supercooling, but still lower than 
the critical value for spontaneous nucleation, many nuclei with opposite chirality to that of 
seed were formed. Similar findings were presented in triazolylketone chiral crystallization 
(Davey et al.,1990). The Embryos Coagulation Secondary Nucleation (ECSN) mechanism 
was applied to the explanation of this phenomenon (Qian and Botsaris, 1998).  
In addition, crystal size distribution (CSD) is an important factor in the production 
of high-quality solid products and determines the efficiency of downstream operations, 
such as filtration and washing.  Many works have been reported to show the benefits of 
controlling the supersaturation in batch crystallization (Mullin and Nyvlt, 1971; Jones and 
Mullin 1974; Rousseau, 1987; Rohani and Bourne, 1990). These advantages include larger 
crystals and narrower crystal size distribution. This means product purity could be 
 5
improved in the filtration and washing process (Mersmann, 1995; Matthews and Rawlings, 
1998), which is especially important for chiral purification (Courvoisier et al, 2003). 
All of these perspectives, i.e. metastable zone, critical supersaturation and crystal 
size distribution, clearly underline the importance of controlling the supersaturation of the 
target enantiomer to a certain extent to inhibit the nucleation of its isomer and get high 
quality crystal products during preferential crystallization process. In order to get effective 
supersaturation control, system characterization, thermodynamic data and crystallization 
kinetics are required to predict the operating concentration profiles with population 
balance modelling (Randolph and Larson, 1988). The newly developed on-line monitoring 
and controlling techniques provide good tools to facilitate this kind of investigation 
(Barrett and Glennon, 2002; Elsner et al., 2005). For preferential crystallization, such a 
systematic procedure to consider all of the above issues to optimize process operation has 
been rarely reported in literature.  
 
The main objective of this project is to present a systematic approach to integrate 
thermodynamics, crystal nucleation and growth kinetics, optimal control and in-situ 
monitoring to study preferential crystallization. In addition to system characterizations as 
solids and in solutions, the special metastable zone width characteristics of different 
racemates were experimentally investigated and the crystallization kinetics was measured. 
Accordingly, the critical supersaturation control concept and the systematic approach were 
illustrated by the preferential crystallization of 4-hydroxy-2-pyrrolidone to get optically 
pure products with good crystal habit. This application was also attempted to the direct 
crystallization of a racemic compound. 
Chapter 2 is literature review. 
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In Chapter 3, all the chemicals and experimental and theoretical methods 
implemented in the thesis have been detailed including the principle of the technique, 
experimental set-up and procedures. 
Chapter 4 characterizes four racemates, namely 4-hydroxy-2-pyrrolidone, N-
methylephedrine, propranolol hydrochloride, and atenolol by their binary melting point 
phase diagrams and various spectroscopic techniques. Based on a thermodynamic cycle 
involving the solid and liquid phases of the enantiomers and racemic species, the melting 
point, enthalpy, entropy and Gibbs free energy of the racemic species were derived from 
the thermodynamic data. 4-hydroxy-2pyrrolidone and N-methylephedrine can be 
classified as racemic conglomerate forming systems.  The characteristic of melting point 
phase diagram of propranolol hydrochloride is similar to the one of a conglomerate 
forming system, but the evidently negative value of the difference in the enthalpies of 
fusion of (R)- and (RS)- indicates it is a racemic compound favoring system.  Atenolol is 
an ideal pseudoracemate forming system. 
 In Chapter 5, the solubilities, metastable zone widths and ternary phase diagrams 
at different enantiomeric excess (ee) for the above four racemates in the chosen solvents 
were measured using Lasentec FBRM and PVM. All the chosen solvents were found 
suitable for cooling crystallization in the studied temperature ranges. 
The solubilities of the two conglomerates increase with decreased ee. The 
metastable zone widths of both studied conglomerates were found independent of 
enantiomeric excess at different cooling rates, which is consistent with classical nucleation 
theory and indicates the characteristic of two enantiomers forming separate crystals for a 
racemic conglomerate. The solubility characterization and ternary phase diagram of 
racemic compound propranolol hydrochloride were found similar to that of conglomerate, 
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but its metastable zone width was dependent on the enantiomeric excess. A solubility ratio 
2 of racemate to pure enantiomer was found closely correlated with the different MSZW 
situations for racemic compound.  This indicates that metastable zone width can be used 
as an additional characteristic to identify these two kinds of racemates. More importantly, 
the regressed primary nucleation rates of 4-hydroxy-2-pyrrolidone suggest the existence of 
critical supersaturation beyond which the nucleation of opposite isomer could occur. This 
appears to be the first experimental and theoretical investigation of metastable zone in the 
chiral system. The solubility, metastable zone will be the thermodynamic basis for the 
critical supersaturation control in the preferential crystallization process. 
Chapter 6 is on the crystal nucleation and growth kinetics, which is essential for 
the crystallization modeling and control. Laplace transform method was successfully   
developed and applied to the estimation of crystallization kinetics of (R)-4-hydroxy-2-
pyrrolidone and (S)-4-hydroxy-2-pyrrolidone in isopropanol. A more suitable Laplace 
transform variable s range was employed for current crystallization system. The size 
dependence of crystal growth was found negligible using modified s-plane approach. The 
crystal nucleation rate seems independent on the experimental temperature range. The two 
enantiomers show similar characteristics in crystal nucleation and growth. 
In Chapter 7, based on the measured thermodynamics and crystallization kinetics, 
the concept of critical supersaturation control in preferential crystallization was proposed 
and applied to the preferential crystallization of 4-hydroxy-2-pyrrolidone in isopropanol. 
The orthogonal collocation method and the second momentum were combined to solve the 
mathematical model of batch preferential crystallization. The in-situ monitoring, product 
purity and crystal morphology showed that relatively high supersaturation of the target 
enantiomer induced spontaneous nucleation of the undesired enantiomer. This kind of 
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unwanted nucleation was successfully inhibited by the proposed optimal temperature 
trajectory to control the critical supersaturation and therefore produced almost pure 
crystals with good habits. Furthermore, a series of batch operations were experimentally 
studied under various supersaturations to seek the optimal operating strategy without loss 
of product optical purity. It was proven essential and useful to integrate thermodynamics, 
crystallization kinetics and population balance simulation in the critical supersaturation 
control for preferential crystallization.  
 Chapter 8 tried to extend the above investigations to the direct crystallization of a 
racemic compound coupling with semi-preparative HPLC. Direct crystallization of 
propranolol hydrochloride was conducted with the same initial composition as that 
partially resolved from HPLC. Based on the solubilities and MSZWs of (R)- and (RS)-
propranolol hydrochloride, the direct crystallization progression was clearly illustrated 
under seeding and non-seeding processes. With the relative solubility and supersaturation 
control, optically pure crystal product could be obtained from the partially resolved 
sample within certain safe supersaturation limit.  
 In Chapter 9, the conclusions were drawn and some suggestions were provided for 
the future work. 
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 CHAPTER 2   LITERATURE REVIEW 
 
2.1 Overview of chirality 
An object is chiral when it lacks reflectional symmetry. Molecules that are 
nonsuperimposable on their mirror images are called enantiomers. Most chiral molecules 
contain a tetrahedral carbon atom, a carbon atom attached to four different functional 
groups (Rosanoff, 1906). The carbon atom is then an asymmetric centre of the molecule. 
A racemate will consist of 1:1 mixture of enantiomers, if the compound has one chiral 
center (1:1:1:1, if it has two chiral centers). Unlike diastereomers and geometric isomers, 
which are chemically distinct and physically different entities, enantiomers have exactly 
the same physical and chemical properties (except for optical rotation of polarized light) in 
an achiral (symmetrical) environment. However, they will differ when they are exposed to 
a chiral environment (e.g. in the human body, because most enzymes are chiral as well.).  
Most pharmaceuticals, agrochemicals (herbicides, insecticides and fungicides) but 
also flavours, fragrances and food stuffs are chiral molecules (Sheldon, 1993; Collins et 
al., 1997). Some of them even contain more than one asymmetric centre. A molecule 
containing two or three asymmetric centres has four or eight different stereoisomers 
respectively. For molecules with two asymmetric centres the term diastereomers is used. 
Since only two forms can be mirror images, enantiomers occur always in pairs. The 
importance of separating a racemic mixture (a mixture containing an equal amount of a 
pair of enantiomers) has been emphasised by many authors (e.g. Sheldon, 1993; Agranat 
and Caner, 1999; Caldwell, 2001; Caldwell and Leonard, 2001; Maier et al, 2001). Often 
only one enantiomer (the eutomer) shows the desired effect, the other (the distomer) is 
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either less effective, shows no effect at all or even worse has undesired side-effects. 
Probably the most well-known example is the sedative thalidomide (trade name: 
Contergan®) which was distributed in the 1960s as a racemate (Botting, 2002). It was not 
known that although the (R)-enantiomer is an effective sedative, the (S)-enantiomer is 
highly teratogenic (causes fetal abnormalities). Another recent example is the 
development of single isomer β-agonist, which plays a significant role in the treatment of 
asthma albuterol, a bronchodilator used to treat acute asthma, is a racemic drug that is 
improved without one enantiomer, as shown from recent studies (Nelson et al., 1998). The 
(R)-albuterol (a.k.a. levalbuterol, because it rotates polarize light to the left) is found to be 
the effective enantiomer of the racemic albuterol, whereby its counterpart (S)-albuterol 
lacks any therapeutic benefit. In fact, (S)-albuterol has been found to have an adverse 
effect of airway hyperactivity and potentially pro-inflammatory action with long-term 
usage. Studies have shown that by administering the pure (R)-albuterol to the asthmatic 
patients, the duration of the therapeutic efficacy was found to be longer than that of the 
racemic albuterol, with almost 8 times less dosage of the pure enantiomer than the 
racemate. 
Besides these tragic cases there are many other examples for (toxic) side-effects, 
different therapeutic effects or different flavours or scents of two enantiomers. Some 
agents with their specific properties were described by Sheldon (1993). 
Furthermore the US Food and Drug Administration (FDA) published a Policy 
Statement for the development of new stereoisomeric drugs (Anon, 1992). According to 
this Policy Statement the admission of a new drug is only given if adequate information on 
pharmacologic and toxicologic assessment, proper characterization of metabolism and 
distribution, clinical studies etc. are done for the pure enantiomers.  
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Separating a chiral drug which is distributed as a racemate at present into 
enantiomers may extend the patent for it, because a stereochemically pure compound 
derived from the available racemate will be treated as a new drug. This strategy is referred 
to as the “chiral switch” (sometimes also referred to as “racemic switch”) (Agranat and 
Caner,1999). Companies now begin to separate the racemic mixtures of their drugs which 
patents are about to expire into its enantiomers and distribute only the eutomer. Several 
examples of companies specialized in chirotechnology applying for the approval of single 
enantiomers, either to distribute them on their own or to profit from licensing the patents 
back to the innovator firms or third parties are reported (Anon, 1993; van Annum, 1999; 
Stinson, 2001). An elaborate description with case histories is presented by 
(Agranat and Caner, 1999). 
For agrochemicals the advantage of using pure enantiomers is that the desired 
effect can be achieved with a lower environmental burden (Buser et al., 2000). When the 
distomer is less effective, only half of the agent must be brought on the field.  
According to Anon, Stinson and Rouhi (Anon, 1993; Stinson, 2001; Rouhi, 2002), 
the market of single enantiomers in chiral drugs and intermediates and agrochemicals as 
well as other sectors is expected to grow greatly in the near future.  
Due to the advantages of single enantiomers and the big chiral market, production 
of enantiomerically pure materials using asymmetric methods, both in synthesis and 
separation, has become important. As the more common techniques of separation used 
elsewhere in chemical industry cannot be employed to racemic mixtures (due to the 
identical properties for the two enantiomers), research in the field of alternative resolution 
methods and research for a better understanding of the known resolution techniques 
become more and more important. Over decades, engineers and scientists have been 
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putting much effort to develop cost- and time-efficient techniques to produce pure 
enantiomers (Sheldon, et al., 1993; Collins et al., 1997). 
 
2.2 Methods to obtain pure enantiomers 
There are many different ways to obtain pure enantiomers (Crosby, 1991; Sheldon, 
1993; Collins et al, 1997; McCague, 1998; Challener, 2001; Maier et al, 2001; Rekoske, 
2001). Figure 2.1 gives an overview of the methods available. 
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               Figure 2.1   An overview of methods to obtain pure enantiomers 
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Basically they are divided into three classes, which are chirality pool, asymmetric 
synthesis and separation of racemates.  
For most natural chiral substances, probably the easiest and cheapest way to obtain 
them as pure enantiomers is a classical extraction, because in nature often only one single 
enantiomer exists. Other methods using microorganisms or synthesis of pure enantiomers 
from chiral starting material are also frequently used. All chiral molecules which are 
available from nature or are obtained by classical synthesis of chiral or prochiral starting 
materials are referred to as the “chirality pool” (Sheldon,1993, 1996). Therefore all chiral 
molecules belonging to the chirality pool are readily available in large amounts. Using the 
chirality pool whenever possible is the first choice to obtain pure enantiomers because 
technical effort and process costs are low. 
The invention of asymmetric synthesis dates back Monsanto’s original work on the 
synthesis of l-dopa (Reinhold et al, 1968), and it has gained much progress and scope in 
the development of pure enantiomers during the last decade. Various methods of 
asymmetric synthesis have been developed and used to obtain high enantiomeric excess 
materials. Most of known asymmetric reactions are substrate-controlled, auxiliary-
controlled, reagent-controlled and catalyst-controlled (Lin et al, 2001). However, in most 
cases, they are quite complicated and the product is highly diluted and its recovery is 
expensive. Even by asymmetric synthesis, a totally pure enantiomer cannot be yielded. A 
product of 90% enantiomeric excess is normally considered to be a satisfying result. 
Although extensive research has been conducted on the laboratory-scale, against the 
totality of examples of the manufacture of optically active materials, at the industrial level, 
asymmetric syntheses are still relatively scarce. Hence, alternatives have to be sought to 
solve this problem. 
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The third main branch is the separation of a racemic mixture. A racemic mixture 
can be separated with chromatography using either a chiral mobile phase additive 
(CMPA) or a chiral stationary phase (CSP). For large-scale application, only the latter has 
been approved. The simulated moving bed (SMB) chromatography developed in the late 
1960s is the most widely used technique. There is much literature about employing SMB 
for separation of chiral systems (Routhven and Ching, 1989; Juza et al., 2000; Wang and 
Ching, 2005). This technique, however, employs a substantial amount of solvent and 
requires significant capital investment in the form of expensive chiral stationary phase and 
high-pressure equipment. In addition, the product stream is obtained from the process in 
extremely dilute form, and thus a further expensive concentration step is required to 
recover the desired compound. 
Another approach for separating chiral molecules is a method called kinetic 
resolution (Noyori et al., 1995). One of the enantiomers of a racemate is more readily 
converted to product than the other. As it is easy to see, this method cannot be employed if 
both enantiomers are valuable products. 
Diastereoisomer crystallization, which uses a resolving agent to form a pair of 
diastereomeric salts, is also widely used. The resulting salts can be separated easier, 
because they have distinct properties. Wilen et al.(1977) have provided guidelines which 
permit a rational approach with a high probability of success. The methodology, principles 
of the technique and criteria for good resolving agents have been well described in many 
literatures (Jacques et al., 1994). Advancements in the use of computer aided molecular 
modelling have provided some assistance to researchers in the rational design and 
selection of resolving agents. Many types of pharmaceuticals have been prepared utilizing 
crystallization of diastereoisomeric salts as a means of obtaining optically pure 
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intermediates, for example, Ampicillin, Ethambutol, Choramphenicol, Fosfomycin, 
Thiampenicol, Naproxen, and Diltiazem etc (Sheldon, 1993; Collins et al., 1997; Collet, 
1998).  
Despite the effectiveness and wide applicability of this method, a limitation of this 
procedure is that only enantiomers with appropriate functionality can form diastereomeric 
salts of acids or bases. Thus simple hydrocarbons and other unfunctionalized compounds 
cannot be derivatized and then separated in this manner. Other difficulties such as 
recovery of the resolving agent and racemization of the unwanted isomer are also 
troublesome. 
One of the most attractive methods of resolution is separation of enantiomers by 
preferential crystallization (Secor, 1963; Collet et al, 1980; Coquerel et al, 1988, 1990; 
Sheldon, 1993; Jacques et al., 1994; Coquerel, 2003). In this method, no derivatization or 
reaction of the starting material is required. It is regarded as an effective and cheap 
technology to produce pure enantiomers at different scales. The progress of preferential 
crystallization will be reviewed in detail in Section 2.5. 
 
2.3 Characterization of racemic species 
A racemic species can exist as racemic conglomerates, racemic compounds or 
pseudoracemates. In order to choose the suitable resolution method, it is essential to 
determine the type to which the crystalline racemate belongs (Collet et al., 1980; Jacques 
et al., 1994; Li et al, 1999). There are mainly two different kinds of techniques used to 
identify the racemic species, namely thermal analysis and structural studies by 
spectroscopy.  
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The binary melting point phase diagram or ternary phase diagram with solvent is 
widely used to determine the characteristic of racemic species. The first to characterize 
racemic species by their phase diagrams was Roozeboom (1899). Roozeboom identified 
the three fundamental types of the binary melting point phase diagrams: a racemic 
conglomerate, a racemic compound and a pseudoracemate. Subsequently, various thermal 
analysis techniques have been applied to construct binary melting point phase diagram, 
but Differential Scanning Calorimetry (DSC) and Differential Thermal Analysis (DTA) 
are the most popular instruments used today (Collet et al., 1980; Jacques et al., 1994; Li et 
al., 1999; Lorenze et al., 2002). Coquerel (2000) had a comprehensive review on binary 
phase diagrams of chiral systems considering also reversible transitions which may occur 
between condensed phases such as polymorphism, reversible decomposition of racemate.  
Based on the Schroder-Van Laar or Prigogine-Defay equations (Prigogine and 
Defay, 1954), all the required features of binary phase diagrams of conglomerates and of 
true racemates, or even of diastereomer mixtures exhibiting eutectics, can be calculated 
out. This has been known for long time but not much applied because of the difficulty of 
measuring heats of fusion, especially on small samples (Wilen et al., 1977). The 
introduction of DSC has changed this situation. To calculate the differences in the 
thermodynamic quantities between a racemic compound and its corresponding racemic 
conglomerate, Jacques et al. (Collet et al, 1980; Jacques et al., 1994) developed a 
thermodynamic approach by using thermodynamic cycles. Li et al. (1999) modified this 
approach and applied to circa 25 chiral pharmaceuticals. These differences were even 
considered as ways to reveal the driving force for the formation of racemic compound 
versus a racemic conglomerate or a pseudoracemate. 
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On the other hand, it is not unusual that the racemic species exist as a metastable 
racemic compound or as a racemic conglomerate (Collet et al., 1980; Brock et al., 1991; 
Li and Grant, 1997; Houllemare-Druot and Coquerel, 1998). Sometimes the reversible 
transitions may occur between condensed phases such as polymorphism, reversible 
decomposition of racemate (Coquerel, 2000; Dufour et al., 2004). In this case, 
examination of binary phase diagram alone is not adequate to identify them. Comparison 
of solid state spectra of pure enantiomer and its racemate is necessary to identify or prove 
the solid nature of racemic species. These structural differences usually come from X-ray 
diffraction patterns or from spectroscopic techniques such as infrared (IR), Raman and 
solid-state NMR (Collet et al., 1980; Jacques et al., 1994; Li et al., 1999). All properties of 
conglomerate crystals are independent of chirality, which means that their densities, 
specific heats, refractive index etc. are identical for the enantiomers and the racemic 
mixture; while this identity does not exist with racemic compounds and pseudoracemates. 
Therefore, the comparison of IR/Raman or XRD spectra of enantiomers and of the 
corresponding racemate in the solid state will provide an excellent test to identify the 
nature of the racemic species (Jacques et al., 1994). The spectra of enantiomers are 
identical to that of a racemic conglomerate but different from that of a racemic compound.  
The X-ray diffraction of a powdered sample is analyzed to determine the long 
range order of the crystal lattice (the distance between two adjacent planes within a crystal 
lattice can be determined). A spectroscopic technique such as solid-state infrared or 
Raman spectroscopy is used to determine differences in the short range order of the 
samples (due to different relative arrangement of the molecules within the lattice different 
vibration modes are caused). Solid-state 13C nuclear magnetic resonance spectroscopy is 
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also used to diagnose the difference in the arrangement of pure enantiomer molecules in 
the crystal lattice for different racemic species (Jacques et al, 1994; Li et al., 1999).  
The above mentioned techniques have been extensively used to characterize 
racemic species (Collet et al., 1980; Bettinetti et al, 1990; Dwivedi et al, 1992; Coquerel 
and Petit, 1993; Neau et al, 1993; Jacques et al., 1994; Miyazaki et al., 1994; Prankerd and 
Elsabee, 1995; Kommuru et al, 1998; Pena et al, 1998; Gervais and Coquerel, 2002; 
Lorenz and Seidel-Morgenstern, 2002; Shiraiwa et al., 1992, 1994, 1996, 1997, 1998, 
2002, 2003, 2005). Coquerel’s group also has shown that the family of 5-alkyl-5-
arylhydantonins exhibits a very high frequency of conglomerates (Coquerel and Petit, 
1993; Gervais and Coquerel, 2002).  
 Another approach for studying enantiomeric interactions in the solid state is 
molecular modelling. A molecular modelling study with lattice energy calculation was 
explored to look for the factors of chiral discrimination in the crystalline state (Li et al., 
2001). The results might explain that why salt forms favour the formation of racemic 
conglomerate (Collet et al., 1980, Jacques et al., 1994). Leusen et al. (1993; 2003) and 
Gervais (Gervais and Coquerel, 2002) also tried crystal structure prediction of 
diastereomeric salts which could be a step toward rationalization of racemate resolution.  
 
2.4 Solubility and metastable zone 
2.4.1 Solubility of enantiomers 
Solubility data (solid-liquid equilibrium) is the prerequisite for crystallization from 
solution. The knowledge and use of solubility properties of enantiomer mixtures is not 
only a matter of theoretical interest, but also allows one to carry out resolutions in a more 
rational manner than usually obtainable (Jacques et al., 1994).  
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For a conglomerate, Meyerhoffer (1904) first rationalized the “double solubility” 
rule which means that a conglomerate has a solubility equal to the sum of the solubilities 
of the corresponding enantiomers. The non-ideal (dissociation/association) effects were 
analyzed and a good agreement was obtained between the experimental data and the 
foregoing theoretical considerations (Collet et al., 1980). They also derived the favourable 
conditions for preferential crystallization from ternary phase diagram (Collet et al.,1980; 
Jacques et al., 1994). If the solubility ratio α of racemic mixture to enantiomer is less than 
2, the resolution process is more favourable. A similar conclusion was drawn by Watanabe 
and Noyori (1969) with the industrial-scale resolution of glutamic acid. The ternary phase 
diagram was also used widely to describe preferential crystallization process (Collet et al., 
1980; Elsner et al., 2005). Unlike conglomerate, no matter whether solvation is present or 
not, the solubility of the racemic compound is not related to that of the enantiomers. The 
solubility can be either higher or lower (Jacques et al., 1994).  There have been only few 
literatures reported on the influence of solvent and the interactions in solution between 
enantiomers (Druot et al., 1996; Profir and Rasmuson, 2004).     
 
2.4.2 Metastable zone width 
 The metastable zone width (MSZW) is a critical parameter in the crystallisation 
process as it allows an insight into the nucleation behaviour of the system (Mullin, 2001; 
Teja and Rousseau, 2004). It was Ostwald that first proposed the terms “labile” (unstable) 
and “metastable” supersaturation, referring to supersaturated solutions in which 
spontaneous deposition of solid phase, in the absence of solid nuclei, will or will not 
occur, respectively (Ostwald, 1897).  The metastable zone was later divided into the first 
and the second areas (Ting and McCabe, 1934). 
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 A number of factors influence the value of MSZW including the rate of cooling, 
agitation, the presence of foreign particles and impurities (Young and Van Sicklen, 1913; 
Nyvlt et al, 1985). Many efforts have been reported to express the metastable zone width 
with certain parameters as semiempirical relationships (Nyvlt et al., 1970; Sohnel and  
Nyvlt, 1975; Kim and Ryu,1997, Ulrich and Strege,2002). Polythermal method is widely 
used to measure MSZW (Nyvlt, 1968; Nyvlt et al., 1970; Sohnel and  Nyvlt, 1975; Mullin 
and  Jancic,1979; Kim and Ryu, 1997, Mullin, 2001). Experimental values of the 
metastable zone width for a given system depend very strongly on the method of 
determination. The onset of nucleation can be detected visually or instrumentally. Various 
instrumental techniques have been employed to detect the onset of nucleation, e.g. 
electrozone sensing, optical turbidity, laser diffraction or scattering etc (Mullin and Jancic, 
1979; Gerson et al, 1991; Barrett and Glennon, 2002; Barrett et al, 2005). Among these 
methods, Focused Beam Reflectance Measurement (FBRM) is a recently available 
technique. The advantage of FBRM method is that it does not depend on the presence of a 
threshold nuclei concentration before a nucleation event is detected (Sparks and Dobbs, 
1993; Tadayyon and Rohani, 1998; Barrett and Glennon, 1999, 2002; Barrett et al, 2005). 
A simplified model based on integral growing of nucleus in nucleation was introduced to 
predict the metastable zone width (Mersmann and Bartosch, 1997; Kim and Mersmann, 
2001). 
 Although metastable zone width is very useful in understanding the crystallization 
process in chiral resolution, not much attention has been paid on the measurement and 
interpretation of MSZW in the enantiomeric systems. Hongo et al. (1981) identified the 
metastable region into two areas where the second one was more unstable.  The 
dependence of MSZW on the enantiomeric excess was reported in the compounds of 
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mandelic acid (Perlberg A et al., 2002, 2003). Metastable zone widths were measured for 
establishing a basis for growth kinetics investigations via isothermal seeded batch 
experiments in the chiral system mandelic acid/water (Perlberg et al., 2005). Ching’s 
group recently started a series of characterization of MSZW of both conglomerate and 
racemic compound systems (Wang et al., 2002, 2003, 2004, 2006; Lu and Ching, 2006).    
 
2.5 Enantiomeric resolution by direct crystallization 
As introduced before, the classical resolution via diastereoisomer crystallization is 
making use of the solubility difference of the diastereoisomers. If the racemate is a 
conglomerate, although the solubilities are almost the same for the two isomers, it is still 
possible to separate the two enantiomers by direct crystallization from their mixtures. 
Separation of enantiomers via direct crystallization is the more attractive option as no 
derivatization or reaction of the starting material is required. There are basically two kinds 
of resolution methods, namely simultaneous crystallization and preferential crystallization. 
Collet et. al (1980,1994 ) had a great review on this subject.  
 
2.5.1 Simultaneous crystallization 
This method makes use of the advantages of the spontaneous resolution of the two 
enantiomers for a racemic conglomerate. Louis Pasteur (1848) was apparently the first 
person to pioneer this area in 1848. He successfully separated the dextrorotatory and 
levorotatory crystals constituting the racemic double salt sodium ammonium tartrate by 
manual sorting (Pasteur, 1848; Kauffman and Myers, 1975). This laborious technique is 
now only occasionally used to collect the first crystals of enantiomer required to apply the 
technique of resolution by entrainment. Other variants of this technique include 
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localization of crystallization of individual enantiomers on suitably disposed seeds in a 
supersaturated racemic solution (Zaugg, 1955), fluidized bed system (Sato, et al., 1969; 
Brugidou et al., 1974; Dolling et al.,1978). Dowling (1959) reported an ingenious 
resolution procedure through seeding of a racemic supersaturated solution with relatively 
large seeds of one enantiomer in the purification of glutamic acid salts and this procedure 
was later applied to acetylglutamic acid (Watanabe and Noyori, 1969). This method has 
been used in the preparation of α-methyl-L-dopa and for the C3-synthon glycidyl-3-
nitrobenzenesulfonate etc (Merck, 1965; Challener, 2001).  
 
2.5.2 Preferential crystallization 
 Preferential crystallization is also called resolution by entrainment. It is mainly 
dependent on the differences in the rates of crystallization of the enantiomers in a solution 
supersaturated with respect to the racemate. 
 The first example to show the way of resolution by entrainment was reported by 
Gernez (Collet et al., 1980) who got only dextrorotatory crystals when he seeded the 
supersaturated solution of the double salt sodium ammonium racemate with a particle of 
dextrorotatory salt. Jungfleisch (Collet et al., 1980) confirmed the similar observations, 
but this method was ignored for a long time until 1914 that Werner (1914) rediscovered 
the same phenomenon in the cobalt bromide system. Surprisingly, this discovery was 
again forgotten for almost two decades until 1934 that Duschinsky showed the efficiency 
of resolution by preferential crystallization of histidine monohydrochloride (Duschinsky, 
1934).  From then onwards, this technique began to get attention of chemists and 
especially those in industry.  
The process of enantiomer separation by preferential crystallization is visualized 
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best in the ternary phase diagram of the two enantiomers (D and L) and solvent (S). 
 
Figure 2.2 Preferential crystallization in the ternary phase diagram (Jacques et al., 1994) 
As shown in Figure 2.2, the solubility of the enantiomer mixture in the solvent is 
given by the line A’EA. For starting the process a racemic solution is enriched artificially 
by adding a pure enantiomer or a partially resolved solution obtained by a different 
method. The solution is cooled until it is slightly supersaturated (1). Subsequently pure 
seed crystals of the more abundant enantiomer (L in this case) are added, as a result the L-
enantiomer starts to crystallize. Crystallization of the other enantiomer does not take place 
if the seed crystals show a selective effect (no suitable nuclei inducing crystallization of 
the opposite enantiomer is present in the solution and the degree of supersaturation is not 
sufficient for nucleation to take place). The concentration of the more abundant 
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enantiomer (L) in solution decreases (1→2). Crystals are collected from the solution when 
the enrichment by the opposite enantiomer (D in this case) has reached the same value as 
in the initial solution (2). The same amount of crystalline racemate as collected as crystals 
is added to the solution. Subsequently the temperature is increased to dissolve the 
additional racemate (not shown in Figure 2.2). After cooling to the operation temperature 
seed crystals (pure D-enantiomer) are added to the (slightly supersaturated) solution (3). 
Crystallization (3→4) yields pure D-enantiomer and a solution enriched by the L-
enantiomer (4). Dissolving of racemate and cooling to the operation temperature the initial 
solution (1) is attained and the process can be repeated. 
The first preferential crystallization process was commercialized by Merck (1965) 
to produce α-methyldopa. It has been used in the synthesis of chloramphenicol and 
intermediates for benzothiazepines (Collins et al., 1997; Challener, 2001). In some cases, 
direct crystallization occurs simultaneously with spontaneous in-situ racemization of the 
enantiomer that remains in excess in the solution, for example, the preferential 
crystallization of 1,4-benzodiazepene derivatives. This crystallization occurs with 
spontaneous racemization in solution at room temperature and one enantiomer crystallizes 
in 75% yield (Hongo et al., 1983; Murakami et al, 1992, 1993; Sheldon, 1993). In spite of 
the limitations of this method, the preferential crystallization process still has great 
potential and real economic importance in both the pharmaceutical and chemical 
industries. It is not only applied to resolution of racemic conglomerates but also possible 
to purification of partially resolved racemic compounds which are prepared by other 
methods (Lim et al, 1995; Lorenz et al., 2001; Wibowo and O’Young, 2005).  
By 1980s, circa 250 conglomerates had been identified (Jacques et al., 1994). So 
far about 5-10% of chiral compounds have been reported as conglomerates (Jacques et al., 
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1994; Collet, 1999). To date, a lot of efforts are still being put in the inventory of 
enantiomer mixtures that exist as conglomerates and the preferential crystallization are 
applied in the resolution. Among these, Shiraiwa’s group has extensively screened for 
racemic amino acids and other compounds (Shiraiwa et al., 1992, 1994, 1996, 1997, 1998, 
2002, 2003, 2005;Miyazaki et al., 1994). Coquerel’s group also has shown that the family 
of 5-alkyl-5-arylhydantonins exhibits a very high frequency of conglomerates (Coquerel 
and Petit, 1993; Gervais et al., 2002).  
 
2.5.3 Mechanism of preferential crystallization 
 As mentioned by Jacques et al. (1980, 1994), the application of preferential 
crystallization requires the mastery of the factors that control the rate of crystallization. 
These factors include the properties of the ternary phase diagram itself and the 
experimental character such as stirring and seeding etc. Duschinsky (1934) first 
investigated the resolution mechanism using histidine monohydrochloride. A more 
systematic search was later conducted by Amiard’s group (Velluz and Amiard, 
1953;Velluz et al., 1953; Amiard, 1956; Amiard, 1959) on the resolution of threonine and 
thero-p-nitrophenyl-2-amino-1,3-propanediaol and accordingly the concept of residual 
supersaturation and the definition of entrainment of crystallization was introduced. 
 As mentioned before, the solubility ratio α of racemate to enantiomer  in solutions 
is crucial for the preferential crystallization process (Watanae and Noyori,1969; Collet et 
al.,1980). A smaller solubility ratio α of racemate to enantiomer will result in a more 
favourable preferential crystallization operation.  This has led to systematic search of 
dissociable derivatives by combining substrates to be resolved with a variety of achiral 
reagents (Yamada et al., 1973, 1975) as it is more possible to find a ratio α that is less than 
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2 in salts than organic compounds. In the optical resolution of (±)-N-acylnorfenfluramine 
derivatives, the preferential crystallization under isothermal conditions failed primarily 
due to unfavourable solubility ratio α (Coquerel et al., 1990). A molecular modelling study 
based on lattice energy calculations was explored later to explain this phenomenon (Li et 
al., 2001). Leusen et al (1993, 2003) also tried crystal structure prediction of 
diastereomeric salts which could be a step toward rationalization of racemate resolution. 
 Factors such as metastable supersaturation, seeding and stirring etc. were also 
discussed by Collet et al.(1980). A good example is the industrial-scale resolution of 
glutamic acid hydrochloride with ultrasonic irradiation to produce large number of 
optically pure microcrystalline seeds (Merck, 1965). 
 From the processes and phenomenon of purity decrease during the optical 
resolution of DL-threonine by preferential crystallization, it was found that onset of the 
purity decrease was strongly related to the consumption of the supersaturation of the 
crystallizing enantiomer (L-threonine) and to the surface morphology changes of the seed 
crystals (Matsuoka et al., 1990,1997; Profir and Matsuoka, 2000).  
 Perez-Garcia and Amabilino (2002) had a detailed review on the spontaneous 
resolution under supramolecular control. The non-covalent interactions were discussed in 
explaining the transfer of chirality from molecule to bulk and in particular the spontaneous 
resolution of enantiomers. The mechanism of an unusual enantiomeric resolution 
phenomenon caused by polymorphic transition during crystallization of mixed crystals 
composed of two enantiomers were studied  and a mechanism of preferential enrichment 
was proposed based on the unique polymorphism of the compounds , their metastable and 
stable crystal structures, the association mode and the aspects of polymorphic transition 
etc. (Tamura et al., 2002).  
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 The effect of unstable racemic compound on the performance of preferential 
crystallization of α-methylbenzylamine chloroacetate was investigated and various routine 
tests were recommended to avoid derivatives which may possibly give the unstable 
racemic compound (Houllemare-Druot and Coquerel, 1998). A later study by the same 
group showed the similar impact on the resolution of chiral acids and bases (Dufour et al., 
2001). The limited entrainment effect observed with Pasteur salt was found consistent 
with the presence of a metastable racemic compound (Petit and Coquerel, 2003).  In the 
preferential crystallization of (±)-ephedrine and (±)-mandelic acid, not only this kind of 
unstable compound was found, a new polymorphic form was also reported to contribute to 
the limited entrainment effect (Dufour et al., 2004). A rare temperature-dependent racemic 
compound-conglomerate crystallization of 2,3:6,7-dibenzobicyclo[3.3.1]nona-2,6-diene-
4,8-dione was studied in detail and it was found that higher temperature induced the 
formation of conglomerate (Levkin et al.,2003).  
 The combined effect of polymorphism and process on preferential crystallization 
with (+/-)-5(4’-methylphenyl)-5-methylhydantoin was investigated and the genuine 
impact of polymorphism was highlighted (Courvoisier et al., 2003). The AS3PC 
programme, stable polymorph and pre-treatment of the solid particles were recommended 
to achieve the best results in terms of robustness, yield and scale-up. Effect of the 
polymorphic form of the seeds on the preferential crystallization was also discussed with 
5(4'-methylphenyl)-5-methyl-hydantoin (Courvoisier et al., 2001). 
 
2.5.4 Preferential crystallization process 
 In the application of preferential crystallization process, the conventional method 
is conducted under isothermal condition (Jacques et al., 1994). The saturated solution is 
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cooled to the target temperature, seed is added in the supersaturated solution, keep the 
solution for a time period and finally the crystals are filtrated out. This approach is called 
as Classical Seeded Isothermal Preferential Crystallization (SIPC) programme by 
Coquerel’s group (Coquerel et al., 1995). As mentioned before, it was found that such 
isothermal method was not suitable for the preferential crystallization where solubility 
ratio α is bigger than 2 (Coquerel et al., 1990). Subsequently, an Auto Seeded 
Programmed Polythermic Preferential Crystallization (AS3PC) was proposed and applied 
to the preferential crystallization (Coquerel et al., 1995; Ndzie et al., 1997; Beilles et al., 
2001; Courvoisier et al., 2001, 2002; Dufour et al. 2001; Wermester et al., 2005). The 
influence of the process on the mechanisms and the performances of the preferential 
crystallization were investigated with (+/-)-5-(4-bromophenyl)-5-methylhydantoin 
(Courvoisier L et al., 2001). More than 25 different molecules have been tested by using 
this programme. AS3PC process was found more efficient than SIPC process for purity, 
yield, scale-up and filtration. 
 More recently, Elsner et al. (2005) presented an interesting investigation of 
preferential crystallization with focus on aspects of quantification and application using 
simplified mathematical description. The optimal initial conditions for isothermal 
preferential crystallization were also tried in this group (Angelov, et al., 2006). The amino 
acid threonine was used as model system to analyze the isothermal single step 
crystallization experiments. Some preliminarily satisfying agreement was shown but 
further model improvement and more detailed experimental works are necessary.  An 
optical resolution technique by natural cooling crystallization combined with pulse heating 
was proposed, in which a "tailor-made" additive was used as a separation agent in the 
purification of asparagine to improve the optical purity (Doki et al., 2004). On-line 
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polarimetry (Rodrigo et al., 2004) in combination with measurements of an on-line density 
meter was attempted to monitor the resolution process. 
 From the system engineering perspective, Ng et al. (Berry and Ng., 1997; Wibowo 
and Ng, 2000; Schroer, et al. 2001) had studied the synthesis of chiral crystallization 
processes by considering the separation steps in the flowsheet as movements on phase 
diagrams. Ching’s group (Lim et al., 1995) attempted the recovery of praziquantel from 
racemic mixture by continuous chromatography and crystallization. A systematic 
procedure has been recently presented for the synthesis of chromatography-crystallization 
hybrid separation processes (Fung et al., 2005). An approach that couples equilibrium 
phase behavior and kinetics was proposed for the design of chiral crystallization 
processes. A generic model that accounts for reaction, as well as crystal nucleation, 
growth, and dissolution kinetics was developed (Schroer and Ng, 2003). 
 
2.6 Chiral nucleation  
 Preferential crystallization is normally conducted with seeding. In the seeded 
crystallizer, secondary nucleation plays an important role and the mechanism has been 
well studied by experiments with single crystal seeds (Clontz and McCabe, 1971; Denk 
and Botsaris, 1972; Rousseau et al., 1975, 1976) and in suspension crystallizers (Evans et 
al., 1974; Qian et al., 1987, 1989; Randolph and Larson, 1988). An embryo-coagulation 
secondary nucleation (ECSN) mechanism was also proposed to explain some unusual 
observations and phenomenon (Qian and Botsaris, 1996, 1997). In the nucleation 
experiments conducted with chiral NaClO3, at low supercoolings, almost all the nucleated 
crystals had the same chirality as the seed. Above a certain supercooling, however, 
crystals of both chiralities were obtained (Denk and Botsaris, 1972; Kondepudi et al., 
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1990, 1993, 1995, 1998; McBride and Carte, 1991; Yokota and Toyokura, 1992; Qian and 
Botsaris, 1997, 1998). Davey et al. (1990) also showed the similar findings in 
triazolylketone chiral crystallization. This transition was thought consistent with the 
ECSN mechanism (Qian and Botsaris, 1998). It was argued that the origin of the nuclei 
was the solution layer next to the crystal and the van der Waals forces, which brought the 
embryos close to the seed were non-discriminating. Therefore, embryos of both chiralities 
were thought attracted by and concentrated around the seed and their coagulation could 
produce nuclei of either chirality.  
 In a later study, it was also found that this phenomenon could be related with the 
way that the seed crystals were prepared (Qian and Botsaris, 2004). The primary 
nucleation was also investigated by the same group with the same system (Botsaris et al., 
1999). Their experiments with spontaneous crystallization by air bubbling supported the 
idea of a single progenitor in cases of spontaneous nucleation by cooling. It was also 
pointed out that in many processes that are perceived as cases of primary nucleation, only 
one crystal is actually generated primarily and all the others are bred from it by secondary 
nucleation. 
 Kondepudi et al. (1990, 1993, 1995, 1998) have outlined an explanation for the 
production of one-chirality crystals based on the physical nucleation model. They 
introduced the idea that a parent crystal can breed secondary nuclei only when it reaches a 
minimum size. The stirring effects on this phenomenon were also discussed (Mcbride and 
Carter, 1991). 
 The effect of supersaturation degree on the optical purity was reported as early as 
1950 in the system of β-phenylglyceric acid (Furberg and Hassel, 1950). Very low 
supersaturation was required to get high purity. Another typical example is in the 
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synthesis of agrochemical paclobutrazol where resolution of a racemic chiral ketone is 
involved (Black et al., 1989; Collins et al., 1997). Only when very low supersaturation (1 
oC undercooling) was used, did the effects of nucleating the unwanted isomer disappear to 
give the product with a high optical purity. It was suggested that if high supersaturations 
within the metastable zone are used, some conglomerates will form crystals that contain 
domains of both lattices in a single crystal, which means that the enantiomerically pure 
seed could nucleate the other enantiomer at its surface. 
 The stability of supersaturation in the preferential crystallization process was first 
quantitatively described in the optical resolution of DL-serine-4-sulfonate dehydrate in the 
early 1980s (Hongo et al., 1981). The metastable region was divided into the first and the 
second metastable regions. The first region was the one where the supersaturation degree 
was lower than a constant value and no spontaneous crystallization of the unseeded isomer 
was observed. The second metastable region was the one where the supersaturation was 
stable for only a certain time and spontaneous crystallization was ready to take place. 
Consequently, the waiting time for the spontaneous crystallization of the unseeded isomer 
was predicted by a conventional calculation method (Hongo et al., 1981).  
 For the effects of additives in the chiral nucleation, Weissbuch et al. (2003) had a 
good review. The delicate interplay between stereochemical control, monitoring at the 
subnanometer level, and an understanding of crystal nucleation were probed. The effects 
of chiral additive and wetting agent in the preferential crystallization of (+/-)-5-ethyl-5-
methylhydantoin were experimentally studied in Conquerel’s group (Ndzie et al., 1999; 
Beilles et al., 2001). Some salts have been used to stabilize the supersaturated solution in 
the optical resolution (Soichiro, 1983; Harada et al., 1986). 
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2.7 Crystallization kinetics 
 Crystal growth and nucleation kinetics are the basis of modelling, design and 
operation of a crystallizer. There are two basic categories of techniques to evaluate 
crystallization kinetics, namely, steady state method and dynamic method. For the former 
one, the most famous is the classical continuous method proposed by Randolph and 
Larson (1988) with mixed-suspension, mixed-product-removal (MSMPR) crystallizer. 
  Dynamic method is an alternative approach for the estimation of kinetics using 
unsteady-state data from batch experiments. Various dynamic techniques have been 
reported with batch crystallizations. These include thermal response technique (Omran 
and King, 1974) and mass balance approach (Garside et al., 1982; Halfon and Kaliaguine, 
1976). But most of the proposed methods using batch crystallization process are based on 
crystal size distribution (CSD) analysis (Garside and Jancic, 1976; Way, 1985; Tavare and 
Garside, 1986;  Nyvlt, 1989; Witkowski et al., 1990; Qiu and Rasmuson, 1991, 1994;  
Farrell and Tsai, 1994; Yokota et al., 2000; Garside et al., 2002; Zhang and Rohani, 2003; 
Hu et al., 2004). These include moment method (Tavare and Garside, 1986), nonlinear 
optimization algorithm (Nyvlt, 1989; Witkowski et al., 1990; Qiu and Rasmuson, 1991, 
1994; Farrell and Tsai, 1994; Yokota et al., 2000; Zhang and Rohani, 2003; Hu et al., 
2004) and s-plane analysis (Tavare and Garside, 1986). The details will be discussed in 
Chapter 6. 
 For chiral crystallization, only Elsner et al. (2005) recently attempted to use 
moment method to determine crystallization kinetics of L-/D-threonine in water with 
difficulty in nucleation rate prediction. 
 
2.8 Optimal operation of batch crystallization 
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Many works have been reported to show the benefits of controlling the 
supersaturation in batch crystallization (Mullin and Nyvlt, 1971; Jones and Mullin 1974; 
Rohani and Bourne, 1990). These benefits include larger crystals and narrower crystal size 
distribution. This means product purity could be improved in the filtration and washing 
process (Mersmann, 1995; Matthews and Rawlings, 1998), which is especially important 
for chiral purification (Courvoisier et al, 2003).  
 Numerous efforts have been put on optimal operation of batch crystallizer. Mullin 
and Nyvlt (1971), Jones (1974), and Jones and Mullin (1974) did the pioneer work both 
theoretically and experimentally. Mayrhofer and Nyvlt (1988) dealt with a general 
derivation of a theoretical cooling curve of a batch crystallizer. Rohani and Bourne (1990) 
derived a simplified optimal cooling curve by assuming constant nucleation and 
supersaturation. Various objectives have been chosen to optimize batch crystallization, 
such as mean crystal size and coefficient of variation (Chianese et al., 1984; Choong and 
Smith, 2004; Costa and Maciel Filho, 2005), seed ratio (Bohlin and Rasmuson, 1992; 
Mathews and Rawlings, 1998; Chung et al., 1999) and even shape (Ma et al., 2002). The 
newly developed on-line monitoring and controlling techniques greatly facilitate these 
investigations (Barrett and Glennon, 2002; Elsner et al., 2005).  
 
2.9 Summary 
 The application of direct crystallization, particularly preferential crystallization, in 
the enantiomeric separation of pharmaceuticals and fine chemicals has become 
increasingly important from both practical (clinical/environmental etc.) as well as 
economic (cost/efficiency etc.) viewpoint. However, most of the past studies are focused 
on the chemistry aspects and the thermodynamic behaviours of solid phases. Little 
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attention has been given to the crystallization process itself from the system engineering 
perspective.  Both the previous studies on chiral nucleation and unstable metastable zone 
and the implications of crystal habits control suggest that supersaturation plays a crucial 
role in preferential crystallization process. The philosophy of the present work was to 
develop a systematic engineering approach to study preferential crystallization, especially 
on the metastable zone measurement and interpretation, and application of critical 
supersaturation control in the optical resolution. Accordingly, the preferential 
crystallization was investigated from system characterization and thermodynamics, to 
metastable zone and chiral nucleation analysis and crystallization kinetics determination, 
and finally to the process modelling, optimal operation and in-situ monitoring.  
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CHAPTER 3   EXPERIMENTAL SET-UP AND 
METHODOLOGY 
 
3.1 The studied chiral systems 
The (R)- and  (S)-4-hydroxy-2-pyrrolidone, (+)- and (–)-N-methylephedrine, (R)-, 
(S)- and (RS)-propranolol hydrochloride and (R)-, (S)- and (RS)-atenolol were purchased 
from Sigma-Aldrich Pte Ltd (Singapore) and were used as received. All enantiomers were 
stored in a refrigerator at about 5 °C to reduce the risk of decomposition. In the following 
Figures 3.1-3.4 show their chemical structures of all enantiomers and their physical 













         Figure 3.1 Chemical structure of (R)- and (S)-4-hydroxy-2-pyrrolidone 
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Table 3.1  Properties and specifications of 4-hydroxy-2-pyrrolidone 
Name (R)-4-Hydroxy-2-Pyrrolidone (S)-4-Hydroxy-2-Pyrrolidone 
Synonyms (R)-β-Hydroxy-γ-butyrolactam (S)-β-Hydroxy-γ-butyrolactam 
Molecular Formula C4H7NO2 C4H7NO2 
Molecular Weight 101.1 g/mol 101.1 g/mol 
Melting Point 156-160 °C 156-160 °C 
Purity Puriss. ≥ 99.0% (GC, sum of 
enantiomers) 
Puriss. ≥ 99.0% (GC, sum of 
enantiomers) 
Optical rotation [α]D20=+41±3° (c=1 in EtOH) [α]D20=-41±3° (c=1 in EtOH) 
Optical rotation [α]54620=+50±3° (c=1 in EtOH) [α]54620=-50±3° (c=1 in EtOH) 
 
4-hydroxy-2-pyrrolidone is a versatile chiral intermediate for the synthesis of 
many biological active compounds. Examples are the drugs (R)-γ-amino-β-hydroxybutyric 
acid (GABOB), which is an antiepileptic agent (Aubé et al., 1991), (R)-carnitine 
(vitamin BT) and 4-hydroxy-2-pyrrolidone acetamide (oxiracetam), which is a nootropic 
(acting selectively on the cerebral cortex) agent used in the treatment of amnesic condition 
(Di Silvestro et al., 1993; Huang et al., 1999). One of the enantiomers could be isolated 
from the European fly agaric (Amanita muscaria (L. ex. Fr.)), but the amount contained in 

























Figure 3.2  Chemical structure of (+)- and (-)-N-methylephedrine 
 
N-methylephedrine contains two asymmetrical centres; therefore four 
stereoisomers of this substance exist. The two forms (1S, 2R)-(+)-N-methylephedrine and 
(1R, 2S)-(-)-N-methylephedrine are the erythro pair of the diastereomers, the 
corresponding threo pair consists of (1R, 2R)-(-)-N-methylpseudoephedrine and (1S, 2S)-
(+)-N-methylpseudoephedrine (Kawasuji et al., 1996; Herráez-Hernández and Campíns-
Falcó, 2001).  
N-methylephedrine belongs to the class of ephedrines, which are potential central 
nervous stimulant drugs (Herráez-Hernández and Campíns-Falcó, 2001). The substances 
belonging to the class of ephedrines are very similar; the chemical structure of the 
different forms differentiates only in the two groups which are attached to the nitrogen 
atom. 
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Methylephedrine is an antitussive, which is contained in many over-the-counter 
cough and cold mediations, often mixed with other drugs (Inoue and Suzuki, 1990; 
Ishigooka et al., 1991; Kunsman et al., 1998). 
 
Table 3.2 Properties and specifications of N-methylephedrine 





Molecular Formula C11H17NO C11H17NO 
Molecular Weight 179.3 g/mol 179.3 g/mol 
Melting Point 87-90 °C 86-88 °C 
Purity 99% 99% 
















S-propranolol hydrochloride  
Figure 3.3  Chemical structure of (R)- and (S)-propranolol hydrochloride 
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Table 3.3 Properties and specifications of propranolol hydrochloride 
Name (R)-Propranolol Hydrochloride (S)-Propranolol Hydrochloride 
Molecular Formula C16H21NO2·HCl C16H21NO2·HCl 
Molecular Weight 295.81 g/mol 295.81 g/mol 
Melting Point 193-195 °C 193-195 °C 
Purity Puriss. ≥ 99.0% (HPLC, sum 
of enantiomers) 
Puriss. ≥ 99.0% (HPLC, sum 
of enantiomers) 
Optical rotation [α]D20=+26±1° (c=1 in EtOH) [α]D20=-26±1° (c=1 in EtOH) 
 
Propranolol hydrochloride is a synthetic beta-adrenergic receptor blocking agent 








                   
(R)-Atenolol                                               (S)-Atenolol 
 
Figure 3.4  Chemical structure of (R)- and (S)-atenolol 
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Table 3.4 Properties and specifications of atenolol 
Name (R)-Atenolol (S)-Atenolol 
Molecular Formula C14H22N2O3 C14H22N2O3 
Molecular Weight 266.34 g/mol 266.34 g/mol 
Melting Point 148-152 °C 148-152 °C 
Purity Puriss. ≥ 99.0% Puriss. ≥ 99.0% 
Optical rotation [α]25=+16° (c=1 in 1N HCl) [α]25=-16° (c=1 in 1N HCl) 
 
Atenolol is a drug belonging to the group of beta blockers, a class of drugs used 
primarily in cardiovascular diseases. Introduced in 1976, atenolol was developed as a 
replacement for propanolol in the treatment of hypertension. 
 
Other chemicals: 
Analytical and HPLC grade isopropanol, methanol, acetone and hexane were 
purchased from Aik Moh Paints & Chemicals Pte Ltd (Singapore) and were used as 
received. The ultra pure deionized water was obtained through a Millipore ultrapure water 
system (Milli-Q Gradient A10 System). 
 
3.2 Characterization and analysis methods 
3.2.1 Differential scanning calorimetry (DSC) 
In this work, all differential scanning calorimetry measurements were performed 
using a Mettler Toledo DSC822e Module (heat flux DSC), together with the STARe–
software. Samples of 2-7 mg are prepared in standard 40 µl aluminium crucibles using a 
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Mettler Toledo XS205 microbalance. The crucibles were sealed with a perforated cover. 
The flow rate of purging gas nitrogen was 40 mL/min. Preceding investigation of samples, 
the DSC apparatus was calibrated using a pure indium sample. 
3.2.1.1 Analysing the thermogram 
Two routines are available for converting the set of DSC experiments (the 
experiments for different compositions of the binary mixture) to the binary melting point 
diagram. They are the enthalpy/liquid fraction routine (DIN 51004, 1994; 
Di Silvestro et al., 1993) and the more commonly used routine where beginning and end 
of fusion are determined from the thermogram by means of some characteristic points 
(Jacques et al., 1994; Lorenz and Seidel-Morgenstern, 2002).  
In this work, determination by characteristic points of the thermogram was used to 
evaluate the melting points. A pure substance (e.g. a single enantiomer) was examined 
first. Due to the fact that a pure substance melts at a definite temperature, the peak is 
narrow and the melting point is determined as the point of intersection of the tangent on 
the leading edge of the fusion peak with the baseline. The angle between the leading edge 
and the straight line passing through the maximum peak point was recorded as the 
correcting angle. If the phase diagram shows a eutectic, two peaks appear in the 
thermogram. The first peak marks the beginning of fusion (and therefore the solidus line), 
where the first liquid-phase (of eutectic composition) is formed. This peak is followed by 
a second one, which is most often diffuse. The same correcting angle as determined for the 
pure enantiomer was employed to the peaks of the thermograms for the other 
compositions. Therefore, the beginning and end of fusion, which represents the solidus 
and liquidus line, respectively, are obtained directly from the thermogram.  
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3.2.2 Powder X-ray diffraction (PXRD) 
The wavelength of X-ray lies between 10-12 and 10-8 m, which is the same 
magnitude as the distance of two adjacent planes within a crystal lattice. The phenomenon 
of diffraction occurs whenever the wavelength of electromagnetic radiation and a 
characteristic dimension of interfering matter are of the same magnitude. From the 
diffraction pattern the distance of two adjacent planes within the crystal can be determined 
if the frequency of the X-ray radiation is known using Bragg’s law 
(Atkins and dePaula, 2002). Even if a large crystal without inclusions or other 
imperfections is available, measurement of all different crystal faces is difficult, that is 
why most often a powder is examined (Powder X-ray diffraction, PXRD). In a powder the 
number of particles is big enough, that even with small samples all different orientations 
are exposed to the X-ray beam simultaneously. Due to the small size of particles no 
orientation will be preferred when the powder is attached to an inert carrier such as paper. 
The distances between adjacent planes of different orientation are unique for each 
substance and even for different polymorphs of the same substance. That is why a racemic 
conglomerate should have the same diffraction pattern as a pure enantiomer, but a 
different diffraction pattern than a racemic compound. The depiction of Ewing (1985) 
provides information on the instrumentation. 
 
                                         d = λ / (2sinθ)                                                  (3.1) 
 where θ is the diffraction angle. 
 In this work, the PXRD patterns of both the racemates and pure enantiomers were 
determined at room temperature using a Bruker D8 Advance diffractometer with Cu-Kα 
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radiation at 40 mA, 40kV. The samples were packed into an aluminum holder and scanned 
with the diffraction angle 2θ increasing from 5-70o, with a step size of 0.02o for 1 sec. 
 
3.2.3 Fourier transform infrared spectroscopy (FT-IR) 
In this work, the FT-IR spectra of both the racemates and pure enantiomers were 
obtained in the range of 400-4000 cm-1 with a Bio-Rad FTS 135 FTIR spectrometer using 
the KBr disk method. The scans were performed with a resolution of 4 cm-1 and the 
number of scans was 40.  All spectra were collected at ambient temperature. 
 
3.2.4 Raman spectroscopy 
Infrared (IR) and Raman spectroscopy both measure the vibrational energies of 
molecules. Raman spectroscopy is based on the Raman effect, which is the inelastic 
scattering of photons by molecules. Raman spectroscopy complements IR spectroscopy. 
For a vibrational motion to be IR active, the dipole moment of the molecule must change. 
But for a vibration to be Raman active, the polarizability of the molecule must change 
with the vibrational motion. The spectra are plotted with intensity vs. Raman shift in cm-1. 
In this work, a Renishaw’s inVia Raman microscope was used. It is with 
Renishaw’s WiRE™  2.0 software and  RenCam CCD detector.  A 785 nm laser was used 
to measure the Raman spectra in the range of 0-2000 cm-1.  
 
3.2.5 Nuclear magnetic resonance (NMR) 
Solid state NMR has many potential applications in the characterization of solids 
that are largely intractable by other means. 13C spectra show chemical shifts that are more 
sensitive to the details of structure than are proton shifts. Differences between structural 
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and stereoisomers can easily be seen. In a powdered crystalline material, all orientations 
are present, and the signal observed is a distribution of resonances, hence a relatively wide 
peak is seen, whereas the fluidity of a liquid solution ensures that only a single peak is 
observable.  
In this work, 13C SS-NMR spectra were acquired at 100.613 MHz, using a 
CAMPAS DRX 400 spectrometer. Spinning speeds were 8-10 kHz. 
 
3.3 Solubility and metastable zone width measurement 
The limit of the metastable zone is also referred to as supersolubility. The 
difference in concentration (for constant temperature) or the difference in temperature (for 
constant concentration) between a saturated solution and a solution on the limit of the 
metastable zone is called metastable zone width or maximal allowed temperature of 
supercooling. 
Polythermal method was used to measure the solubility and metastable zone width, 
using 25 - 500 ml jacketed crystallizers equipped with a magnetic stirrer bar (for small 
volume) or an overhead stirrer (for large volume) and a Julabo programmable circulator 
FP25-ME (for small volume) or FP88-HL (for large volume). A Lasentec S400A FBRM 
(Focused Beam Reflectance Measurement) was used to detect the onset of nucleation and 
dissolution. A Lasentec 700 PVM (Particle Vision and Measurement) system was also 
integrated into the experiments. The image has a field of view of 860 x 645 um, with 
resolution down to approximately 5 um and capturing speed up to 10 images per second.  
FBRM and PVM have recently emerged as a widely used technique for the in situ 
characterization of particulate slurries.  
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FBRM instrumentation is composed of three parts: a probe which can be installed 
directly in the crystallizer without the need for sample dilution or manipulation, the 
electronic measurement unit and a computer for data acquisition and analysis (as shown in 
Figures 3.5 and 3.6).  
FBRM measures a chord length distribution (CLD), which is a function of the 
number, size, and shape of particles under investigation. FBRM uses a focused beam of 
laser light, which scans in a circular path. As this light scans across a particle or particle 
structure passing in front of the probe window, light is scattered in all directions. The light 
scattered back towards the probe is used to measure a chord length of the given particle. 
Typically, many thousands of chords are measured per second, providing a robust 
measurement that is sensitive to the change in the size or number of particles under 
investigation. Unlike, for example, optical turbidity or laser diffraction, FBRM does not 
depend on the presence of a threshold nuclei concentration before a nucleation event is 
detected. This is especially for the current studied chiral system, where the suspension 
density is normally very low. A more detailed description of the operation of the FBRM 
probe is provided in the literature (Barrett and Glennon, 1999, 2002; Worlitschek and 
Mazzotti, 2003; Barret et al., 2005).  
FBRM is a useful tool for detecting crystal behaviour during crystallization 
processes. It can accurately detect a nucleation event and characterize the metastable zone 
width.  However, there are a variety of parameters that affect the particle chord length and 
count measurements. Some researchers have tried to interpret the FBRM chord length 
distribution with respect to an actual particle size distribution (Ruf et al, 2000; Heath et 
al., 2002; Worlitschek et al., 2005; Kougoulos et al., 2005; Barthe and Rousseau, 2006; 
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Pons et al., 2006). There is still no generally applicable model to convert chord length 




                                                 Figure 3.5 FBRM probe 
 
 
                   Figure 3.6  FBRM chord length measurement 
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3.4 Direct crystallization experimental set-up 
Direct cooling crystallizations were carried out in an automated apparatus. A 
Mettler Toledo LabMax Automatic Laboratory Reactor system was used to control and 
monitor crystallizer operation. As shown in Figure 3.7, it was equipped with a 1-litre 
jacketed curved-bottom glass crystallizer, a downward glass propeller stirrer driven by a 
heavy duty motor, a temperature sensor, a solenoid diaphragm dosing pump and a balance. 
It performed temperature control and monitoring, solvent addition and stirring speed in an 
automated and highly accurate mode. The temperature of the crystallizer was measured at 
2 s intervals throughout a crystallization run. A Lasentec S400A FBRM and a Lasentec 






Figure 3.7 Experimental set-up: 1– Computer; 2- LabMax; 3- Julabo cooling/heating 
refrigerator; 4- Heavy duty stirrer; 5- Condenser; 6- Temperature sensor; 7- 600ml double-
wall crystallizer; 8- FBRM; 9- PVM; 10- Solvent bottle; 11- Dosing pump;12-Balance 
 
 
3.5 Crystal   analysis and monitoring 
3.5.1 Principle of optical rotation and polarimetry 
Many molecules with a lack of symmetry (e.g. chiral molecules) rotate the plane of 
plane-polarized radiation. The extent of optical rotation caused by optical active molecules 
in a solution depends on the concentration of the solution, the solvent used, the path length 
of the measurement cell, the temperature and the wavelength of radiation used. The optical 
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rotation caused by the two enantiomeric forms of a racemic specie is of the same 
magnitude but of contrary direction, therefore a racemic mixture is optical inactive and the 
optical rotation of any enriched solution is in addition to the factors described above 
dependent on the enantiomeric excess (ee) of the solution (Ewing, 1985). 
For specified solvent, temperature and wavelength, it is common to report not the 





T αα λ =                                                                        (3.2) 
where d is the path length of the measurement cell and c is the concentration of optical 
active solute in solution.  
 In this work, the optical rotations were measured at 589.3 nm using a JASCO P-
1030 digital polarimeter equipped with a quartz cell of 50 mm path length at ambient 
temperature in a solution of isopropanol. 
 
3.5.2 Particle size analysis 
Several methods based on different measurement principles exist to determine a 
particle size distribution. An elaborate description of the different techniques with their 
advantages and disadvantages is presented in the monograph of Allen (1997). A shorter 
overview is given by Rawle (2006). The most important methods are: image analysis 
(e.g. with an optical microscope or electron microscope), sieving, sedimentation, 
electrozone sensing (Coulter Counter) and laser diffraction. 
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The method of laser diffraction or more precisely Low Angle Laser Light 
Scattering (LALLS) is widely used for determining particle size distributions with many 
applications in quality control and research. Advantages are the fast obtained results and 
the coverage of a wide range of particle sizes ranging from 0.1 to 2000 µm. The method, 
applicable for most particles of interest (dry powders, suspensions, emulsions, aerosols, 
sprays, etc.) is volume-based, which means a volume or weight distribution is obtained 
directly. The principle of a low angle laser light scattering instrument is shown in                       
Figure 3.8. To obtain a representative size distribution measurement time should not be 
too short (typically measurements last 10-20 seconds) and data sampling should be as fast 
as possible. This ensures that the measured population is large enough to be representative 
for the investigated sample. The stirring speed should be high enough to ensure a good 
dispersion of the particles present in the sample; additionally the bath should be 
ultrasonically agitated if the particles tend to agglomerate.  
 
                         Figure 3.8   Principle of LALLS instruments (Allen, 1997) 
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In this work, a Malvern Mastersizer 2000 (laser diffraction) was used to measure 
crystal size distribution. In the meantime, a Lasentec S400A FBRM and a Lasentec 
Particle Vision and Measurement (PVM) 700 were also used to in-situ monitor the 
crystallization process.  
 
3.5.3 Field emission scanning electron microscope (FESEM) 
There are two classes of emission source: thermionic emitter and field emitter. 
Emitter type is the main difference between the SEM and FESEM. FESEM produces a 
cleaner and higher resolution topographical image. 
In this work, the crystal morphology was investigated using a Jeol JSM-6700F 
Field Emission SEM. A small amount of samples were scattered on double-sided adhesive 









The basis for any enantiomer separation, but especially for a separation approach 
via crystallization, is the knowledge about the solid-state characteristic of the racemate. 
Racemate crystals can be divided into three types: racemic conglomerates, racemic 
compounds or pseudoracemates (Roozeboom, 1899; Collet et al., 1980; Jacques et al, 
1994; Li and Grant, 1997; Li et al, 1999; Lorenz and Seidel-Morgenstern, 2002). The 
three fundamental types of racemic species are shown in Figure 4.1. 
 
 
                    Figure 4.1 Crystal lattices of the three fundamental types of racemates:  
                    a) a conglomerate; b) a racemic compound; c) a pseudoracemate 
 
 
The crystal lattice of a conglomerate is built up by the same enantiomer molecules 
as shown in Figure 4.1a. A racemate is a mechanical mixture of crystals containing the 
corresponding enantiomers. In a racemic compound, the two corresponding enantiomers 
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are present in equal quantities in a well-defined arrangement within the crystal lattice as 
shown in Figure 4.1b. For a pseudoracemate, two enantiomer molecules coexist in the 
crystal lattice in a random manner as shown in Figure 4.1c. 
The aim of this chapter is to identify and characterize the solid-state nature of 
different racemic mixture with various techniques. First the characterization of racemic 
species by their binary melting point phase diagram was discussed. Based on a 
thermodynamic cycle involving the solid and liquid phases of the enantiomers and 
racemic species, the melting point, enthalpy, entropy and Gibbs free energy of the racemic 
species were derived from the thermodynamic data. Furthermore, racemic species are 
possible to exist as a metastable racemic compound or as a racemic conglomerate (Collet 
et al., 1980; Li and Grant, 1997; Houllemare-Druot and Coquerel, 1998). Sometimes the 
reversible transitions may occur between condensed phases such as polymorphism, 
reversible decomposition of racemate (Coquerel, 2000; Dufour et al., 2004). As such, 
examination of binary phase diagram alone is not adequate to identify them. Additional 
spectroscopic techniques were employed to compare the solid state spectra of pure 
enantiomer and its racemate to identify or prove the solid nature of racemic species.   
 
4.2 Methods for characterization of racemic species 
4.2.1 Characterization by the binary phase diagram 
The binary phase diagram (melting point diagram) is considered to be the most 
important tool for determining the solid-state characteristic. The first to characterize 
racemic species by their phase diagram was Roozeboom (Roozeboom, 1899). The three 
types of racemates are readily distinguished by reference to their melting point diagrams 
as shown in Figure 4.2. A racemic conglomerate is shown in Figure 4.2 a), a racemic 
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compound in Figure 4.2 b) and the case of pseudoracemate in Figure 4.2 c). 
Pseudoracemates are further differentiated in ideal pseudoracemates as shown in Figure 
4.2 c1) and pseudoracemates showing a maximum Figure 4.2 c2) or minimum Figure 4.2 




Figure 4.2 Typical binary phase diagrams of various racemic species; a) racemic 
conglomerate, b) racemic compound, c) pseudoracemate : 1, ideal; 2, with a maximum; or 
3, with a minimum. R, D and L indicate the racemic compound, pure dextrorotatory 
enantiomer and pure levorotatory enantiomer, respectively. E indicates the eutectic point. 
 
 There are a number of reasons why a binary phase diagram should be determined 
first. The sample mass required to determine the binary phase diagram is small, 
measurements require short time and additional information such as the enthalpy of fusion 
can be determined by employing thermal analysis (DTA, DSC) to predict the phase 
diagram. 
In this work, a heat flux DSC apparatus (Mettler Toledo DSC822e) was employed 
to measure the binary melting point phase diagram and enthalpy of fusion. 
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4.2.2 Characterization of racemic species by analytical spectroscopic techniques 
As a matter of fact many organic substances show polymorphism, that means 
different crystalline arrangements in the solid state are observed dependent most often on 
temperature. That is why today the phase diagram alone is not considered to be sufficient 
for an unambiguous characterization of racemic species. Experimentalists have agreed on 
employing additional analytical techniques to ensure a definite recognition of the solid- 
state behavior. The X-ray diffraction of a powdered sample is analyzed to determine the 
long range order of the crystal lattice (the distance between two adjacent planes within a 
crystal lattice can be determined). A spectroscopic technique such as solid-state Infrared 
or Raman spectroscopy is used to determine differences in the short range order of the 
samples (due to different relative arrangement of the molecules within the lattice, different 
vibration modes are caused). Solid-state 13C nuclear magnetic resonance spectroscopy is 
also used to diagnose the difference in the arrangement of pure enantiomers molecules in 
the crystal lattice for different racemic species (Jacques et al, 1994; Li and Grant, 1997).  
The spectra of enantiomers are identical to that of a racemic conglomerate but 
different from that of a racemic compound.  
 
4.3 Results and discussion 
4.3.1 Characterization by the binary phase diagram 
For the characterization of the studied chiral systems by their binary phase 
diagrams, samples of different compositions (different enantiomeric excess) were 
prepared and measured in a differential scanning calorimetry apparatus as described in 
Chapter 3. The resulting thermograms were evaluated and the resulting binary phase 
diagrams are shown and discussed in the following sections. 
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4.3.1.1 Melting point phase diagram of 4-hydroxy-2-pyrrolidone 
The theoretical background about evaluating the thermograms has been explained 
in Chapter 3 already. Because formation of a solvate (with different melting point) was 
reported by Di Silvestro et al (1993), DSC runs of samples prepared by different methods 
were investigated for the binary phase diagram. DSC runs of samples prepared by mixing 
the two enantiomers directly in the crucible were evaluated. Samples prepared with 
crystals recovered from solvent (isopropanol) were also checked on different melting 
points.  
No differences in the thermograms were observed for the different methods of 
preparing the samples. The determined temperature of fusion was only dependent on the 
composition. The unfavourable formation of a stable solvate of 4-hydroxy-2-pyrrolidone 
recovered from a solution containing isopropanol (Di Silvestro et al, 1993) could not be 
confirmed. For dried crystals (dried for four hours at 60 °C under vacuum) recovered from 
a solution in isopropanol, neither a different melting point compared to the untreated 
crystals in DSC measurements nor different FT-IR spectra were obtained. It can be 
concluded that, even if a solvate with different melting point was formed by crystallization 
from isopropanol, it was transformed to unsolvated crystals during drying.  
For 4-hydroxy-2-pyrrolidone, the graphic procedure of determining the 
temperatures of fusion is shown in the following figure (Figure 4.3) for the pure R-
enantiomer and for one exemplary mixture (composition R:S = 82%:18%). 
For thermograms of 4-hydroxy-2-pyrrolidone measured with a heating rate of 2, 5, 
and 10 oC/min, the corresponding angle which was employed to every peak was β = 5.2o, 
6.7o and 7.2o, respectively. 
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       Figure 4.3 Determination of temperatures of fusion (Tf) for 4-hydroxy-2-pyrrolidone 
 
In the case of 4-hydroxy-2-pyrrolidone, the peaks in the thermogram were well 
separated and easy to evaluate. According to the above evaluation method, the 
temperatures of fusion of different compositions were obtained, which are given in Table 
4.1. Based on the determined temperatures of fusion, the binary melting point phase 
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diagram of (R)- and (S)-4-hydroxy-2-pyrrolidone is given in Figure 4.5. For consecutive 
runs and for heating rates of 2 and 5 oC/min, the data are consistent. For heating rate of 10 
oC/min, the data are also close to the above values. Therefore, in Figure 4.4, only the data 
for the heating rate of 5 oC/min are shown. 
From the binary phase diagram of 4-hydroxy-2-pyrrolidone, we can find its 
eutectic composition is the racemic composition (R:S = 50%:50%). This indicates that 
(RS)-4-hydroxy-2-pyrrolidone possesses the important characteristic of a racemic 


















Table 4.1. Temperature of fusion of 4-hydroxy-2-pyrrolidone determined with 
differential scanning calorimetry (DSC) 
 
X Tf [oC]  X Tf [oC]  X Tf [oC]  X TCal [K] TCal [oC] 
100.0 155.3  100.0 155.3  100.0 155.4  100.0 428.48 155.33 
95.0 153.0  95.0 153.0  95.0 153.6  95.0 425.46 152.31 
92.8 151.5  92.8 151.5  92.8 151.8  92.8 424.10 150.95 
90.0 150.0  90.0 150.0  90.0 150.1  90.0 422.33 149.18 
87.0 148.2  87.0 148.2  87.0 149.2  87.0 420.38 147.23 
85.0 145.4  85.0 145.4  85.0 145.7  85.0 419.06 145.91 
82.0 142.8  82.0 142.8  82.0 143.3  82.0 417.03 143.88 
80.0 142.0  80.0 142.0  80.0 142.4  80.0 415.65 142.50 
75.9 139.5  75.9 139.5  75.9 140.1  75.9 412.74 139.59 
75.0 138.0  75.0 138.0  75.0 138.7  75.0 412.08 138.93 
70.0 134.6  70.0 134.6  70.0 134.8  70.0 408.34 135.19 
68.5 134.0  68.5 134.0  68.5 133.8  68.5 407.17 134.02 
65.0 130.0  65.0 130.0  65.0 130.5  65.0 404.39 131.24 
60.0 126.3  60.0 126.3  60.0 126.9  60.0 400.20 127.05 
59.2 125.0  59.2 125.0  59.2 126.2  59.2 399.51 126.36 
55.0 120.0  55.0 120.0  55.0 121.8  55.0 395.76 122.61 
50.0 117.0  50.0 117.0  50.0 118.8  50.0 390.10 117.84 
Heating Rate = 
2 oC/min 
 Heating Rate = 
5 oC/min 
 Heating Rate = 
10 oC/min 
  Simplified Schröder- 
























Experimental melting point_heating rate 5 K/min
Eutectic point
Data from Simplified Schroder_Van Laar Eq





Figure 4.4  Binary phase diagram (melting point diagram) of 4-hydroxy-2-pyrrolidone: ■, 
Experimental data: heating rate 5 oC/min; ▲, Eutectic temperature; ∆, Calculated data 
from Simplified Schröder-Van Laar Equation; ,  Curve from Simplified Schröder-Van 
Laar Equation. 
  
The enthalpies of fusion of the pure (R)- and (RS)-4-hydroxy-2pyrrolidone were 
determined by integrating the melting peaks with the DSC software. The enthalpies of 
fusion and the temperatures of fusion of the pure (R)- and (RS)-4-hydroxy-2-pyrrolidone 




Based on the above data, the corresponding temperatures of fusion for the different 
compositions were also calculated using the simplified Schröder-Van Laar Equation (Eq. 
4.1).  





x −=                                                          (4.1) 
 
As indicated in Table 4.1 and Figure 4.4, the experimental results are in substantial 
agreement with the theoretically calculated values. 
Besides construction and prediction of the binary phase diagram from the DSC 
measurements, the changes in the thermodynamic quantities (such as enthalpies and 
entropies) were also calculated using the thermodynamic approach. The thermodynamic 
cycle was applied to a recemic conglomerate system as follows (Jacques et al., 1994): 
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In this cycle, D and L represent the pure enantiomers, and DL represents the 
racemic mixture. sC and lC  represent the heat capacities of the solids and liquids, 
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respectively. fAT  and 
f
RT  represent the fusion points of the pure enantiomer and the 
racemic mixture, respectively. fAH∆  and fRH∆  represent the enthalpies of fusion of the 
pure enantiomer and the racemic mixture, respectively. mlH∆  and msH∆  represent the 
enthalpies of mixing of the enantiomers in the liquid and solid states, respectively.  
If the enantiomers are perfectly immiscible in the solid state and if their mixture is 
ideal in the liquid state, then msH∆  and mlH∆ equal zero. We may then write 
  
)3.4())((





























Since lC > sC and fAT  > fRT , it follows that fRfA HH ∆>∆ . Typically the difference 
in the enthalpies of fusion of the pure enantiomer and the racemic mixture lies between 
(1600 and 5100) J mol-1 for a conglomerate forming system (Jacques et al., 1994). This is 
in fact what is observed in Table 4.2. 
Likewise, the changes in entropy can be determined with the thermodynamic cycle 
shown below: 
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Figure 4.6 Thermodynamic cycle for calculation of entropies for   a  racemic 
conglomerate system 
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In this cycle, fAS∆  and fRS∆  represent the entropies of fusion of the pure 
enantiomer and the racemic mixture, respectively. mlS∆  and msS∆  represent the entropies 
of mixing of the enantiomers in the liquid and solid states, respectively. For a 
conglomerate, sDL exists in the form of two separate phases, sD  and sL , which are 
present as a mechanical mixture. Consequently, msS∆ =0 and    






















































The value of mlS∆  calculated with Equation (4.5) is shown in Table 4.2. It is close 
to the value expected from theory, which indicates that (RS)-4-hydroxy-2-pyrrolidone is a 
conglomerate. The agreement with the data published by Li et al. (1999) is satisfying. 
 
Table 4.2. Melting points and enthalpies of fusion of (R)-4-hydroxy-2-pyrrolidone and 
(RS)-4-hydroxy-2-pyrrolidone; entropy of mixing of (R)- and (S)-4-hydroxy-2-


























[J mol-1 K-1] 
 
391.95 428.45 36.5 23413 25217 1804 5.28 
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4.3.1.2 Melting point phase diagram of N-methylephedrine 
For N-methylephedrine, the graphic procedure of determining the melting point is 
shown in Figure 4.7 for the pure (+)-enantiomer and for one exemplary mixture 
(composition (+):(-) = 90%:10%). 
 For thermograms of N-methylephedrine collected with a heating rate of 5 oC/min, 
the correcting angle which was employed to every peak was β = 6.4 oC (HR = 2 oC/min, β 
= 5.1 o; HR = 10 oC/min, β = 7.3 o). Only samples with high enantiomeric excess could be 
evaluated. For samples closer to the racemic mixture (low ee), no clear second peak was 
obtained in the thermograms. As example the thermogram of a sample with lower 
enantiomeric excess ((+):(–)=77%:23%), for which an evaluation was not possible, is also 
shown in Figure 4.7. 
 
       Figure 4.7 Determination of temperatures of fusion (Tf) for N-methylephedrine 
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It should be noted that some difficulties were encountered in preparing samples of 
N-methylephedrine for the DSC measurements. For N-methylephedrine, samples can be 
molten only once, because heating for the second or third time, peaks representing melting 
of the racemic mixture were observed at temperatures approximately 5 °C lower than 
those upon the first melting. The endothermic peaks were accompanied by preceding 
exothermic peaks. This behaviour was only observed for the mixtures of two enantiomers. 
For both pure enantiomers, the reproducible peaks were obtained for repeatedly melting. 
Therefore decomposition due to thermal stress can be excluded for this behaviour, but no 
unambiguous explanation can be given. A possible explanation is the formation of a 
different polymorphic phase. For example a different polymorph (e.g. a racemic 
compound) can be obtained upon recrystallization if the crystallization is very slow for the 
stable phase. Then a different polymorph even when thermodynamically not stable can be 
formed if the rate of crystallization is faster. This phenomenon is frequently observed in 
crystallization and known as “law of successive reactions” or “Ostwald’s rule of stages” 
(Jacques et al, 1994; Mullin, 2001). Sometimes the metastable polymorph can be 
transformed into the stable form by heating to a transition temperature. In some cases the 
solid-solid transformation is extremely slow and therefore the metastable form is virtually 
stable. The appearance of the thermograms for N-methylephedrine was akin to the cases 
of polymorphism in binary systems discussed by Jacques et al (1994), but no definite 
explanation can be given from the thermograms alone. As stated in the same monograph, 
it is difficult to determine polymorphism in a binary system. However, also a comparison 
of the IR-spectra of the once molten and recrystallized sample revealed no differences to 
the pure enantiomers or the racemic mixture before being molten.  
Preparing samples of crystals recovered from solvent was also not applicable. The 
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melting point of the racemic mixture was about 63 °C. Therefore drying at ambient 
pressure was ineffective due to the limited temperature. Attempts to dry the crystals under 
vacuum resulted in partially sublimation of the sample. Due to the fact that the vapour is 
always racemic as long as both enantiomers are present in the sample 
(Jacques et al, 1994), the actual sample composition is no longer known. 
The mixture attained by preparing the samples with the mortar method was 
sufficient to evaluate the peaks obtained during the first run of the DSC program (peaks 
obtained from poorly mixed samples were not smooth and broader than those where good 
mixing was achieved). For samples with low enantiomeric excess the liquidus temperature 
can not be determined, because the two peaks representing melting of the racemic mixture 
and subsequently melting of the enantiomer in excess were overlapping too much. That is 
why additional to the heating rate of 5 °C/min, heating rates of 2 and 10 °C/min were 
applied with the aim of better separated peaks for the lower heating rate and larger peaks 
in the case of the higher heating rate. The desired effects were observed, but due to the 
drawbacks of very small peaks (lower heating rate) or even more overlapping of peaks 
(higher heating rate), those runs were not advantageous for evaluating the temperatures of 
fusion. 
The second peak for N-methylephedrine was not as distinct as that for 4-hydroxy-
2-pyrrolidone. The reason might be the lower heat of fusion ( 164.5SLMEh J g∆ = , 
249.4SLHPh J g∆ = ), resulting in overall smaller peaks. Furthermore a slow dissolution was 
observed in the solubility experiments. If this is also true for dissolution in the melt, the 
peaks would be more diffusive and therefore more overlapping. Probably a combination of 
both effects caused the poorly separated peaks in the thermogram. 
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In the case of N-methylephedrine, only the compositions with high enantiomeric 
excess can be evaluated and no consecutive runs were possible, but reproducible 
thermograms were obtained analysing samples of constant composition. The temperatures 
of fusion of different compositions and binary melting point phase diagram of (+)- and (-)-
N-methylephedrine are given in Table 4.3 and Figure 4.8, respectively. 
From the binary phase diagram of N-methylephedrine, we can find its eutectic 
composition is the racemic composition. This indicates that (±)-N-methylephedrine 
exhibits the dominant characteristic of a conglomerate forming system.  
Similarly, using the thermodynamic cycles (Figures 4.5 and 4.6) the difference in 
the enthalpies of fusion for pure (+)- and (±)-N-methylephedrine as well as the entropy of 
mixing of  the enantiomers in the liquid state was calculated and shown in Table 4.4.  
The temperatures of fusion for the corresponding compositions were also 
calculated using the simplified Schröder-Van Laar Equation (Eq.4.6). 
                        





x −=                                                 (4.6) 
 
For sufficiently separated peaks (obtained for samples with high enantiomeric 
excess) the data attained are scattered around the values predicted by the simplified 
Schröder-Van Laar equation. The agreement of the experimentally determined liquidus 
line data with the theoretical values predicted by the Schröder-Van Laar equation is not so 
good as for 4-hydroxy-2-pyrrolidone, nevertheless no experimental point does differ more 
than ±2 °C from the predicted value. 
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Table 4.3. Temperature of fusion of N-methylephedrine determined with 
differential scanning calorimetry (DSC) 
 
X% Tf [oC]  X% Tf [oC]  X% Tf [oC]  X% TCal [K] TCal [oC] 
100 86.8  100 86.6  100 87  100 357.22 84.07 
87.5 82.3  91.0 81.1  84.8 78.5  90 356.07 82.92 
78.6 79.4  84.2 80.7  74.4 77.4  80 352.05 78.90 
50 63  83.4 78.4     70 347.60 74.45 
   50 63.5     50 336.87 63.72 
Heating Rate = 
2 oC/min 
 Heating Rate = 
5 oC/min 
 Heating Rate = 
10 oC/min 





























Experimental melting point_heating rate 2 ºC/min
Experimental melting point_heating rate 5 ºC/min




Figure 4.8 Binary phase diagram (melting point diagram) of N-methylephedrine: ■, 
Experimental data: heating rate 2 oC/min; ▲, Experimental data: heating rate 5 oC/min; ∆, 
Experimental data: heating rate 10 oC/min; □, Eutectic temperature; , Curve from 
Simplified Schröder-Van Laar Equation. 
 
 
Table 4.4. Melting points and enthalpies of fusion of (+)-N-methylephedrine and (±)-N-

























[J mol-1 K-1] 
 
336.65 359.75 23.10 26576 30531 3955 5.44 
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 The values of (∆HAf – ∆HRf ) and ∆Slm are closed to the values expected from 
theory, which indicates  that (±)-N-methylephedrine is a conglomerate (Li et al., 1999). 
The binary phase diagram is considered to be the most important evidence for 
classification of racemic species. Both 4-hydroxy-2-pyrrolidone and N-methylephedrine 
show the typical binary phase diagram of a conglomerate forming system. In the case of 
N-methylephedrine, the liquidus line data for intermediate compositions can not be 
determined and therefore also a classification as a racemic compound came into 
consideration. Though, due to the distinct melting peak observed for the racemic 
composition, which occurs at the lowest temperature in the system, the typical binary 
phase diagram of a racemic compound (Figure 4.2b) may not be possible, to ensure the 
classification of both racemic species as racemic conglomerates, the results of three 
additional techniques (IR, Raman-spectroscopy and powder X-ray diffraction) would be 
presented in the later sections (4.3.2 – 4.3.4). 
 
4.3.1.3 Melting point phase diagram of propranolol hydrochloride 
For propranolol hydrochloride, the graphic procedure of determining the melting 
point is shown in Figure 4.9 for the pure (S)-enantiomer and for one exemplary mixture 
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Thermogram R-PN-Cl:S-PN-Cl = 90:10
    
Figure 4.9 Determination of temperatures of fusion (Tf) for propranolol hydrochloride 
 
For thermograms of propranolol hydrochloride collected with a heating rate of 5 
oC/min, the correcting angle which was employed to every peak was β = 5.3 o (HR = 2 
oC/min, β = 5.3 o; HR = 10 oC/min, β = 6.1 o). 
The temperatures of fusion of different compositions and binary melting point 
phase diagram of (R)- and (S)-propranolol hydrochloride are given in Table 4.5 and 





                      β = 5.3 o 
Heating Rate: 5 oC/min 
endotherm
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Table 4.5. Temperature of fusion of propranolol hydrochloride determined with 
differential scanning calorimetry (DSC) 
 
X% Tf [oC]  X% Tf [oC]  X% Tf [oC] 
100 197.9  100 197.9  100 197.9 
95 195.1  95 195.1  95 195.1 
90 192.6  90 192.6  90 192.6 
85 190.7  85 190.7  85 190.7 
80 188.9  80 188.9  80 188.9 
75 187.1  75 187.1  75 187.1 
70 184.8  70 184.8  70 184.8 
65 181.7  65 181.7  65 181.7 
60 177.3  60 177.3  60 177.3 
55 173.4  55 173.4  55 173.4 
50 167.2  50 167.2  50 167.2 
























Experimental melting point_heating rate 5ºC/min
Eutectic point
Figure 4.10   Binary phase diagram (melting point diagram) of  propranolol 




From Figure 4.10, it can be seen that the eutectic composition of propranolol 
hydrochloride is the one of racemate. It seems to have the same characteristics as a 
conglomerate.  
 If the thermodynamic cycles (Figures 4.5 and 4.6) which are applicable for a 
racemic conglomerate were used to calculate and verify the characteristic of propranolol 
hydrochloride, the results of the difference in the enthalpies of fusion of (S)-propranolol 
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hydrochloride and (RS)-propranolol hydrochloride as well as the entropy of mixing of 
(R)- and (S)-propranolol hydrochloride in the liquid state are given in Table 4.6. 
 
Table 4.6. Melting points and enthalpies of fusion of (S)-propranolol hydrochloride and 
(RS)-propranolol hydrochloride; entropy of mixing of (S)- and (R)-propranolol 
hydrochloride in the liquid state 
 
  
 It is noticed that the value of (∆HAf – ∆HRf) is negative. A negative value of (∆HAf – 
∆HRf) may reveal the probability of formation of a racemic compound, which is 
enthalpically favorable. This is consistent with the conclusion that the racemic compound 
has greater stabilization energy than the individual enantiomers. There were some 
arguments on the solid nature of propranolol hydrochloride as a racemic conglomerate or a 
racemic compound (Barrans and Cotrait, 1973; Ammon et al, 1977; Roberts and Rowe, 
1994; Shankland and Knight, 1996; Li et al, 1999; Wang et al, 2002; Bredikhin et al, 
2003, 2004). In order to get the unambiguous chiral discrimination of propranolol 
hydrochloride, the solid-state IR spectra, Raman spectra, Powder XRD spectra and solid-
state NMR spectra of (R)- and (RS)-propranolol hydrochloride were further examined to 
identify the characteristic of propranolol hydrochloride in the later sections (4.3.2 - 4.3.5).  
Chapter 5 will also show that the metastable zone width measurements could be 
























[J mol-1 K-1] 
 
440.35 471.05 30.7 35271 32725 -2546 5.04 
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4.3.1.4 Melting point phase diagram of atenolol  
For atenolol, the melting points of different compositions were measured using the 
DSC under different cooling rates of 2 oC/min, 5 oC/min and 10 oC/min. It was found that 
the melting peaks were almost superimposable for the same sample under the different 
cooling rates, and only one distinct peak was obtained for any prepared sample regardless 
composition. The thermograms (heating rate = 5 oC/min) are given in Figure 4.11.  
The graphic procedure of determining the melting point of atenolol is shown in 
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Figure 4.11 DSC thermograms of atenolol with different enantiomeric compositions 
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From the DSC thermograms, we can find the temperatures of the melting peaks of 
different compositions are approximately identical (Table 4.7 and Figure 4.13). This 
indicates that atenolol is an ideal pseudoracemate. This was also observed in Burger et al’s 
work (Burger et al, 1999),while a very small difference (3 oC) was reported elsewhere (Li 
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Heating Rate: 5 oC/min 
β = 6.4 o 
 78
Table 4.7. Temperature of fusion of atenolol determined with differential scanning 
calorimetry (DSC) 
 
X% Tf [oC]  X% Tf [oC]  X% Tf [oC] 
100 148.0  100 148.0  100 148.0 
83.50 148.0  83.50 148.0  83.50 148.0 
76.99 148.0  76.99 148.0  76.99 148.0 
75.79 147.8  75.79 147.8  75.79 147.8 
66.10 148.2  66.10 148.2  66.10 148.2 
57.08 148.3  57.08 148.3  57.08 148.3 
54.97 148.0  54.97 148.0  54.97 148.0 
50 148.0  50 148.0  50 148.0 






















Experimental melting point_heating rate 5 K/min
 
Figure 4.13 Binary phase diagram (melting point diagram) of atenolol: ■, Experimental 
data: heating rate 5 oC/min. 
 
The results of difference in the enthalpies of fusion of (R)- and (RS)-atenolol as 
well as the entropy of mixing of (R)- and (S)-atenolol in the liquid state are given in Table 
4.8. The negative value of mlS∆  also indicates the evident difference from a racemic 







Table 4.8. Melting points and enthalpies of fusion of (R)-atenolol and (RS)-atenolol; 




4.3.2 Characterization by powder X-ray diffraction spectra (PXRD) 
4.3.2.1 Powder X-ray diffraction spectra of 4-hydroxy-2-pyrrolidone 
In Figure 4.14, the X-ray diffraction patterns of (R)- and (RS)-4-hydroxy-2-
pyrrolidone are presented. For easier comparison only the region where most of the 
characteristic peaks appeared (glancing angles (2θ) 10 to 35°) is shown. The intensity 
(counts) is plotted versus the glancing angle. 
All patterns were collected under the same experimental conditions and equipment 
settings. Only a small difference between patterns of the pure enantiomer and the racemate 
was observed. The most important information of the patterns is the position of the peaks 
(at which glancing angel does a peak occur). The peak position is the same for the pure 
and racemic samples, so that no difference in the crystal lattice could be revealed leading 

























(J mol-1 K-1) 
 
421.15 421.15 0 34623 36533 1910 -4.54 
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Figure 4.14 Powder X-ray diffraction patterns of (R) and (RS)-4-hydroxy-2-pyrrolidone 
(glancing angles 2θ = 10 – 35o) 
 
4.3.2.2 Powder X-ray diffraction spectra of N-methylephedrine 
The PXRD patterns of pure enantiomer and racemic mixture of N-methylephedrine 
are shown in Figure 4.15. The peak positions in the recorded PXRD patterns are 
almost the same for the racemic mixture and the pure enantiomer. The difference in 
peak intensity may be from the preferred orientation (Li et al., 1999).  
This would be the case if the two separate enantiomers are present as a mechanical 
mixture, which confirms that (±)-N-methylephedrine is a racemic conglomerate. 
 82











         
Figure 4.15 Powder X-ray diffraction patterns of (+) and (±)-N-methylephedrine 
(glancing angles 2θ = 10 – 35o) 
 
4.3.2.3 Powder X-ray diffraction spectra of propranolol hydrochloride 
 The PXRD patterns of pure enantiomer and racemic mixture of propranolol 
hydrochloride are shown in Figure 4.16. The PXRD patterns show that most of the peak 
positions and intensities differ significantly between (S)- and (RS)-propranolol 
hydrochloride which means different crystal lattice structures. It may indicate that the 
racemic mixture of propranolol hydrochloride is a racemic compound.  
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racemic PNCl 
pure S- PNCl 
 
Figure 4.16 Powder X-ray diffraction patterns of (S) and (RS)-propranolol hydrochloride 
(glancing angles 2θ = 5 – 70o) 
 
4.3.3 Characterization by solid state fourier transform infrared spectra (FT-IR) 
4.3.3.1  FT-IR spectra of 4-hydroxy-2-pyrrolidone 
 The solid state FT-IR spectra of (R)- and (RS)-4-hydroxy-2-pyrrolidone are shown 
in Figure 4.17. As common practice in FT-IR spectroscopy, the spectra are plotted as 








               Figure 4.17 FT-IR spectra of (R)- and (RS)-4-hydroxy-2-pyrrolidone    
 
 All spectra were collected under the same experimental conditions and equipment 
settings. Two factors varying from run to run were affecting the appearance of the spectra: 
the thickness of the analysed pellet and the concentration of the studied substance in the 
potassium bromide carrier. That is why the absolute transmittance was not the same for 
each sample, but more important than the absolute transmittance is the position of the 
peaks along the abscissas (at which wavenumber radiation is absorbed) and their relative 
amplitude (intensity of absorption).  
 Comparing the different spectra, the position and the relative peak intensity are 
almost the same for pure enantiomer and racemic mixture, which lead to the conclusion 
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that all samples contained crystals constituted from one enantiomer only. The FT-IR 
spectra reveal no hints for the formation of a racemic compound. 
 
4.3.3.2 FT-IR spectra of N-methylephedrine 
 The solid state FT-IR spectra of (+)- and (±)-N-Methylephedrine are shown in 
Figures 4.18.  
500 1000 1500 2000 2500 3000 3500 4000
pure (+) ME 
racemic ME 
 
Figure 4.18 FT-IR spectra of (+) and (±)-N-methylephedrine 
  
 Again, comparing the different spectra, the positions and the relative peak 
intensities are almost the same for pure enantiomer and racemic mixture, which lead to the 
conclusion that all samples contained crystals constituted from one enantiomer only. The 
FT-IR spectra reveal no hints for the formation of a racemic compound. 
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4.3.3.3 FT-IR spectra of propranolol hydrochloride 
 The solid state FT-IR spectra of (S)- and (RS)-propranolol hydrochloride are 
shown in Figure 4.19. 














                Figure 4.19 FT-IR spectra of (S) and (RS)-propranolol hydrochloride 
  
 The FT-IR spectra show that most of the peak positions and intensities in the range 
of 1700-3500 cm-1 differ obviously between (S)- and (RS)-propranolol hydrochloride. It 
may imply that the racemic mixture of propranolol hydrochloride is a racemic compound. 
This is due to the fact that the crystals of the enantiomers and of the racemic compounds 
possess different organizations, such as lattice symmetry and relative arrangement of the 
molecules. These differences will give rise to the differences in their frequencies and 
intensities with vibration modes (Jacques et al., 1994). 
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4.3.4 Characterization by solid state Raman spectra 
4.3.4.1 Raman spectra of 4-hydroxy-2-pyrrolidone  
 The solid state Raman spectra of (R) and (RS)-4-hydroxy-2-pyrrolidone are shown 
in Figure 4.20. 





Figure 4.20 Raman spectra of (R) and (RS)-4-hydroxy-2-pyrrolidone 
 
 Comparing the different spectra, the positions and the relative peak intensities are 
almost same for the pure enantiomer and racemic mixture, which is again consistent with 
the conclusion that all samples contained crystals constituted from one enantiomer only. 
The Raman spectra confirm the formation of a racemic conglomerate for 4-hydroxy-2-
pyrrolidone. 
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4.3.4.2 Raman spectra of N-methylephedrine 
 The solid state Raman spectra of (+) and (±)-N-methylephedrine are shown in 
Figure 4.21. 




                            Figure 4.21 Raman spectra of (+) and (±)-N-methylephedrine 
 
 From the Raman spectra, it can be seen the positions and the relative peak 
intensities are almost same for the pure enantiomer and racemic mixture. It also indicates 
that all samples contained crystals constituted from one enantiomer only. The Raman 
spectra confirm the formation of a racemic conglomerate for N-methylephedrine. 
 
4.3.4.3 Raman spectra of propranolol hydrochloride 
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 The solid state Raman spectra of (S) and (RS)-propranolol hydrochloride are 
shown in Figure 4.22. 




Figure 4.22 Raman spectra of (S)- and (RS)-propranolol hydrochloride 
 
 The Raman spectra show that most of the peak positions and intensities in the 
range of 400-1200 cm-1 differ significantly between (S)- and (RS)-propranolol 
hydrochloride. This is consistent with the IR observations. It indicates that the racemic 






4.3.5 Characterization by solid state nuclear magnetic resonance (NMR)  
 In order to obtain an unambiguous characterization of racemic species for 
propranolol hydrochloride, which is a more complex case, the solid state NMR spectra of 





















Figure 4.23 13C Solid state NMR spectra of (S)- and (RS)-propranolol hydrochloride 
  
 The solid state NMR spectra also differ significantly between (S)- and (RS)-
propranolol hydrochloride. Like the PXRD, the 13C chemical shifts for the pure 
enantiomer and the racemic mixture are quite different, which means the asymmetric unit 
contains two molecules with different molecule conformations which are 
crystallographically nonequivalent (Maciel et al., 1988). This again confirms that the 








Four racemic species, namely 4-hydroxy-2pyrrolidone, N-methylephedrine, 
propranolol hydrochloride and atenolol were characterized with thermal analysis, 
thermodynamic calculation and various spectroscopic techniques. 
From the melting point phase diagrams, 4-hydroxy-2pyrrolidone and N-
methylephedrine can be classified as racemic conglomerate forming systems with a 
eutectic composition of a racemic mixture (R:S =50%:50%). Based on the thermodynamic 
quantities calculated from thermodynamic cycles, the positive values of the difference in 
the enthalpies of fusion of pure-enantiomer and racemic mixture lie between 1600 and 
5100 J mol-1; the values of entropies of mixing of the enantiomers in the liquid states are 
close to Rln2. This is consistent with a typical conglomerate forming system. The close 
match of the FTIR, Raman spectra and the PXRD patterns of pure-enantiomer and of its 
corresponding racemic mixture further confirms that 4-hydroxy-2-pyrrolidone and N-
methylephedrine are racemic conglomerates. 
 In the case of propranolol hydrochloride, although the characteristic of the melting 
point phase diagram is similar to the one of a conglomerate forming system, the evidently 
negative value of the difference in the enthalpies of fusion of (S)- and (RS)-propranolol 
hydrochloride indicates propranolol hydrochloride is a racemic compound favoring 
system. The significant difference of the FT-IR, Raman spectra, PXRD patterns and NMR 
spectra of pure-enantiomer and of its corresponding racemate again confirms that 
propranolol hydrochloride is a racemic compound. 
 The obviously identical melting temperatures for atenolol with different 
compositions undoubtedly indicate that atenolol is an ideal pseudoracemate forming 
system. 
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Part of the results in this Chapter have been reported on Journal of Chemical and 
Engineering Data, 48, pp.1092-1098. 2003, Chirality, 14, pp. 318-324, 2002 and 
Chirality, 16, pp.220-227. 2004.  
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CHAPTER 5   CRYSTALLIZATION 
THERMODYNAMICS: SOLUBILITY AND 
METASTABLE ZONE  
 
5.1 Introduction 
In Chapter 4, four racemates, namely 4-hydroxy-2-pyrrolidone, N-
methylephedrine, propranolol hydrochloride, and atenolol were characterized into three 
different types of racemic species using various techniques. It was shown that the binary 
phase diagram allowed a first characterization of the racemic species of interest. For 
solution crystallization, solvent is normally needed. Hence, it is the ternary phase diagram 
that is essential for design and optimization of a reasonable separation process. The 
prerequisite for direct crystallization from solution is the knowledge of the solid-liquid 
equilibrium of the two enantiomers in a solvent. The introduction of a new third substance 
(the solvent) increases the degree of the system. Therefore the measurement and 
presentation of data are more complicated than those in the case of the binary phase 
diagram. 
Crystallization process can only take place in the supersaturated phase. The rates 
of crystal nucleation and growth, as well as the crystal size distribution, are affected by the 
degree of supersaturation (Mullin, 2001). Therefore, it is required to determine the 
solubility (saturation limit) and supersolubility (supersaturation limit) diagram. The 
difference in concentration (for constant temperature) or the difference in temperature (for 
constant concentration) between solubility and supersolubility is called metastable zone 
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width (Ostwald, 1897; Ting et al., 1934; Nyvlt, 1968; Nyvlt et al., 1970; Sohnel and 
Nyvlt, 1975; Mullin and Jancic, 1979; Kim and Ryu, 1997). 
 For preferential crystallization process, it is essential to keep the freedom of 
supersaturation of the undesired enantiomer within its metastable zone to avoid its 
spontaneous nucleation (Jacques et al., 1994; Collet, 1999). More importantly, the 
metastable zone of the target enantiomer could be also closely related with the nucleation 
of the unwanted isomer (Hongo et al., 1976, 1981; Black et al., 1989; Collins et al., 1997). 
Therefore, to measure and interpret the metastable zone of both enantiomers in solution 
should be very useful in understanding the preferential crystallization process, which has 
been rarely reported. 
The saturation curve (solubility) can be well-defined. For a given system (solute –
 solvent) the saturation concentration is only dependent on temperature and pressure (of 
which the latter can be neglected, unless very high pressure is considered). However, the 
limit of the metastable zone (metastable zone width) is affected considerably by a variety 
of process parameters including saturation temperature, rate of supersaturation generation, 
impurity level, mixing, and solution history etc. It is therefore important to characterize 
the metastable zone width under a specific set of operating conditions, which relate 
closely to the conditions of the final scale crystallization. There are many methods 
available to measure the metastable zone width. The polythermal technique is perhaps the 
most widely used technique for determining the metastable zone width (Nyvlt, 1968; 
Nyvlt et al., 1970; Sohnel and Nyvlt, 1975; Mullin and Jancic, 1979; Kim and Ryu, 1997). 
This methodology involves cooling a saturated solution at a fixed rate until nucleation 
occurs. 
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In practice, the value of metastable zone width strongly depends on the method of 
detecting the onset of nucleation and dissolution. A wide variety of measurement 
techniques can be applied to the detecting, such as visualization, electrozone sensing, laser 
scattering and optical turbidity etc. In this work, the newly developed Lasentec Focused 
Beam Reflectance Measurement (FBRM) (as described in Chapter 3) was used to 
determine the nucleation and dissolution properties of the materials. The four 
characterized racemates, namely 4-hydroxy-2-pyrrolidone, N-methylephedrine, 
propranolol hydrochloride, and atenolol, were measured to obtain their solubility and 
metastable zone data.   
 
5.2 Experimental 
5.2.1 Solvent selection 
The selection of the suitable solvent for an effective crystallization operation is 
crucial. Many factors must be considered. The solute to be crystallized should be readily 
soluble in the solvent. It should also be easily deposited from the solution in the desired 
crystalline form after cooling, evaporation or salting-out with an additive. Furthermore a 
favorable dependency of solubility on temperature is desired if a cooling crystallization 
process is considered. For easy controllability of the crystallization process and low loss 
of solvent due to evaporation, a solvent with low vapor pressure is desired. In addition to 
this, the solvent should be relatively cheap and easily available, not hazardous, stable 
under all process conditions, and show a low viscosity etc. A mixture of two or more 
solvents is sometimes found to possess the best properties for a particular crystallization 
purpose (Nass, 1994; Mullin, 2001). This is especially important for the expensive pure 
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enantiomers of chiral systems. Therefore, some initial experiments were first conducted in 
a 25 ml jacketed glass crystallizer with magnetic stirrer to screen the potential solvents. 
 
5.2.2 Characterizing the metastable zone width and solubility curve using Lasentec 
FBRM and PVM 
The experimental set up (Figure 3.7) has been described in Chapter 3. Recently, 
crystallization practitioners have become increasingly interested in the Focused Beam 
Reflectance Method (FBRM), which allows on-line and in-situ measurements even in 
systems with high solids concentrations. The principle of the FBRM measurement is 
illustrated in Figure 3.6 (Barrett and Glennon, 1999; Worlitschek, 2003). The FBRM is 
implemented using a cylindrical probe which can easily be located within the suspension 
to be characterized. An infrared laser beam rotates at high velocity, propagating into the 
suspension through a sapphire window on the probe tip. When the beam hits a particle, it 
is reflected and propagated back through the probe window. This optical signal is then 
processed by the device electronics and the corresponding chord length s is calculated as 
the product of the measured crossing time ∆t and the beam velocity vb. Chord length 
counts are summed up in a finite number of chord length intervals (channels in the 
Lasentec jargon), thus yielding the chord length distribution (CLD). Several research 
groups have used the FBRM method and proven its reliability to determine the MSZW 
and monitor crystal size distributions on-line (Tadayyon and Rohani, 1998; Barrett and 
Glennon, 1999, 2002; Ruf et al, 2000; Heath et al, 2002; Worlitschek and Mazzotti, 2003; 
Barthe and Rousseau, 2006).  
In this work, the metastable zone width, i.e. the difference between the properties 
of onset of nucleation and dissolution was determined based on the measurements 
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sensitive to the changes in the solid phase with FBRM. These measurements were also 





































A typical procedure for measuring solubility and metastable zone data is as follows. 
A certain amount of sample of known enantiomeric composition was added to a certain 
amount of solvent in a 500 ml cylindrical jacketed glass vessel with diameter of 75mm. 
The solution was continuously stirred with an electronic overhead stirrer, which was 
equipped with a 4-bladed propeller stirrer of diameter 50 mm, at 300 rpm. The 
temperature of solution was controlled using a programmable Julabo FP88-HL 
heating/cooling circulator. Temperature data were recorded on PC via a PT-100 probe 
which was in the crystallizer and connected to the Julabo heating/cooling system. The 
onset of nucleation and dissolution was detected using FBRM probe as shown in Figure 
5.1, and a typical PVM image is shown in Figure 5.2. 
First, relatively fast heat up the mixture of solute and solvent until clear solution was 
attained, and then fast cool down the clear solution until nucleation occurred. After that, 
carefully heat up the suspension solution until the clear solution was attained. The 
temperature of the beginning of dissolution is the saturation temperature (Tsat). After that, 
further heat up the solution to 3 oC above the saturation temperature (Tsat) and keep for 10 
mins, and then cool the solution carefully under the selected cooling rate until nucleation 
occurred. The temperature of the beginning of nucleation is the supersaturation 
temperature (Tsupersat). The metastable zone width of the solution was determined under 
different cooling rates 1, 5 and 10 oC/h. The values of solubilities and metastable zone 
widths were repeated three times to check the reproducibility.      
 
5.3 Results and discussion 
5.3.1 Solubility and metastable zone width of 4-hydroxy-2-pyrrolidone in  
         isopropanol 
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5.3.1.1 Solubility 
For determination of solubilities and metastable zone widths of 4-hydroxy-2-
pyrrolidone with different compositions with respect to the two enantiomers in 
isoprapanol, the well-known polythermal method was applied. The solubilities of 4-
hydroxy-2-pyrrolidone with composition (R) 20% ee, 25% ee, 40% ee, 50% ee, 75% ee, 
pure (R)- and (RS)- in isopropanol are listed in Table 5.1 and shown in Figure 5.3, 
respectively.  
Table 5.1. Solubility of 4-hydroxy-2-pyrrolidone in isopropanol 




































































































Figure 5.3 Solubility of 4-hydroxy-2-pyrrolidone with different enantiomeric excess 
in isopropanol 
  
The solubility curves can be regressed to obtain the following solubility equations. 
 
                             Pure R_4_HP:                C = 0.0008T2 + 0.0139T + 0.7227        (5.1) 
                             RS_4_HP:                      C = 0.0015T2 + 0.0603T + 1.2167        (5.2)       
                             20% ee R_4_HP:           C = 0.0016T2 + 0.0259T + 1.0201        (5.3) 
                     25% ee R_4_HP:           C = 0.0025T2 - 0.0275T + 1.7016         (5.4) 
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                   40% ee R_4_HP:      C = 0.0015T2 + 0.0025T + 1.2751        (5.5) 
                              50% ee R_4_HP:          C = 0.0021T2 - 0.0275T + 1.6271     (5.6) 
                              75% ee R_4_HP:          C = 0.0010T2 + 0.0066T+ 1.1320     (5.7) 
 
 As shown in Figure 5.3, the solubilities of (R)-, (RS)-, 20% ee, 25% ee, 40% ee, 
50% ee, and 75% ee (R)-4-hydroxy-2-pyrrolidone in isopropanol all properly  increase 
with temperature over the range of 0 – 40 oC. The chosen solvent isopropanol is suitable 
for cooling crystallization operation.  
 Figure 5.3 also shows that the solubilities decrease with increased ee. This is in 
agreement with the general findings in conglomerate system that the racemate is more 
soluble than the constituent enantiomers (Jacques et al., 1994).  Actually, the solubility 
ratio α of RS to R is circa 2.0-2.5 in the temperature range of 0 – 40 oC. This is quite close 
to the old empirical “double solubility” rule proposed by Meyerhofer (1904). The current 
system of 4-hydroxy-2-pyrrolidone in isopropanol appears to be close to ideal solution. 
But the dissociation/association among the dissolved molecules of the enantiomers in 
solution can be still observed as indicated by the ratio α of 2.5. 
 The range of the solubility ratio α of RS to R is more than 2, which suggests the 
resolution of this system is not easy to carry out by direct crystallization. It was suggested 
that the classical isothermal preferential crystallization process was not suitable for such 
kind of case (Coquerel et al., 1990). In the case of α less than 2, the degree of 
supersaturation of the undesired enantiomer will decrease during the crystallization and 
therefore it is easy to obtain pure crystals with large extent of resolution. On the contrary, 
when α is bigger than 2, the degree of supersaturation of the undesired enantiomer will 
increase during the crystallization of its isomer and spontaneous nucleation could happen. 
 103
This is the major case for most of organic compounds (Collet et al., 1980; Jacques et al., 
1994).   
  It is also interesting to note that the solubility ratio of RS to R decreases from circa 
2.5 at 35 oC to circa 2.0 at 5 oC. This suggests that the preferential crystallization of 4-
hydroxy-2-pyrrolidone in the chosen solvent is more favorable as temperature decreases. 
As illustrated by Jacques et al. (1994), the decreased solubility ratio of RS- to R-4-
hydroxy-2-pyrrolidone means that the solution tends to decreasingly destabilize during the 
course of the resolution process, with the consequence that the risk of spontaneous 
nucleation of the undesired enantiomer is slowly increased. Therefore, special attention 
should be paid to the supersaturation control for this case during the preferential 
crystallization of this conglomerate. This will be elaborated in Chapter 7. 
 For studies on preferential crystallization, the ternary phase diagram of the two 
enantiomers and solvent is helpful. The purpose of the ternary diagram is the visualization 
of the whole preferential crystallization process as shown in Chapter 2 (Figure 2.2). 
Furthermore it is especially helpful for layout of the crystallization step. More 
importantly, it also assists to identify the racemic species besides the binary phase 
diagram. Tables 5.2 – 5.9 are the solubilities of 4-hydroxy-2-pyrrolidone in isopropanol 








Table 5.2. Solubility of 4-hydroxy-2-pyrrolidone in isopropanol at 40 oC 
 R (wt%) S (wt%) IPA (wt%) 
100ee 2.50 0 97.50 
75ee 2.55 0.36 97.09 
50ee 2.52 0.84 96.64 
40ee 2.56 1.10 96.34 
20ee 2.61 1.74 95.65 
RS (0ee) 2.85 2.85 94.30 
 
 
Table 5.3. Solubility of 4-hydroxy-2-pyrrolidone in isopropanol at 35 oC 
 R (wt%) S (wt%) IPA (wt%) 
100ee 2.16 0 97.84 
75ee 2.21 0.32 97.47 
50ee 2.31 0.77 96.92 
40ee 2.18 0.94 96.88 
20ee 2.25 1.50 96.25 







Table 5.4. Solubility of 4-hydroxy-2-pyrrolidone in isopropanol at 30 oC 
 R (wt%) S (wt%) IPA (wt%) 
100ee 1.78 0 98.22 
75ee 1.95 0.27 97.78 
50ee 1.96 0.65 97.39 
40ee 1.85 0.79 97.36 
20ee 1.88 1.26 96.86 




Table 5.5. Solubility of 4-hydroxy-2-pyrrolidone in isopropanol at 25 oC 
 R (wt%) S (wt%) IPA (wt%) 
100ee 1.51 0 98.49 
75ee 1.64 0.23 98.13 
50ee 1.64 0.55 97.81 
40ee 1.57 0.67 97.76 
20ee 1.56 1.04 97.40 






Table 5.6. Solubility of 4-hydroxy-2-pyrrolidone in isopropanol at  20 oC 
 R (wt%) S (wt%) IPA (wt%) 
100ee 1.29 0 98.71 
75ee 1.45 0.21 98.34 
50ee 1.40 0.46 98.14 
40ee 1.33 0.57 98.10 
20ee 1.28 0.85 97.87 
RS (0ee) 1.52 1.52 96.96 
 
 
Table 5.7. Solubility of 4-hydroxy-2-pyrrolidone in isopropanol at 15 oC 
 R (wt%) S (wt%) IPA (wt%) 
100ee 1.07 0 98.93 
75ee 1.25 0.18 98.57 
50ee 1.24 0.41 98.35 
40ee 1.14 0.49 98.37 
20ee 1.04 0.70 98.26 







Table 5.8. Solubility of 4-hydroxy-2-pyrrolidone in isopropanol at 10 oC 
 R (wt%) S (wt%) IPA (wt%) 
100ee 1.03 0 98.97 
75ee 1.10 0.16 98.74 
50ee 1.15 0.38 98.47 
40ee 1.00 0.43 98.57 
20ee 0.85 0.57 98.58 
RS (0ee) 1.01 1.01 97.98 
 
 
Table 5.9. Solubility of 4-hydroxy-2-pyrrolidone in isopropanol at  5 oC 
 R (wt%) S (wt%) IPA (wt%) 
100ee 0.73 0 99.27 
75ee 1.03 0.15 98.82 
50ee 1.14 0.38 98.48 
40ee 0.82 0.35 98.83 
20ee 0.71 0.47 98.82 
RS (0ee) 0.73 0.73 98.54 
 
 The ternary phase diagram was plotted using the above solubility data as shown in 
Figure 5.5. It is confirmed that 4-hydroxy-2-pyrrolidone exists as a conglomerate during 
the studied temperature range 5 - 40 oC as the shape of the ternary phase diagram keeps 
unchanged with the characteristic of a conglomerate forming system. The transformation 
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of conglomerate to racemic compound is not uncommon (Collet et al., 1980; Houllemare-









5.3.1.2  Metastable zone width (MSZW) 
 The corresponding metastable zone widths of different enantiomeric compositions 
(R-, RS-, 20%ee, 25%ee, 40%ee, 50%ee and 75%ee) under different cooling rates 1, 5, 
and 10 oC/h are given in Figures (5.5 – 5.11). The metastable zone widths were 
determined using FBRM and validated by PVM images. The maximum allowable 
supersaturation was expressed in terms of the maximum allowable undercooling (Tdissolution 




















Figure 5.5 Experimental metastable zone widths of pure R-4-hydroxy-2-pyrrolidone in 























Figure 5.6 Experimental metastable zone widths of RS-4-hydroxy-2-pyrrolidone in IPA 






















Figure 5.7 Experimental metastable zone widths of R-20%ee-4-hydroxy-2-pyrrolidone in 


















Cooling rate = 10 ºC/hr
Cooling rate = 5 ºC/hr
Cooling rate = 1 ºC/hr
Figure 5.8 Experimental metastable zone widths of R-25%ee-4-hydroxy-2-pyrrolidone in 





















Cooling rate = 10 ºC/hr
Cooling rate = 5 ºC/hr
Cooling rate = 1 ºC/hr
 
 
Figure 5.9 Experimental metastable zone widths of R-40%ee-4-hydroxy-2-pyrrolidone in 

























Cooling rate = 10 ºC/hr
Cooling rate = 5 ºC/hr
Cooling rate = 1 ºC/hr
 
Figure 5.10 Experimental metastable zone widths of R-50%ee-4-hydroxy-2-pyrrolidone 



















Cooling rate = 10 ºC/hr
Cooling rate = 5 ºC/hr
Cooling rate = 1 ºC/hr
 
 
Figure 5.11 Experimental metastable zone widths of R-75%ee-4-hydroxy-2-pyrrolidone 
in IPA for different cooling rates 
 
 Figures (5.5 – 5.11) show that a range of 7 - 18 oC metastable zone widths could be 
used if direct crystallization is applied to 4-hydroxy-2-pyrrolidone in isopropanol. These 
values are big enough to be of great practical relevance.  It is clear that the maximum 
allowable undercoolings greatly depend on the saturation temperatures as well as the 
cooling rates. When the cooling rate was constant, the metastable zone widths became 
narrower at higher saturation temperatures. This is consistent with the classical nucleation 
theory (Mullin, 2001). At higher temperature, the saturated solute concentration is higher. 
 116
Therefore, there would be more molecules and more chances for molecule additions to the 
critical cluster which would result in faster nucleation and subsequent growth of the 
observable nucleus.   
 However, it is most interesting to notice that there was no significant difference of 
MSZWs under the similar operating conditions when the enantiomeric excess changed 
from 0 (RS) to 100% (pure R) and the corresponding solubility decreased almost 50%.  
This could be one of the characteristics of a conglomerate forming system.  In solution, 
although the physical properties of both R and S are the same, the two enantiomers 
respond separately to form crystal nucleus, which means that the MSZW will be 
dependent on only concentration of isolated enantiomer. The following relationship of 
MSZWs with cooling rates will give some further quantitative analysis. 
 As discussed by Mullin (2001), the empirical power law is widely used to describe 
the primary nucleation in industrial crystallizer. 
 
n
n ckJ max∆=                                                                                (5.8) 
where J is the primary nucleation rate, kn is the nucleation rate constant and ∆cmax is the 
maximum allowable supersaturation (MSZW).   
 In the mean time, the nucleation rate can be derived from classical nucleation 
relationship ( Nyvlt, 1968) in terms of cooling rate q. 
 
dT
dCqJ *=                                                        (5.9) 
 The relationship of ∆cmax  and  ∆Tmax can be expressed as  
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 dT
dCTc *maxmax ∆=∆                                                                                 (5.10) 
 
 The above Equations (5.8 – 5.10) can be combined to get 
 
nkdT
dCnTnq log*log)1(loglog max +−+∆=                                                       (5.11) 
 This equation indicates that log q is linearly dependent on log ∆Tmax with a straight 
line of slope n. 
 Figures 5.12 and 5.13 present the relationship of log ∆Tmax with log q for RS and 
20ee% respectively. Good linearity can be observed for most of the data points.  Indeed, 
the regressed n for RS is in the range of 5.3 - 7.4. A slope of circa 7-19 could cover most 
of the other data sets, namely for pure R (n=11-19), 20%ee(R) (n=10-19), 25%ee(R) 
(n=10-18), 40%ee(R) (n=7-14), 50%ee(R) (n=7-14) and 75%ee(R) (8-16). This is again 
consistent with the previous observations that MSZW is independent of enantiomeric 
excess. 
  It is obvious that the apparent primary nucleation order of RS is generally smaller 
than those of other cases, especially pure R, 20%ee and 25%ee. As discussed in Chapter 4, 
for conglomerate system, the two isomers respond separately to form crystal nucleus. 
Therefore, for solutions of pure R or with certain R enantiomeric excess, it is expected 
only R form nucleus at least during the very initial  period and ∆Tmax is only related with 
supersaturation of R.  But for RS, two isomers should form nucleus at the same time and 
the contribution to the apparent nucleation rate is the addition of both R and S isomers. If 






n n∆=                                                         (5.12) 
  The nucleation rate constant kn can be considered the same for both R and S 
enantiomers. Therefore, the above equation indicates the apparent primary nucleation 
order n for pure R or with certain ee% should be smaller than that of RS solution, which is 
what was exactly observed.  
  It is also very interesting to note that small apparent primary nucleation order n 
(circa 7-8) was also observed in several cases for (R) 40 ee% -75ee%. This could be due 
to some extent of nucleation of S, which could initiate itself or could be induced by 
spontaneous nucleation of R when the supersaturation surpasses a critical level. 
  Actually, when high supersaturations within the metastable zone are used, some 
conglomerates will form crystals that contain domains of both lattices in a single crystal, 
which means that the enantiomerically pure seed could nucleate the other enantiomer at its 
surface. One typical example is in the synthesis of agrochemical paclobutrazol where 
resolution of a racemic chiral ketone is involved (Black et al., 1989; Collins et al., 1997). 
Only when very low supersaturation (1 oC undercooling) was used, did the effects of 
nucleating the unwanted isomer disappear to give the product with a high optical purity. 
This phenomenon at higher supersaturation was also observed on β-phenylglyceric acid 
(Furberg and Hassel, 1950). 
  Hongo et.al. (1981) showed the stability of supersaturated DL-serine m-xylene-4-
sulfonate dehydrate and identified two metastable regions where the supersaturation was 
relatively unstable in the second region. In the studies of nuclei breeding from a chiral 
crystal seed of NaClO3 (Denk and Botsaris, 1972; Kondepudi et al., 1990, 1993, 1995; 
McBride and Carte, 1991; Yokota and Toyokura, 1992;  Qian and Botsaris, 1997, 1998), it 
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was found that at low supersaturation all nuclei were of the same chirality. At relatively 
high supercooling, but still lower than the critical value for spontaneous nucleation, many 
nuclei with opposite chirality to that of seed were formed. The similar findings were 
reported by Davey et al. (1990) in triazolylketone chiral crystallization. The current 
experimental findings and those found in the literature, all of these suggest that even 
within the metastable zone, the supersaturation of target enantiomer is tightly associated 
with nucleation of its opposite enantiomer. This kind of nucleation is unwanted and should 
be inhibited in the preferential crystallization application. Chapter 7 will discuss the 
strategy to control the supersaturation within a critical range to prevent this undesired 
nucleation.  























Figure 5.12  Relationship of log MSZW (log ∆Tmax) with cooling rate (log q) for RS-4-
hydroxy-2-pyrrolidone 
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Figure 5.13 Relationship of log MSZW (log ∆Tmax) with cooling rate (log q) for 20% ee-
R-4-hydroxy-2-pyrrolidone 
 
5.3.2 Solubility and metastable zone width of N-methylephedrine in the mixture of 
isopropanol and water (Vol 1:3) 
 
5.3.2.1 Solubility 
The solubilities of N-methylephedrine with composition (+) 25% ee, 50% ee, 75% 
ee, pure (+)- and (±)-ME in the mixture of isopropanol and water (Vol = 1:3) are listed in 





Table 5.10.  Solubility of N-methylephedrine in the mixture of isopropanol and water 
(Vol = 1:3) 
 




























































Figure 5.14 Solubility of N-methylephedrine with different enantiomeric excess 
in the mixture of isopropanol and water (Vol 1:3) 
 
The solubility curves can be regressed to obtain the following solubility equations. 
 
Pure_(+)_N_ME:             C = 0.0025T2 - 0.0379T + 1.1465           (5.13) 
(±)_N_ME:                        C = 0.0081T2 - 0.0891T + 2.3685               (5.14) 
25%ee_(+)_N_ME:         C = 0.0075T2 - 0.1721T + 2.8635            (5.15) 
50%ee_(+)_N_ME:        C = 0.0045T2 - 0.0871T + 1.9285            (5.16) 
75%ee_(+)_N_ME:        C = 0.0036T2 - 0.0736T + 1.641              (5.17) 
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 The solubilities of (+)-, (±)-, 25% ee, 50% ee, and 75% ee (+)- N-methylephedrine in 
isopropanol and water properly increase with temperature over the range of 15 – 30 oC.  
The solubility ratio of (±)- to (+)-ME is between 2.5 and 3.1 in the current temperature 
range. It is bigger than that of 4-hydroxy-2-pyrrolidone. Although the solubility ratio of 
(±)- to (+)-ME also decreases from high temperature to low one, this system appears more 
difficult to purify using preferential crystallization technique than 4-hydroxy-2-
pyrrolidone system as the solubility ratio of (±)- to (+)-ME is higher (Jacques et al., 1994).   
 Figure 5.15 shows the ternary phase diagram. Like 4-hydroxy-2-pyrrolidone in 
isopropanol, N-methylephedrine exists as a conglomerate in the chosen solvent during the 
studied temperature range 15-30 oC because the shape of its ternary phase diagram 








Figure 5.15 Ternary phase diagram of  N-methylephedrine in the mixture of isopropanol 
and water (Vol 1:3) 
 
5.3.2.2 Metastable zone width (MSZW) 
 The corresponding metastable zone widths measurements are given in Figure 5.16. 
The metastable zone widths were determined using FBRM and PVM. The maximum 
allowable supersaturation was expressed in terms of the maximum allowable undercooling 
(Tdissolution – Tnucleation).  When the cooling rate was constant, the metastable zone widths 
became narrower at higher saturation temperatures.  
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 Similar to that of 4-hydroxy-2-pyrrolidone system, the MSZW of N-
methylephedrine in water and isopropanol is also independent of enantiomer excess. This 
























Figure 5.16  Experimental metastable zone widths of N-methylephedrine in the mixture of 










Cooling rate = 2 oC/hr 
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5.3.3 Solubility and metastable zone width of propranolol hydrochloride in the 
mixture of methanol and isopropanol (Vol 1:5) 
5.3.3.1 Solubility 
The solubilities of  propranolol hydrochloride with composition (R) 30% ee, 50%ee, 
70% ee, pure R- and RS- in the mixture of  methanol and  isopropanol (Vol=1:5) are listed 
in Table 5.11 and shown in Figure 5.17, respectively.  
 
 
Table 5.11. Solubility of propranolol hydrochloride in the mixture of methanol and 
isopropanol (Vol = 1:5) 
 







































































Figure 5.17 Solubility of propranolol hydrochloride with different enantiomeric excess 
in the mixture of methanol and isopropanol (Vol 1:5) 
  
 
The solubility curves can be regressed to obtain the following solubility equations. 
 
 
Pure_R_PN_Cl:            C = 0.0004T2 + 0.0047T + 0.5092               (5.18) 
 
RS_PN_Cl:                    C = 0.0008T2 + 0.0077T + 0.636                (5.19) 
 
30%ee_R_PN_Cl:         C = 0.0002T2 + 0.0296T + 0.3166               (5.20) 
 
50%ee_R_PN_Cl:         C = 0.0001T2 + 0.0281T + 0.3078               (5.21) 
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70%ee_R_PN_Cl:         C = 0.0002T2 + 0.0196T + 0.3731              (5.22) 
 
As shown in Figure 5.17, the solubilities of (R)-, (RS)-, 30% ee,  50% ee, and 70% 
ee propranolol hydrochloride  in the mixture of methanol and isopropanol  all properly   
increase with temperature over the range of 12 – 35 oC. The chosen solvent is suitable for 
crystallization operation. The mixture of methanol and acetone also gave good solubility 
curves, however, it was found that propranolol hydrochloride was easily decomposed in 
the presence of acetone at ambient temperature (Wang et al, 2002).   
 Figure 5.17 also shows that the solubilities increase with decreasing ee. The excess 
enantiomer could be therefore separated by direct crystallization. This is especially 
meaningful to get pure enantiomer if partially resolved solutions can be supplied by other 
purification processes such as asymmetric synthesis, simulated moving bed (SMB) 






Figure 5.18  The ternary phase diagram of  propranolol hydrochloride in the mixture of 
methanol and isopropanol (Vol = 1:5) 
 
 The ternary phase diagram is shown in Figure 5.18. It keeps as a simple eutectic 
system consisting of two single saturation curves in the studied temperature range. This is 
consistent with the binary melting phase diagram in Chapter 4 as well as that reported by 
Neau et al. (1993). Compared to normal racemic compound systems, it is a special case, 
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which has the most favorable characteristics of ternary solubility diagram to conduct 
direct crystallization. This will be discussed in detail in Chapter 8. 
 
5.3.3.2 Metastable zone 
 Figure 5.19 shows the measured metastable zone widths of (R)- and (RS)-
propranolol hydrochloride in the mixture of methanol and isopropanol (Vol = 1:5). The 



















Figure 5.19 Experimental metastable zone widths of R- and RS-propranolol  
hydrochloride in the mixture of methanol and isopropanol (Vol = 1:5). 
 
 
 However, unlike the conglomerates of 4-hydroxy-2-pyrrolidone and N-
methylephedrine, which have similar MSZWs for the pure enantiomer and its 
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corresponding racemic mixture, the metastable zone widths of pure (R)- and (RS)-
propranolol hydrochloride are quite different. Under the same saturated temperature, (RS)- 
gave a wider MSZW than that of pure (R)-enantiomer, although the solubilities of RS 
were larger than R. This interesting phenomenon could be explained from the arrangement 
of two enantiomer molecules in the crystal lattice for a racemic compound and classical 
nucleation theory. 
 As for a racemic compound, the two enantiomers co-crystallize to form a mixed 
crystal containing both enantiomers in a well-defined arrangement within the crystal 
lattice in equal proportions (Figure 4.1b). According to the classical nucleation theory, the 
MSZW of RS will be dependent on the concentrations of both enantiomers. Since the 
solubility of RS is not definitely related to that of pure enantiomers and it can be either 
greater or smaller than that of pure-enantiomer (Jacques et al., 1994), three cases could 
arise. 
  (i) The solubility ratio α of racemate to pure enantiomer is smaller than 1 (α < 1). 
Because the solubility of racemate is smaller than that of pure enantiomer, it is readily to 
expect that the MSZW of racemate is wider than that of pure enantiomer as less solute 
molecules are in the solution to undergo collision to form embryos and develop into 
nuclei. This case is widely observed in many racemic compound systems such as 
ketoprofen (Lu and Ching, 2006). 
(ii)  The solubility of racemate is bigger than that of pure enantiomer, but the ratio 
is smaller than 2 (1 < α < 2). In this case, although more molecules are in the solution, the 
R-molecules and S-molecules are required to arrange in equal quantities to form RS 
racemate. Therefore, the effective concentration to form nuclei is actually only half the 
total concentration. Since α < 2, the effective R concentration (R:S = 0.5:0.5) is smaller 
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than that of pure enantiomer. Therefore, the MSZW of racemate should be bigger than that 
of pure enantiomer. This is true for current studied racemic compound propranolol 
hydrochloride, where the solubility ratio of RS to R is bigger than 1 but less than 2 (Table 
5.11 and Figure 5.17). The similar phenomenon was also observed in the mandelic acid 
system ((Perlberg et al., 2002, 2003). The solubility of (DL)-mandelic acid is smaller than 
twice that of the (D)-mandelic acid approximately at certain temperature ranges of (0-25 
and 37-60 oC). The corresponding MSZW of (DL)-mandelic acid is bigger than that of 
(D)-mandelic acid. This is unlike the above conglomerate systems where two enantiomers 
are not associated in solution and the MSZW is independent of enantiomeric excess. 
(iii)  The solubility of racemate is bigger than twice that of pure enantiomer (α > 
2). As mentioned above, the effective R concentration is bigger than that of pure 
enantiomer. In this case, the MSZW of racemate should be smaller than that of pure 
enantiomer. This was also observed in the mandelic acid system (Perlberg et al., 2002, 
2003). The solubilities of (DL)-mandelic acid are bigger than twice that of the (D)-
mandelic acid approximately at certain temperature range of 23-36 oC. The corresponding 
MSZW of (DL)-mandelic acid is smaller than that of (D)-mandelic acid. 
  The above analysis indicates a cut value of 2 of α is apparently related to the 
MSZW in racemic compound systems. This could be used as a new additional criterion to 
determine whether a racemate crystallizes as a racemic compound or conglomerate 
crystal. It might be particularly helpful when such a special racemic compound is met 
which shows quite similar other properties (for example, binary/ternary phase diagram of 
propranolol hydrochloride is similar to that of a conglomerate).  
 
5.3.4 Solubility and metastable zone width of atenolol in acetone 
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The solubility and metastable zone width of atenolol in acetone were measured in a 
25 ml jacketed crystallizer with magnetic stirring.  A solubility of 0.5 (wt%) was  always 
obtained at 33 oC for different ee.  Figure 5.20 presents its ternary phase diagram and the 
metastable zone widths are listed in Table 5.12. MSZWs of (R)- are approximately equal 
to those of (RS)-atenolol at the same saturated temperature. All of these are consistent 
with the characteristics of an ideal pseudoracemate. 
  
 















33 27.4 27.6 
30 28.3 28.3 




 The solubilities, metastable zone widths and ternary phase diagrams at different 
enantiomer excess (ee) for four racemates, namely 4-hydroxy-2-pyrrolidone in 
isopropanol , N-methylephedrine in the mixture of isopropanol and water (Vol 1:3), 
propranolol hydrochloride in the mixture of methanol and isopropanol (Vol = 1:5), and 
atenolol in acetone were measured by integrating Lasentec FBRM and PVM.  All the 
chosen solvents were found good for cooling crystallization in the studied temperature 
ranges. 
4-hydroxy-2-pyrrolidone and N-methylephedrine show the similar characteristics 
of solubility as conglomerate systems, i.e., the solubilities decrease with increased ee. But 
the solubility ratio α of (RS)- to (R)-4-hydroxy-2-pyrrolidone is closer than that of N-
methylephedrine to the theoretical value 2 for an ideal conglomerate solution. The 
metastable zone widths of both studied conglomerates were found independent of 
enantiomer excess and the data at different cooling rates were in good agreement with 
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classical nucleation theory. That is consistent with the characteristic of two enantiomers 
forming separate crystals for a racemic conglomerate. The different orders of primary 
nucleation rate at different enantiomeric excess indicate there may exist critical 
supersaturation beyond which the nucleation of opposite isomer could occur. This appears 
to be the first detailed experimental investigation of metastable zone in conglomerate 
system and its implications of supersaturation control of preferential crystallization 
process.  
For the racemic compound propranolol hydrochloride, its solubility characteristics 
and ternary phase diagram are quite similar to that of a conglomerate, but its metastable 
zone width was obviously dependent on the enantiomer excess. A cut value 2 of solubility 
ratio α was found to be correlated with the MSZW differences between racemate and pure 
enantiomers. This reflects the properties of the evenly distributed molecules in the crystal 
lattice of a racemic compound. It suggests that metastable zone width can be used as an 
additional characteristic to identify these two kinds of racemates.  
The solubility curve, ternary phase diagram and metastable zone of atenolol show 






Part of the results in this Chapter have been reported on Journal of Chemical and 
Engineering Data, 48, pp.1092-1098. 2003, Chirality, 14, pp.318-324, 2002 and Chirality, 
16, pp.220-227. 2004.  
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CHAPTER 6   CRYSTALLIZATION KINETICS 




As discussed in Chapter 1, the supersaturation of the target enantiomer should be 
carefully controlled to inhibit the spontaneous nucleation of the undesired isomer. In 
designing operation conditions for the preferential crystallization, the kinetic data such as 
crystal growth rate G, and nucleation rate B, are necessary. In this Chapter, the batch 
dynamic method was employed and developed to measure the crystallization kinetics of 4-
hydroxy-2-pyrrolidone in isopropanol.  
 
6.2 Characterization of crystallization kinetics 
6.2.1 Steady state method 
There are two basic categories of techniques to evaluate crystallization kinetics, 
namely, steady state method and dynamic method. For the former one, the most famous is 
the classical continuous method proposed by Randolph and Larson (1962, 1988) with 
mixed-suspension, mixed-product-removal (MSMPR) crystallizer.  
In a MSMPR crystallizer,  
 
)/exp( τGLnn o −=                                                                  (6.1)                   
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τGLnn o /lnln −=                                                                  (6.2) 
GnB o=                                                                          (6.3) 
In a semilog plot, the crystal population density ln n can be plotted with L to obtain 
the intercept no and slope –1/Gτ (τ is the residence time). Therefore, the crystal growth 
rate G and nucleation rate B are readily to get. However, this steady state methodology is 
laborious and time consuming. For expensive pharmaceuticals and fine chemicals, it is not 
practical to use a large amount of chemicals required for this continuous scale 
experimental set up. Moreover, there is experimental evidence to show that the steady-
state kinetic parameters do not correctly describe unsteady-state operations partly due to 
the underlying assumptions such as the size-independent growth rates (Tadayyon  et al., 
2002). 
 
6.2.2 Dynamic method 
Dynamic method is an alternative approach for the estimation of kinetics using 
unsteady-state data from batch experiments. Batch crystallizer is easier to operate and less 
time-consuming. More importantly, it is obvious that many variables such as temperature, 
CSD, concentration, and crystal suspension density are all changing with time in one batch 
crystallization operation. A single batch run will provide rich information over a wide 
range of operating conditions. However, as all the variables in the batch crystallizers are 
changing with time and crystal size, leading to hyperbolic partial differential equations 
(PDEs), these significantly increase the computational complexity of dynamic methods. 
These equations either need to be solved by transformation to an ordinary differential 
equations ODE or by use of an appropriate numerical technique. 
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Various dynamic techniques have been reported with batch crystallizations. These 
include thermal response technique (Omran and King, 1974) and mass balance approach 
(Halfon and Kaliaguine, 1976; Garside et al., 1982). But most of the proposed methods 
using batch crystallization process are based on crystal size distribution (CSD) analysis 
(Garside and Jancic, 1976; Way, 1985; Tavare and Garside, 1986; Nyvlt, 1989; 
Witkowski et al., 1990; Qiu and Rasmuson, 1991, 1994; Farrell and Tsai,1994; Yokota et 
al., 2000; Garside et al., 2002; Zhang and Rohani, 2003; Hu et al., 2004).  
The moment method converts the population balance to a set of ODEs. The kth 




dLnLu kk                                             (6.4)       
The kinetic parameters can be expressed in terms of moments with respect to size 

















                                                 (6.7) 
 
It was shown (Tavare and Garside, 1986) that a large scatter of the parameter 
estimates resulting from moment analysis, compared to actual values, was identified with 
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tail effects. The errors in the measurement of experimental responses toward the tail ends 
have significant influence on the moment evaluations and hence the parameter estimates. 
In principle, the most accurate approach for the estimation of kinetic parameters is 
accomplished by using a nonlinear optimization algorithm, a full mathematical description 
of a batch crystallizer, and reliable experimental data. A lot of efforts have been put in this 
area (Nyvlt, 1989; Witkowski et al., 1990; Qiu and Rasmuson, 1991, 1994; Farrell and 
Tsai, 1994; Yokota et al., 2000; Zhang and Rohani, 2003; Hu et al., 2004). A major 
advantage of this method is that the estimation of growth and nucleation rates and their 
kinetic parameters in the mathematical method is performed simultaneously. The kinetic 
constants in the mathematical model are adjusted by the optimization algorithm to 
minimize an objective function.  
Another method available is the so called s-plane analysis (Tavare and Garside, 
1986). This method is based on population balances for discrete parts of the crystal size 
distribution. The change in number of crystals in discrete parts of the particle size 
distribution for consecutive samples can give an estimate of the growth rate of the crystals 
in this size range.  
The crystallization kinetics measurements in preferential crystallization process are 
rarely reported. Elsner et al (2003, 2005) recently attempted to use moment method to 
determine crystallization kinetics of L-/D-threonine in water but found it was difficult to 
predict nucleation rate. 
 
6.3 s-Plane analysis 
The s-plane analysis proposed by Tavare and Garside is a simple and yet reliable 
method of extracting both crystal nucleation and growth kinetics from the population 
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curves obtained during batch crystallization (Tavare and Garside, 1986; Tavare, 1995; 
Jacobsen et al., 1998; Myerson and Ginde, 2002). This method is based on population 
balances for discrete parts of the crystal size distribution. We used this technique to 
estimate crystal nucleation and growth kinetics.  For batch crystallization, assuming the 
crystal growth is size independent, and since the crystal suspension density used is less 
than 5% and the solution is well mixed, it is acceptable to assume that no crystal breakage 








n                                                                                   (6.8) 
 
The boundary conditions for the nuclei population density can be represented by 
the relation 
 
B = noG                                                                 (6.9) 
The experimentally measured population density n(t,L) can be converted into 
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stnd                                       (6.11) 
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In the above equation 6.11, the crystal growth rate G and the initial population 
density n(0) are functions of time. However, in a small time interval ∆t, they can be 
assumed to be constant and therefore the resulting parameters will have an average value 
over this interval. In this case, using initial boundary conditions, the population balance 




stnd                                             (6.12) 





∆ ),(),(                                                  (6.13) 
 
where  
12 ttt −=∆                                                                (6.14) 
),(),(),( 12 stnstntsn −=∆                                      (6.15) 
                       
     (6.16)  
 
Over an optimal range of the Laplace transform variable, a plot of  ttsn ∆∆ /),(  
versus ),( stns  should give a straight line with slope equal to - G  and an intercept B . 
Therefore, the above equation can be used to determine the crystal nucleation and growth 
rates from a pair of population density curves at two times ∆t interval.  
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The estimated nucleation B and growth rate G can then be correlated with the 
degree of supersaturation ∆c and slurry density MT using the widely used power law 
expressions in conventional crystallization (Randolph and Larson, 1988; Tavare, 1995; 
Mullin, 2001). 
g




bb MGRTEkB )/exp(−=                                                               (6.18) 
 
6.4 Size-dependent growth 
In the previous deduction procedure, it was assumed that all crystals grow at the 
same rate. However, there is some evidence that crystals of different sizes may grow at 
different rates even though they are under the same driving force (supersaturation). This is 
called size-dependent crystal growth (Zumstein and Rousseau, 1987, 1989; Randolph and 
Larson, 1988). This phenomenon of growth dispersion could be due to various reasons.  
The growth rate of large crystals could be increased because of an increase in their fluid 
settling velocity, but this can not explain some observed large differences of growth rate 
among crystals of different sizes in the same suspension. Berglund and Larson (1982) 
showed that larger crystals had an inherent higher growth rate. Garside et al. (2002) 
suggested that growth rate appears to depend on the origin of nuclei.  In particular, it is not 
unusual that many organic crystals growth rates are size dependent (Kougoulos et al., 
2005).   
Abegg et al.(1968) had shown that the following form can be used to fit most data 
for the case of size-dependent crystal growth, where G0 is size- independent crystal 
growth rate and α is experimentally determined constants (O’Dell and Rousseau,1978). 
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n α                                                              (6.20) 
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∫∞ −=
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2 )exp(),(),( dLsLLLtnstn                                                           (6.22) 
Similarly, over a small time interval ∆t, G0 and n(0) can be assumed to be constant 
and therefore the resulting parameters will have an average value over this time interval. 
Using initial boundary conditions, the population balance equation can be transformed to 
 a series of multiple-variable linear equations. These equations can be solved to get 









1 α                                                 (6.23) 
 
6.5 Experimental  
A total of eight batch experiments were carried out to measure the crystallization 
kinetics with 4-hydroxy-2-pyrrolidone in isopropanol using the experimental set-up 
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described in Chapter 3 (Figure 3.9). Four batch experiments were for R-4-hydroxy-2-
pyrrolidone and another four batch experiments were for S-4-hydroxy-2-pyrrolidone. 
Typical loads of crystallizer were 13.89 g R-4-hydroxy-2-pyrrolidone and 800 ml 
isopropanol. The operation temperature range was 5-36 oC. Circa 8-15 ml samples were 
taken every 15-83 minutes for crystal size distribution, crystal slurry concentration, and 
solute concentration analyses. The solution concentrations were calculated using mass 
balance. The crystal size distribution was measured using a Malvern Mastersizer 2000 
with a Hydro 2000µP dispersion cell unit. Analytical n-hexane, in which 4-hydroxy-2-
pyrrolidone is almost insoluble, was used as the liquid dispersion medium.  
 
6.6 Results: Crystal nucleation and growth kinetics 
6.6.1 Crystal suspension density and supersaturation 
Four batches of experiment were performed to measure the crystal nucleation and 
growth kinetics of R-4-hydroxy-2-pyrrolidone. As mentioned in the experimental section, 
in each run, a series of samples were taken from the crystallizer to analyze the crystal 
suspension density MT, the solute concentration c and the crystal size distribution. The 
obtained MT and c are listed in Table 6.1 to Table 6.4. The solubility data c* of 4-
hydroxy-2-pyrrolidone at each temperature have been measured in Chapter 5. 
Accordingly, the supersaturation ∆c were calculated and listed in the tables. The 
corresponding concentration profiles of crystal suspension density MT, solute 
concentration c and supersaturation ∆c are shown in Figure 6.1 to Figure 6.4. In all of the 
four batch runs, the solute concentration c decreased smoothly and the crystal suspension 
density MT increased accordingly. The change of supersaturation ∆c was moderate and 
this supports the constant assumption over a small time interval ∆t. Moreover, the 
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measured crystal suspension density MT and solute concentration c held a good mass 
balance for the batch crystallization system.  













Figure 6.1 Concentration profiles of crystal suspension density MT, solute concentration c 
and supersaturation ∆c in Run1 
 
∆t (min) MT(g/ml) c (g/g solvent)  T(oC) c*(g/g solvent) ∆c (g/g solvent)
0 0.00228 0.0176 19.7 0.011610 0.004790
36 0.00347 0.0161 16.8 0.010548 0.004452
20 0.00472 0.0139 10.7 0.009713 0.004187
18 0.00511 0.0134 9.2 0.009284 0.004116
17 0.00624 0.0120 8.1 0.008983 0.003017
29 0.00673 0.0114 5.8 0.008389 0.003011
28 0.00708 0.0109 4.4 0.008050 0.002850
18 0.00799 0.00975 2.7 0.007659 0.002091
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Figure 6.2 Concentration profiles of crystal suspension density MT, solute concentration c 





∆t(min) MT(g/ml) C (g/g solvent)  T(oC) C*(g/g solvent) 
 
∆C (g/g solvent) 
0 0.00177 0.0183 22.5 0.014031 0.004269
21 0.00223 0.0177 20.8 0.013293 0.004407
33 0.00392 0.0156 18.2 0.012245 0.003355
33 0.00502 0.0142 15.5 0.011254 0.002946
46 0.00737 0.0112 11.8 0.010044 0.001156
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Figure 6.3 Concentration profiles of crystal suspension density MT, solute concentration c 






∆t(min) MT(g/ml) C (g/g solvent)  T(oC) C*(g/g solvent) 
 
∆C (g/g solvent) 
0 0.00230 0.017 20.1 0.013001 0.003999
55 0.00320 0.0158 18.2 0.012245 0.003555
39 0.0041 0.0147 16.9 0.011756 0.002944
42 0.00534 0.0131 15.5 0.011254 0.001846
83 0.00612 0.0121 12.8 0.010355 0.001745
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Figure 6. 4 Concentration profiles of crystal suspension density MT, solute concentration 





∆t(min) MT(g/ml) C (g/g solvent)  T(oC) C*(g/g solvent) 
 
∆C (g/g solvent) 
0 0.00234 0.0169 22.1 0.013853 0.003047
54 0.00319 0.0159 20.1 0.013001 0.002899
61 0.00384 0.0150 13.4 0.010548 0.004452
67 0.00472 0.0139 10.7 0.009713 0.004187
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time 3 (33 mins later)
6.6.2 Crystal size distribution (CSD) 
The crystal size distribution was measured using a Malvern Mastersizer 2000 with 
a Hydro 2000µP dispersion cell unit. Fig 6.5 shows typical crystal distribution of two 
samples collected at two different time in Run 2. The crystal growth can be observed as 
the volume percentage distribution shifts to the right side of larger size.  
 
 
           Figure 6.5 Typical crystal size distribution in kinetic measurement 
 
Using the definition of population density n (Eq 6.24), Eq 6.26 can be obtained to 




dNn =                                                                (6.24) 
The number of crystals in the size range is calculated from the mass and shape 












∆=∆=∆                                        (6.25) 












∆= 3ρ                                           (6.26) 
where iL  is the average crystal size in the given range.  
Figure 6.6 shows the typical population density functions versus particle size 
calculated from crystal size distribution data shown in Figure 6.5. This figure illustrates 
the characteristic appearance of CSD from a batch crystallizer (Tarvare, 1995). They are 
quite different from those shown in continuous MSMPR crystallizer, which are normally 
straight lines on semi-log plot.  
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time 3 (33 mins later)
 
Figure 6.6 Typical crystal population density distribution 
 
6.6.3 s-Plane analysis on the measured data 
The Laplace s-plane method described in section 6.3 was used here to estimate the 
crystal nucleation rate B and growth rate G. The advantage of Laplace method is to 
estimate model parameters in the Laplace transform domain rather than in the time 
domain. From Eq 6.10, it is clear that a suitable value of the Laplace transform variable s 
must be chosen to reduce the sensitivity to experimental errors.  As indicated by Tarvare 
(1995), if s is too small, the tail of the response will be heavily weighted. On the other 
hand, if s is too big, too much emphasis will be given to the front portion of the response. 
In either case, a poor estimate of the weighted moments will result. There should be an 
optimum value of s, which lies between these two limits. The s-plane analysis described 
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by Tavare and Garside (1986) and Tavare (1995) showed that the limits on the Laplace 
transform parameter s used should be considered by sfL2 ≈ 1-2, where L2 is the population 
average size at time t2.  
Once s is decided, a fix number of points are chosen over this range s at regular 
intervals. Here 50 points were used. No further improvement can be obtained with more 
data points.  For each value of s, the Laplace transformed population densities can be 
calculated as 
 
∑∫ ∆−=−= ∞ LsLLtndLsLLtnstn )exp(),()exp(),(),( 1
0





22                         (6.27) 
The s-plane analysis was performed for 50 equally spaced s-values. The results of 
analysis of two typical sets of data from Run2 and Run3 are shown in Figure 6.7 to Figure 




Figure 6.7  s-plane analysis of data in Fig 6.6.   
sL=0.1, G=0.37 µm/min, B=8.1×104 #/min liter solvent 
 















y = - 0.37*x + 8.1e+004
data
   linear regression, sL=0.1
),( stns , #/µm liter solvent
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Figure 6.8  s-plane analysis of data in Fig 6.6, 
 sL=1,  G=0.41 µm/min, B=8.2×104 #/min liter solvent 
 
 
















y = - 0.41*x + 8.2e+004
data 
   Regression, sL=1 
),( stns , #/µm liter solvent
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),( stns , #/µm liter solvent 
 
Figure 6.9 Typical s plane analysis to estimate crystal nucleation and growth rates in     




),( stns , #/µm liter solvent 
 
Figure 6.10.  s plane analysis to estimate crystal nucleation and growth rates in Run3. 
sL=1, G=0.32 µm/min, B=2.5×104 #/min liter solvent 
 
Our analysis showed that sfL2 ≈ 0.05-0.1 was most suitable, which gave better 
linear regression with growth rates similar to the independent moment method. This is 
consistent with the later findings from Garside’s group (Jacobsen et al., 1998).  
From linear regression, G and B can be obtained from the slope and intercept 
respectively. Table 6.5 lists the estimated crystal nucleation rate B and growth rate G from 
the four kinetic experiments. 
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Table 6.5 Estimated crystal nucleation rate B and growth rate G with s plane analysis 














Run1 0.18 1.20E+04 0.004572 0.00288 291.3
 0.47 7.70E+04 0.004152 0.00492 282.9
 0.45 6.50E+04 0.003014 0.00649 279.9
 0.11 1.60E+04 0.002471 0.00754 276.6
Run2 0.40 5.70E+04 0.004338 0.00200 294.6
 0.37 8.10E+04 0.003881 0.00308 292.5
 0.16 1.70E+03 0.002051 0.00620 286.6
Run3 0.51 3.70E+04 0.003777 0.00275 292.2
 0.27 2.50E+04 0.003250 0.00365 290.6
 0.10 1.40E+04 0.002045 0.00573 287.2
Run 4 0.26 9.90E+03 0.002108 0.00406 292.2
 0.26 3.00E+05 0.004320 0.00428 285.0
 
Regression of the data in Table 6.5 with linear least squares provided the following 
kinetic expressions for the crystal growth and nucleation of R- 4-hydroxy-2-pyrrolidone. 
 
47.09.16104.3 TMGB ×××=                                                     (6.28) 
35.15 )/15000exp(104.4 cRTG ∆×−××=                                (6.29) 
The observed nucleation power dependency 0.47 on the suspended crystal density 
is lower than those found in industrial inorganic crystallization process. This could be due 
to the relatively low crystal mass concentration used here. Another possibility is that the 
primary nucleation occurred especially in the case that the supersaturation was under 
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somewhat arbitrary control in the kinetic measurement experiments. The power 
dependency 1.9 on crystal growth rate is comparable to those found in literature (Tavare, 
1995; Garside et al., 2002). It appears that the nucleation rate dependency on the 
temperature could be ignored under present experimental conditions. 
The order of the growth rate with respect to supersaturation 1.35 is consistent to 
those reported. However, the relatively low activation energy 15 kJ/mol indicates that the 
crystal growth could be more likely to be diffusion controlled (Garside et al, 2002). 
The method proposed in Section 6.4 for size-dependent growth considerations 
(Equation 6.23) was applied to the experimental data. The obtained values α   were very 
small (circa 0.00036) or even negative. The crystal growth size dependency could be 
therefore negligible here.  
 
6.6.4.   Crystallization kinetics of S-4-hydroxy-2-pyrrolidone in isopropanol 
The same methodology has been used to estimate the crystal nucleation and 
growth kinetics of S-4-hydroxy-2-pyrrolidone in isopropanol. Table 6.6 lists the measured 
























Run1 0.86 1.20E+05 0.007790 0.00167 286.3
 0.78 7.00E+04 0.006965 0.00302 283.9
 0.41 4.10E+04 0.006291 0.00407 281.7
Run2 0.57 1.60E+04 0.007623 0.00120 280.2
 0.41 4.10E+04 0.005131 0.00416 274.8
 0.54 6.00E+04 0.004587 0.00480 273.6
Run3 0.53 5.80E+04 0.005311 0.00134 283.2
 0.28 8.00E+03 0.004700 0.00169 282.4
Run 4 0.2 6.00E+03 0.003885 0.00166 280.6
 0.1 2.00E+03 0.002841 0.00227 278.6
 
 
Regression of the data in Table 6.6 with linear least squares provided the following 
kinetic expressions for the crystal growth and nucleation of S- 4-hydroxy-2-pyrrolidone. It 
is not surprising to see that the results are in good agreement with that of its isomer. This 
is again consistent with the identical physical properties of two enantiomers (Collet et al., 
1980; Jacques et al., 1994). 
 
57.085.16104.4 TMGB ×××=                                                     (6.30) 





Eight batches of crystallization kinetics measurements have been performed to 
determine the crystal nucleation and growth kinetics of R- 4-hydroxy-2-pyrrolidone and S- 
4-hydroxy-2-pyrrolidone in isopropanol. The two enantiomers show similar characteristics 
in crystal nucleation and growth. The Laplace transform method was successfully 
developed and applied to the estimation of crystallization kinetics. A more suitable 
Laplace transform variable s range was employed for current crystallization system. The 
size dependence of crystal growth was found negligible with using modified s-plane 
approach. The crystal nucleation rate seems independent on the experimental temperature 
range. These crystallization kinetics data will be used to guide the supersaturation control 











Part of results in this chapter has been reported on Chemical Engineering Science (Vol 
61, pp.2406-2417. 2006) 
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CHAPTER 7   OPTIMAL OPERATION OF 





In Chapter 4 and Chapter 5, the thermodynamics properties of 4-hydroxy-2-
pyrrolidone in isopropanol have been studied. The crystal nucleation and growth kinetics 
have been measured in Chapter 6. With the mastery of these factors that control the rate 
difference of crystallization between the two enantiomers, this chapter combined and 
applied them in the optimal control and in-situ monitoring of preferential crystallization.  
From the thermodynamics issue, in order to avoid spontaneous nucleation of the 
undesired enantiomer, its upper limit of supersaturation is within its metastable zone. In 
this aspect, the solubility diagrams and supersaturation data are the thermodynamic basis 
for preferential crystallization for the racemic conglomerates (Jacques et al., 1994; Collet, 
1999).  
As mentioned in Chapter 1, it is also important to control the supersaturation of the 
target enantiomer. This can be elaborated in the following three aspects. (i) Firstly, this 
supersaturation should be kept at least within its metastable zone to prevent spontaneous 
nucleation of the target enantiomer. Most of the preferential crystallization processes are 
run with only a slight excess of the target enantiomer and the concentrations of the two 
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enantiomers are quite close. Considering the identical physical properties of the two 
isomers in solutions, the spontaneous nucleation is expected to occur simultaneously for 
both enantiomers, which implies that the spontaneous nucleation of the target enantiomer 
could initiate the nucleation of the unwanted isomer. This is the most important issue that 
should be avoided in the chiral resolution by direct crystallization (Jacques et al., 1994; 
Collet, 1999). 
 (ii)  Secondly, the supersaturation of the target product should be kept further 
lower than its spontaneous nucleation metastable zone. In Chapter 5, the metastable zone 
width measurement and nucleation analysis indicate that there exists a critical 
supersaturation level beyond which the nucleation of unwanted isomer could occur. In fact, 
if high supersaturations within the metastable zone are used, some conglomerates will 
form crystals that contain domains of both lattices in a single crystal, which means that the 
enantiomerically pure seed could nucleate the other enantiomer at its surface. One typical 
example is in the resolution of a racemic chiral ketone (Black et al., 1989; Collins et al., 
1997), where the nucleation of the unwanted  isomer disappeared only under very low 
supersaturation (1 oC undercooling). This phenomenon at higher supersaturation was also 
observed on β-phenylglyceric acid (Furberg and Hassel, 1950). In the studies of the 
stability of the supersaturation state of DL-serine m-xylene-4-sulfonate dehydrate (Hongo 
et al., 1981), two metastable regions were identified where the supersaturation was 
relatively unstable in the second region.  In the studies of nuclei breeding from a chiral 
crystal seed of NaClO3 (Denk and Botsaris, 1972; Kondepudi et al., 1990, 1993, 1995; 
Yokota and Toyokura, 1992; Qian and Botsaris, 1997, 1998; McBride and Carter, 1991), 
it was found that at low supersaturation all nuclei were of the same chirality. At relatively 
high supercooling, but still lower than the critical value for spontaneous nucleation, many 
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nuclei with opposite chirality to that of seed were formed. Davey et al. (1990) also showed 
the similar findings in triazolylketone chiral crystallization. The Embryos Coagulation 
Secondary Nucleation (ECSN) mechanism was applied to explanation of the phenomenon 
(Qian and Botsaris, 1998). Both the second metastable zone and critical supersaturation 
indicate the importance of controlling the supersaturation to a critical extent to inhibit the 
nucleation of the undesired enantiomer during preferential crystallization.  
(iii) Finally, the crystal size distribution (CSD) is an important factor not only for 
the production of high-quality products, but also for determining the efficiency of 
downstream operations, such as filtration and washing.  The advantages of controlling the 
supersaturation in batch crystallization have been extensively shown (Mullin and Nyvlt, 
1971; Jones and Mullin 1974; Rohani and Bourne, 1990). With good control of the 
supersaturation, larger crystals with narrower crystal size distribution can be obtained, 
which means product purity could be improved in the downstream filtration and washing 
process (Mersmann, 1995; Matthews and Rawlings, 1998; Rodriguez-Hornedo and 
Murphy, 1999). This is especially important for chiral purification (Courvoisier et al., 
2002, 2003).  Reflecting upon the above considerations, it is important to control the 
supersaturation of the target enantiomer in preferential crystallization process.  
Numerous efforts have been reported on optimal operation of batch crystallizer. 
Mullin and Nyvlt (1971), Jones(1974), and Jones and Mullin (1974) did the pioneer work 
both theoretically and experimentally. Mayrhofer and Nyvlt (1988) dealt with a general 
derivation of a theoretical cooling curve of a batch crystallizer. Rohani and Bourne (1990) 
derived a simplified optimal cooling curve by assuming constant nucleation and 
supersaturation. Various objectives have been chosen to optimize batch crystallization, 
such as mean crystal size and coefficient of variation (Chianese et al., 1984; Choong and 
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Smith, 2004; Costa and Maciel Filho, 2005), seed ratio (Bohlin and Rasmuson, 1992; 
Matthews and Rawlings, 1998; Chung et al., 1999), and even shape (Ma et al., 2002).  
In order to control the supersaturation, with the thermodynamics data, crystal 
nucleation and growth kinetics, the population balance model is needed to predict the 
concentration profiles (Randolph and Larson, 1988). The newly developed on-line 
monitoring techniques such as FBRM greatly facilitate these investigations (Barrett and 
Glennon, 2002; Elsner et al., 2005).  
 
7.2 Mathematic model in batch crystallization 
7.2.1 Population balance equation 
The classical population balance equation (Randolph and Larson, 1988) is normally 
employed to describe the complex crystallization process. For a batch crystallizer, some 
general assumptions are made in order to simplify the mathematical model.  
i. The crystallization process proceeds in a batch crystallizer without input or 
output. 
ii. Crystal agglomeration and breakage are negligible. 
iii. The crystals in the crystallizer are well suspended without accumulation of 
crystals. 
iv. Crystal nuclei have negligible size. 








tLn                                                                       (7.1)                    
where n is the population density of crystals and G is the crystal growth rate . 
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BtLn                                                                                 (7.2) 
where Bo is the rate of formation of new crystals (nucleation rate) at size of  L0=0. 
 
7.2.2 Crystallization kinetics 
From the population balance equation, it is known that crystal nucleation and 
growth kinetics appear as the boundary condition. As mentioned in Chapter 6, empirical 





bb MtLGtRTGktB ),()](/exp[)( −=                                                     (7.3) 
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gg tctRTGktLG )()](/exp[),( ∆−=                                                         (7.4) 
 
where MT is the crystal suspension density and  the supersateration ∆c is the difference of 
the real concentration c(t) and the solubility c* at temperature T(t) 
 
))((*)()( tTctctc −=∆                                                           (7.5) 
 
7.2.3 Mass balance equation 
Since the crystal growth and nucleation rate are dependent on solute concentration 
and temperature, mass and energy balances are required to complete the description of 
crystallization process.  
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For a batch crystallizer, the mass balance can be made based on the solute. 
 
00)()()()( VctVtMtVtc T =+                                                   (7.6) 
where c is the solute concentration and V is the volume of slurry.  
Under the assumption that the slurry volume remains constant during 





tdc T )()( −=                                               (7.7) 
 
If m3 is defined as the 3rd moment of crystal size distribution, 
 
dLnLm 3
03 ∫∞=                                                   (7.8) 
then the crystal suspension density MT can be replaced as  
 
3mkM VT ρ=                                                         (7.9) 
where ρ is the crystal density and kV is its shape factor. 








)()( 3ρ−=                                         (7.10) 
The necessary initial conditions are  
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0)0( cc =                                                          (7.11) 
03 )0( mm =                                                        (7.12) 
 
7.2.4 Energy balance 
If the shaft work is assumed negligible, the rate of change of the enthalpy of the 









)()( 3∆−+−=                                                                 (7.13) 
The first term on the right-hand side is the rate of cooling, while the second term is 
the enthalpy rate change due to the heat of crystallization. The second term is often 
negligible compared to the rate of cooling. 
All the equations given above form a set of nonlinear integro-differential equations 
for a batch crystallizer. Analytical solutions do not exist. Numerical methods are required 
to solve the problems.  
 
7.3 Model solution  
7.3.1 Moment method 
The moment transformation approach is the most common method used to replace 
the partial differential equations by a set of ordinary differential equations, which 
simplifies the simulation and optimization of the batch crystallizer.  Multiplying Equation 
7.1 by Lj, integrating over L, and placing on a per-mass-of-solvent basis (Hulburt and 





dm =0                                                                      (7.14) 







01 += −                                                (7.15) 
If the crystal growth rate is dependent on crystal size and the expression proposed 
by Randolph and Larson (1988) is used as 
)1(0 LGG α+=                                                   (7.16) 







01 )( ++= − α                                            (7.17) 
Various numerical methods have been proposed to solve specific models on a 
case-by-case basis. Rawlings et al. (1993) had a good review on this aspect. It was also 
indicated that the recovery of the crystal size distribution (CSD) from the quantities 
resulting from this transformation was difficult and accordingly the use of second moment 
of the distribution for mass and energy balances were suggested. 
In a special case for moment transformations, Mayrhofer and Nylt (1988) 
presented a good analysis of the programmed cooling batch crystallizers, starting with the 
solution of the momentum equations of the population balance. 
In a batch crystallizer, it is assumed (i) crystal growth rate G is constant and (ii) 
crystal nucleation rate B is constant. The assumption (i) is useful for mathematical 
simplification, which results in a moderate supsersaturation rise with the temperature 
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falling. Crystal growth rate generally diminishes with falling temperature but this drop 
could be compensated by the supersaturation rise. A similar consideration also holds for 
nucleation rate.  





dNc =                                                                    (7.18) 














c =                                                    (7.21) 
where Nc is the crystal numbers, Ac is the surface area of the crystals, and β is the surface 
factor.  
The momentum equations 7.18 –7.21 can be solved and combined with mass 
balance equation to get the temperature profile at constant supersaturation for the time 0 ≤ 
t ≤ tc, where N0 is the initial seed numbers and the solubility is linearly dependent on 
temperature. 
 
)]/1(1[)/()/()( 300 ccf ttKttTTTT −−=−−                                  (7.22) 
1
0 )]/(41[
−+= cBtNK                                                        (7.23) 
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If the nucleation is negligible compared to seeding, which means K→0, then the 




00 )/()/()( cf ttTTTT =−−                                                             (7.24) 
On the other hand, if nucleation is prevailing (no seeding) in the process, which 
means K→1, the following equation is readily obtained. 
 
4
00 )/()/()( cf ttTTTT =−−                                                           (7.25) 
This relationship has been discussed earlier (Nyvlt, et al., 1973; Nyvlt, 1983).This 
model determines the optimum cooling curve for a batch crystallizer with an arbitrary 
seeding and nucleation ratio. Indeed, as shown in Figure 7.1, for different K values, there 
is no significant difference in the cooling trend. Choong and Smith (2004) showed that the 
optional cooling profiles were normally convex curves in batch crystallizers. 
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Figure 7.1 Typical convex cooling curves from Equation 7.22 
 
7.3.2 Orthogonal collocation method  
The orthogonal collocation method is very efficient for solving differential 
equations (Villadsen and Michelsen,1978). Miller (1993) discussed the application of 
orthogonal collocation with Lagrange polynomials in solving population balance 
equations. Hu et al. (2004) used the orthogonal collocation method to discrete the 
population density along the size for batch crystallization and successfully applied it in 
nonlinear kinetic parameter estimation from batch cooling seeded crystallization.  
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Figure 7.2   Population density discretization 
 
As shown in Fig 7.2, the batch time period is divided into k time steps, each with 
length of ∆t. At the time t=j ∆t, m+1 points are chosen to calculate the population density 
for the time t= (j+1)∆t, with the size Lj,0, Lj,1, …, Lj,m and  population densities nj,0, nj,1, …, 
nj,m. The first index (j=0,1,…,k) denotes the time interval number and the second index 
indicates the series number of points of the crystal size distribution.  
In the case that crystal breakage and agglomeration are neglected, for seeded 






















~                                                  (7.26) 
It was thus proved that the solution of the above finite-difference analog converges 







Lj,0     Lj,1          Lj,i           Lj,m                   L 
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Crystal size L can be expressed as 
 
ijijij LtjLGL ,,,1 ),( +∆≈+                                                    (7.27) 
Since the seed size distribution is known, n0,i and L0,i are available. Therefore, nj+1,i 
and  Lj+1,i for j=0,1,…,k-1 and i=0,1,…,m-1, can be solved iteratively by the above 
equations 7.26 and 7.27. 
For the newly formed crystals, it is assumed that the secondary nuclei have the 























                                            (7.28) 
for j=0,1,…,k-1 and i=0,1,…,j+1, with the boundary conditions of Equation 7.2 and Lj,0=0.  
 
7.4 Optimal operation profile of 4-hydroxy-2-pyrrolidone preferential crystallization 
in isopropanol 
As highlighted in the introduction, it is paramount to control supersaturation within 
a critical value in preferential crystallization process to avoid spontaneous nucleation of 
both enantiomers, to inhibit possible secondary initiated nucleation of undesired isomer 
when the supersaturation surpasses a critical range, and to obtain good crystal size 
distribution. Several works have mentioned supersaturation effects in preferential 
crystallization process (Hongo et al., 1981; Ndzié et al., 1997; Collins et al., 1997; Beilles 
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et al., 2001; Courvoisier et al., 2003), but no effort has been reported to control the critical 
supersaturation in preferential crystallization. 
 
7.4.1 Methodology 
As discussed in Section 7.3, the orthogonal collocation method is very efficient for 
solving differential equations. It was developed and used here to predict the cooling 
profile to control the supersaturation in preferential crystallization of 4-hydroxy-2-
pyrrolidone in isopropanol. 
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Crystal size L can be expressed as 
 
ijijij LtjLGL ,,,1 ),( +∆≈+                                               (7.31) 
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Crystallization kinetics 
 
47.09.16104.3 TMGB ×××=                                                     (7.33) 
35.15 )/15000exp(104.4 cRTG ∆×−××=                                (7.34) 
))((*)()( tTctctc −=∆                                                        (7.35) 
It was known that the recovery of the crystal size distribution (CSD) from the 
quantities resulting from this transformation was difficult (Rawlings et al., 1993). 
Therefore, here the second moment of the distribution was used for mass balances, where 






Vρ−=                                                                (7.36) 
Solubility equation was obtained in Chapter 5, 
 
26 )273(108)273(000139.0007227.0)(* −×+−+= − TTTc                       (7.37) 
The above equations are combined together to obtain temperature profile for a 
given supersaturation ∆c. 
 
7.4.2 Thermodynamics considerations  
A saturated solution of 20%ee R-enantiomer was used as the starting point to 
illustrate how to apply the above equations to control the supersaturation during the 
preferential crystallization by using the thermodynamics data and crystallization kinetics. 
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From the solubility data (Chapter 5, Figure 5.3), the starting temperature T0 is circa 35 oC. 
After seeding with R-enantiomer crystals, the solution can be cooled down until circa 18 
oC where the solution tends to be racemic RS (0% ee). In this region, only R-enantiomer is 
supersaturated. Based on the MSZW data (Chapter 5, Figures 5.5-5.11), the 
supersaturation should be kept within circa 7 oC to avoid spontaneous nucleation. Figure 
5.7 indicates that the applicable supersaturation for S-enantiomer is 7-18 oC. Therefore it 
is acceptable to set the final targeted temperature at circa 5 oC.  
It should be noted that MSZW were measured under homogenous condition and 
they should be narrower in the real world as large amount of crystals existed in the seeded 
preferential crystallization. More importantly, as discussed before, at relatively high 
supercooling, but still lower than the critical value for spontaneous nucleation 
supercooling, many nuclei with opposite chirality to that of seed could form. Hongo et al. 
(1981) also pointed out that the supersaturated solution was unstable in a relatively higher 
second metastable region.  Therefore, the supersaturation should be kept even low. 
 
 7.4.3 Optimal cooling profile  
As all the above factors are taken into considerations, a critical range of 2-3 oC (the 
corresponding ∆c= 0.001-0.0015 kg/kg solvent) was first chosen as the control objective. 
The time interval used is 12 s. The simulation process showed that the orthogonal 
collocation method combined with the second moment approach is good enough for this 
batch cooling crystallization process. 
Fig 7.3 shows the calculated temperature profile with respect to time when ∆c= 
0.0015 kg/kg solvent was used. It is a typical cooling curve for batch crystallizer and is 
comparable to the cooling profiles in other systems (Rohani and Bourne, 1990; Matthews 
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and Rawlings, 1998). The initial temperature decreases very slowly to prohibit unwanted 
nucleation while the temperature decreasing trend accelerates with time.  











 Figure 7.3  The simulated optimal cooling profile for  ∆c= 0.0015 kg/kg solvent 
 
The calculated crystal population density distribution is shown in Figure 7.4. As 
mentioned in Chapter 6, the crystal growth rate for this system is size independent. 
Therefore, the seed distribution does not change the shape and it simply moves forward 
along the crystal size. The newly formed crystals from nucleation are also clearly shown 
in Figure 7.4. Accordingly, the simulated crystal size distribution at the final time is 
presented in Figure 7.5, where it clearly indicates the final product is composed of seeded 
crystals and newly formed crystals. The simulated results are comparable to other system 
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with similar method (Hu et al., 2005). The variations of solute concentration and crystal 
suspension density are reflected in Figure 7.6 and Figure 7.7, respectively. 
 









seed crystals at initial time  seed crystals at final time 
 












































Figure 7.6 Concentration with time, ∆c= 0.0015 kg/kg solvent 
 

































 Figure 7.7  Crystal slurry suspension density with time 
 
For the supersaturation control in preferential crystallization of 4-hydroxy-2-
pyrrolidone, the simplified approach proposed by Mayrhofer and Nyvlt (1988) is also of 
particular interest. It determines the optimal cooling curve for a batch crystallizer with an 
arbitrary seeding and nucleation ratio. This is very meaningful and useful for preferential 
crystallization as seeding is always needed.   
According to the crystal growth kinetics (Equation 7.22), if ∆c=0.001 kg/kg 
solvent at 35 oC, G=0.11 µm/min, while G=0.10 µm/min at 5 oC with ∆c=0.0015 kg/kg 
solvent. This suggests that it is quite acceptable to assume constant G during the operation 
while the supersaturation is still well controlled within a safe region 2-3 oC.   The crystal 
nucleation rate expression (Equation 7.33) indicates a low dependency on the crystal 
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suspension density MT. A low MT was used in this work. Therefore, it is also reasonable to 
assume constant B in the process. The solubility dependency on temperature can be 
approximately assumed linear. In this case, the Equation 7.22 can be directly applied to 
control the supersaturation in the preferential crystallization of 4-hydroxy-2-pyrrolidone. 
As the mean size of seed is circa 140 µm, for a target product of 230 µm mean size, the 
operation time is tc = (230-140)/0.11=818 min=13.6 hour.  Figure 7.8 shows the obtained 
cooling profile. It is comparable to that obtained by orthogonal collocation method (Figure 
7.3).  
 
Figure 7.8 The calculated optimal cooling profile from Equation 7.22 
 
7.5 Preferential crystallization operation 




















The batch preferential crystallization experiments were carried out using the 
experimental set up shown in Figure 3.9 (Chapter 3). Two types of cooling profiles, 
namely optimal cooling and forced cooling (natural cooling), were used respectively. First, 
20%ee R-enantiomer saturated solutions were prepared at circa 36 oC.  After slightly 
supersaturated, that is to say, at 35 oC, pure R-enantiomer seeds were added into the 
solutions and cooled down from 35 oC to 5 oC according to the specified cooling profiles. 
The seeds were prepared by fast evaporating the solution of certain amount of pure R-
enantiomer in isopropanol.  Seed preparation and seeding program is another important 
factor in crystallization (Girolami and Rousseau, 1986; Beilles et al., 2001; Dufour et al. 
2001; Ndzié et al., 1997; Qian and Botsaris, 2004). A typical seed CSD is shown in Figure 
7.9. 
 
Figure 7.9  A typical seed CSD  
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The optical purity of crystal products were measured using a Mettler Toledo DSC 
822e Module (heat flux DSC), together with the STARe software. Samples of 6-10 mg 
were prepared in standard 40 µl aluminum crucibles. The crucibles were sealed with a 
perforated cover. The optical purity was also verified using a JASCO P-1020 digital 
polarimeter, which was equipped with a sodium vapor lamp emitting light with a 
wavelength of λ = 589.3 nm and a quartz cell of 50 mm path length. The crystal size 
distribution was also measured using a Malvern Mastersizer 2000 with a Hydro 2000µP 
dispersion cell unit with n-hexane as the liquid dispersion medium.   
  The crystal morphology was investigated using a Jeol JSM-6700F Field Emission 
SEM. A small amount of samples were scattered on double-sided adhesive carbon taps 
mounted on SEM stubs, and were coated with Au/Pd in a Cressington 208 sputter coater. 
 
7.6 Results and discussion 
7.6.1 Operation and in-situ monitoring 
The temperature of the solutions inside the crystallizer was controlled by the 
LabMax system and the corresponding real temperature was recorded. It is shown in 
Figure 7.10. For comparison, a forced cooling profile was applied. The LabMax system 
can precisely track and control the proposed temperature profile very well. Indeed, the 
proposed temperature curves and the controlled curves are almost the same. The chord 
length distribution over the whole crystallization process was recorded using FBRM as 
shown in Figure 7.11. The number of fine counts in the range of 1 – 5 µm was used as the 




















Figure 7.11 FBRM data of the number of fine counts with two different temperature 
profiles (1µm <chord length<5µm):  1-optimal cooling, 2-Forced cooling 
 
7.6.2 Progression of preferential crystallization  
From the recorded forced cooling temperature profile in Figure 7.10, an obvious 
increasing peak was observed at the point (3890 s, 16.2 oC). This indicates that a sudden 
exothermic phenomenon - nucleation might occur in the solution at this point. This 
phenomenon was also confirmed in the corresponding FBRM measurement as shown in 
Figure 7.11. There was a steep increase of fine counts at the same moment. In contrast, for 
the optimal cooling temperature profile, there was no any evident change recorded.  The 
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subsequent effects of different cooling profiles were reflected in the following product 
properties.  
 
7.6.3 Optical purity of final products  
Prior to determining the optical purity of crystallization products by means of DSC, 
a calibration curve of melting temperature with enantiomeric excess (ee%) was 
constructed in Figure 7.12. The examination for each sample was conducted under three 
different heating rates - 2, 5, and 10 oC/min. The reproducible results indicate the melting 
temperature is independent of the heating rates within 2 – 10 oC/min. The DSC 
thermograms of final crystal products obtained from the experiments under optimal 
cooling and forced cooling profiles as well as the pure R-enantiomer were shown in 



















Figure 7.12 Calibration curve of melting temperature with enantiomeric excess 
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1-Pure R-4HP     
                 
2-Optimal cooling





Figure 7.13 DSC thermograms for final crystallization products and pure R- 
enantiomer 
 
The optical purity of the final crystal products were also verified by means of 
polarimetry methods. Similarly, a calibration curve of optical rotation with concentration 
for pure R-enantiomer was constructed in Figure 7.14. The relationship of concentration 
of pure R-enantiomer C with optical rotation α is expressed as Equation 7.38. 
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                        C = 6.91 α                                                                                            (7.38) 
The optical purities of the final crystal products from the crystallization 
experiments, which were analyzed using the above-mentioned methods, were listed in 
Table 7.1. 
































Figure 7.13 and Table 7.1 show that pure R-enantiomer crystal product was 
obtained from the controlled crystallization experiment. This indicates the optimal 
operation strategy was successful. The induced nucleation of S-enantiomer was effectively 
inhibited by controlling the supersaturation of R-enantiomer within the critical value. 
Based on the added R-enantiomer, circa 52% yield was obtained. This is comparable to 
the theoretical value 68% when the filtration lost and extra unconsumed supersaturation 
are considered.  
 On the contrary, only 78.5%ee crystal product was produced from the forced cooling 
crystallization experiment (Table 7.1), and two peaks were obviously observed in the DSC 
thermograms shown as Figure 7.13. The crystal nucleation and growth of S-enantiomer 
must occur in this operation. Indeed, both Figure 7.10 and Figure 7.11 show that a 
significant nucleation happened at 16.2 oC, which should contribute to the poor optical 
purity. But at this temperature, the S-enantiomer was still far away from its metastable 
zone. This indicates that the nucleation of S-enantiomer could be induced by R-
enantiomer nucleation. The R-enantiomer induced nucleation could be due to either or 












[(35-5) oC, 14 hrs] 
9.05 155 180 0.2602 100 
Forced cooling 
[(35-5) oC, 14 hrs] 
6.61 148 180 0.2047 78.5 
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both, (i) the spontaneous nucleation of both R and S enantiomers when the supersaturation 
of R-enantiomer surpassed its metastable zone; (ii) the supersaturation of R-enantiomer 
was still within its metastable zone, but surpassed a critical limit that its secondary 
nucleation would breed the nucleation of S-enantiomer (Qian and Botsaris, 1998). It was 
also argued that if high supersaturations within the metastable zone are used, some 
conglomerates will form crystals that contain domains of both lattices in a single crystal, 
which means that the enantiomerically pure seed could nucleate the other enantiomer at its 
surface (Black et al., 1989; Collins et al., 1997). 
  The present results support the findings in the metastable zone measurements 
(Chapter 5) where some extent of nucleation of S could initiate itself or could be induced 
by spontaneous nucleation of R when the supersaturation surpassed a critical level.  This is 
also consistent with the observations of, (i) very low supersaturation required for high 
optical purity (Furberg and Hassel, 1950; Black et al., 1989; Collins et al., 1997), (ii) a 
relatively lower second metastable region (Hongo et al., 1981), (iii) and the importance of 
controlled cooling program highlighted by Coquerel’s group (Ndzié et al., 1997; Beilles et 
al., 2001; Dufour et al. 2001; Courvoisier et al., 2003). 
 
7.6.4 Crystal size distribution   
The crystal size distribution (CSD, volume basis) and the population density of the 
prepared seeds as well as the product crystals obtained from the crystallization 
experiments under controlled cooling profile and forced cooling profile are shown in 
Figure 7.15. It should be noted that the measured CSD and population density do not 
match the simulated results (Figure 7.5) so well although the main shapes and the newly 
formed crystals are consistent with each other. This difficulty in recovering CSD and n 
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from moment transformations has been well discussed by Rawlings et al. (1993). Other 
factors such as crystallization kinetics could also contribute to the deviation. Figure 7.15 
shows that the optimal cooling profile produced larger particles with narrower distribution 
and much less fine crystals compared to forced cooling. The crystal weighted mean size of 
optimal operation is 247 µm (this is comparable to the targeted 230 µm) with 59% 
coefficient of variation (CV), while the forced cooling gave crystals with 193 µm 
weighted mean size and 78% coefficient of variation. Figure 7.16shows typical SEM 
images of final product crystals obtained from the experiments under optimal cooling and 
forced cooling profiles. It is apparent that the crystals from controlled cooling profile are 
of bigger size and smoother surface than those obtained from forced cooling profile.  A 
good crystal habit would be very helpful to the downstream filtration/washing operation to 























































Figure 7.15 Crystal size distribution of pure R-enantiomer seeds and crystal products 






























Figure 7.16 SEM images of final crystal products from different cooling profiles: 
(a) Controlled cooling, (b) Forced cooling 
 
The above in-situ monitoring observations, final product purity and crystal habit 




critical range to prevent the nucleation of S-enantiomer in preferential crystallization. The 
proposed optimal cooling profile was successful in 4-hydroxy-2-pyrrolidone resolution. 
 
7.6.5 Critical supersaturation range 
In Section 7.6.1-7.6.5, the used critical supersaturation was safely chosen as 2-3 oC 
(corresponding ∆c= 0.001-0.0015 kg/kg solvent) as various factors were considered. 
According to the metastable zone data, the applicable supersaturation is more than 7 oC. 
Therefore, it is interesting to investigate that if the operation supersaturation can be further 
increased. This is especially important when operation time is key factor in the industrial 
application. 
The mathematical model and the methodology developed in Section 7.4.1 were 
again employed here to predict the cooling profiles at different supersaturations. As the 
critical supersaturation can not be predicted with current theory development ((Mersmann 
and Bartosch, 1997; Kim and Mersmann, 2001), three supersaturations, namely ∆c= 
0.0018; 0.0020 and 0.0022 kg/kg solvent, were used to simulate the batch crystallization 
process.  The calculated temperature via time curves are shown in Figures 7.17-7.19 
respectively. The three cooling curves are pretty similar to that of ∆c= 0.0015 kg/kg 
solvent, but the operation periods are shorter with higher supersatuartion. The 
corresponding operation time is circa 630, 500 and 400 minutes, respectively. 
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Figure 7.17  Cooling profile, ∆c= 0018 kg/kg solvent 
 
 198





























Figure 7.19 Cooling profile, ∆c=0022 kg/kg 
 
The temperature of the solutions inside the crystallizer was well controlled 
according to the proposed curves (Figures 7.17-7.19) by the LabMax system.  The chord 
length distributions over the whole crystallization process were recorded using FBRM as 
shown in Figures 7.20-7.21 respectively.  A deep increase of fine counts (1-5 µm) was 
observed when ∆c=0022 kg/kg solvent was used, which implies that a sudden nucleation 
could happen at this time. There was no any evident change  in the fine counts (1-5 µm) 





Figure 7.20 FBRM record of the number of fine counts, ∆c=0018 kg/kg solvent 
 
 




Figure 7.22  FBRM record of the number of fine counts, ∆c=0022 kg/kg solvent 
 
The DSC thermograms of final crystal products obtained from the three 
experiments as well as the pure R-enantiomer and RS racemate are shown in Figure 7.23.  
The optical purity of the final crystal products were also verified by means of polarimetry. 
Table 7.2. lists the optical purities. When the supersaturation is ∆c= 0.0018 and 0.0020 
kg/kg solvent, the final crystals still show very pure optical purity. This again indicates 
that the induced nucleation of S-enantiomer was effectively inhibited by controlling the 
supersaturation of R-enantiomer within the current critical value (0.0020 kg/kg). This is 
also shown in the FBRM observations (Figures 7. 20 and 7.21). Therefore, under current 
experimental conditions, the optimal operation time could be further reduced to circa 8.5 
hours. From the economic viewpoint in industrial applications, cutting operation time 
means low investment cost and/or efficient usage of equipment and so on. 
However, when the supersaturation exceeds this critical point, i.e.  0.0022 kg/kg 
solvent, the product optical purity begins to decrease to circa 85%. As discussed 
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previously, this purity drop could again come from the induced S-enatiomer nucleation 
(Furberg and Hassel, 1950; Hongo et al., 1981; Black et al., 1989; Collins et al., 1997; 
Qian and Botsaris, 1998) when the supersaturation surpasses a certain level. Indeed, as 
shown in Figure 7.22, a sudden nucleation was observed from the in-situ chord length 
distribution using FBRM.  
 















In the aspect of crystal size distribution and crystal habits, it is interesting to find 
that there is no significant difference for the three operations at different supersaturations. 
Figure 7.24 presents the crystal distribution for the final crystal products. The SEM 
imagines are shown in Figure 7.25. All the crystal products show good crystal habits 
although more small crystals can be seen from the SEM imagines when ∆c= 0.0022 kg/kg 
was used, which could be due to the observed nucleation from FBRM observations 
(Figure 7.22).  As mentioned before, many efforts have been tried to optimize batch 
crystallization using various objectives, such as mean crystal size and coefficient of 
variation (Chianese et al., 1984; Choong and Smith, 2004; Costa and Maciel Filho, 2005), 
seed ratio (Bohlin and Rasmuson, 1992; Matthews and Rawlings, 1998; Chung et al., 
1999) and even shape (Ma et al., 2002). But for preferential crystallization process, current 
results show that the supersaturation is the most important factor to get high optical purity. 
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3.31 155 180 0.2601 100 
∆c=0.0022 kg/kg 
 




















Figure 7.25 SEM images of final crystal products from different cooling profiles. 
From top to bottom: ∆c=0.0018; kg/kg; ∆c=0.0020 kg/kg; ∆c=0.0022 kg/kg 
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7.7 Summary 
The critical supersaturation control in preferential crystallization was proposed. 
Mathematical model and solution were developed for batch cooling preferential 
crystallization process. The orthogonal collocation method and the second momentum 
were combined to solve the population balance and mass balance equations. The 
methodology was successfully used in establishing the cooling profiles for the preferential 
crystallization of 4-hydroxy-2-pyrrolidone in isopropanol. A series of batch operations of 
4-hydroxy-2-pyrrolidone were experimentally studied under various supersaturatiuons. 
In-situ monitoring showed that relatively high supersaturation of the target 
enantiomer induced spontaneous nucleation of the undesired enantiomer, which 
accordingly resulted in low optical purity and poor crystal size distribution. The proposed 
optimal temperature trajectory to control the critical supersaturation successfully inhibited 
the induced nucleation of the undesired enantiomer, and hence produced almost pure 
crystals with good habits. Further investigations presented the optional operating strategy 
without sacrifice of product optical purity. The critical supersaturation control used here is 
expected to be applicable widely for preferential resolution. The integration of 
thermodynamics, crystallization kinetics and population balance modeling was proved 
essential and helpful to establish this control strategy.  
 
 
Part of results in this chapter has been reported on Chemical Engineering Science (Vol 61, 
pp.2406-2417. 2006) 
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CHAPTER 8   APPLICATION OF DIRECT 





Direct crystallization plays an important role in the resolution of a racemic 
conglomerate (preferential crystallization) or purification of a partially resolved racemic 
compound (direct crystallization) whenever it is applicable. As illustrated in Chapter 7, 
direct crystallization is feasible for the resolution of a conglomerate, which has been also 
highlighted by many authors (Collet et al., 1980; Sheldon, 1993; Jacqueas et al., 1994; 
Beilles et al., 2001; Elsner et al., 2005). With the big progress made in the field of 
asymmetric synthesis and SMB chromatography etc, the partially resolved chiral samples 
are easily available. However, these samples are often highly diluted and the enantiomeric 
purity is insufficient. It would require much more extra efforts to acquire an optically pure 
product rather than a partially resolved sample using asymmetric synthesis or SMB alone. 
Instead, direct crystallization can be applied to further purify these partially resolved 
samples. In the aspects of low cost and advantages of solid product, direct crystallization 
also shows big advantages for the enrichment of chiral compounds (Lorenz, et al, 2001; 
Schroer et al, 2001). This Chapter will explore the application of direct crystallization to 
racemic compound coupling with chromatography.  
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As we learned from Chapter 5, the feasibility and yield of pure enantiomer 
obtainable by direct crystallization is determined by the shape of the phase diagrams 
(binary or ternary phase diagram) of the system and the initial enantiomeric composition 
of the feed to the crystallizer. For a racemic compound, three possible situations are 
illustrated in Figure 8.1. We can see that the knowledge of the phase equilibria is even 
more important for a racemic compound because the existence region of the pure 
enantiomers in the phase diagram, which is defined by the position of the ternary eutectic 
point, in most cases, is much smaller than a racemic conglomerate. A pure enantiomer can 
only be produced by direct crystallization when the initial solution composition is located 
inside the existence region of the pure enantiomers covered by AED or A’E’L. In the most 
favorable case, as shown in Figure 8.1 (c), the racemic compound exhibits an ideal phase 
diagram with the maximum operating region to obtain pure enantiomers by crystallization. 
In the case of a combined process of chromatography and crystallization, the previous 
chromatographic step must deliver a minimum enantiomeric enrichment which exceeds 
that of the eutectic point in the ternary phase diagram. Subsequently, the resulting highly 
diluted and undersaturated solution has to be evaporated to reach a composition in the 





Figure 8.1 Ternary phase diagrams for a racemic compound: (a) unfavorable; (b) more 
favorable; (c) most favorable 
(a) (b) (c) 
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Propranolol hydrochloride, as shown in Figure 8.2, is a synthetic beta-adrenergic 
receptor blocking agent widely used in the treatment of hypertension. Although it is 
administrated as the racemate form, only (S)-enantiomer has the desired beta-adrenergic 
blocking effect. In Chapter 4, it was identified as a racemic compound forming system. 
The ternary phase diagram of propranolol hydrochloride dissolved in the mixture of 
methanol and isopropanol (Figure 5.17) has the most favorable shape as shown in Figure 
8.1 (c) for obtaining the pure enantiomer by direct crystallization. The mixture having the 
eutectic composition is the racemate. The racemate can be readily separated by 
chromatography. Furthermore, the two pure enantiomers are commercially available at a 
reasonable price. Therefore, propranolol hydrochloride dissolved in the mixture of 
methanol and isopropanol was chosen as a suitable model system to explore the 














S-propranolol hydrochloride  
Figure 8.2 Chemical structure of (R)- and (S)-propranolol hydrochloride 
The resolution of propranolol hydrochloride via chromatography has been reported 
by Ching et al. (2000) and Gritti & Guiochon (2004). However, the mechanism of 
crystallization process for propranolol hydrochloride, which is a racemic compound, has 
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been rarely investigated. This Chapter presents such an effort to obtain a certain 
enantiomerically enriched propranolol hydrochloride starting from a racemic composition 
using a HPLC with a semi-preparative chiral column. A subsequent systematical study of 
direct crystallization process starting from the same enantiomeric composition with the 
partially resolved propranolol hydrochloride from the HPLC was conducted. The critical 
supersaturation control strategy and the scheme to obtain pure enantiomer via direct 
crystallization for the partially resolved racemic compound propranolol hydrochloride 
were investigated. The crystallization progression was illustrated in terms of the diagram 
of solubilities and metastable zone widths with different compositions.  
 
8.2 Experimental setup and procedure 
Semi-preparative HPLC separation of propranolol hydrochloride was performed 
using an Agilent 1100 series HPLC system with Chiralcel OD-H semi-preparative column 
(10mm ID x 250mm L). The mobile phase was 100% isopropanol. The flow rate was 1.0 
ml/min. Isopropanol was chosen as the main eluant for HPLC separation due to the 
solubility of propranolol hydrochloride in pure alcohols such as 100% isopropanol or 
methanol are much higher than hexane/isopropanol solvent mixtures. 
The batch direct crystallization experiments with and without seeding were carried 
out using the experimental set-up shown in Figure 3.9.  The 36.7%ee (consistent with the 
above HPLC partial separation composition) R-enantiomer saturated solutions were 
prepared at 35 oC. For seeding experiments, after slightly supersaturated, that is to say, at 
34 oC, pure R-enantiomer seeds were added into the solutions and cooled down from 35 
oC to 23 oC, 20.5 oC, and 17 oC, respectively. The seeds were prepared by fast cooling the 
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solution of certain amount of pure R-enantiomer in isopropanol.  Typical load of 
crystallizer was a solute mixture of 3.602 g of (RS)-propranolol hydrochloride and 2.091 g 
(R)-propranolol hydrochloride dissolved in 471 ml of solvent mixture of methanol and 
isopropanol (V:V = 1:5).  
The optical purity was measured using an Agilent 1100 series HPLC system with 
Chiralcel OD-H analytical column. The mobile phase was a mixture of 
hexane/isopropanol (v/v = 80/20). The flow rate was 1.0 ml/min. The detection 
wavelength was 254 nm.  
The optical purity of crystal products were also verified using a Mettler Toledo 
DSC 822e Module (heat flux DSC), together with the STARe software. Samples of 2-4 mg 
were prepared in standard 40 µl aluminum crucibles. The crucibles were sealed with a 
perforated cover. Preceding investigation of samples, a calibration curve of standard 
samples with different enantiomerical excess was recorded. The examination for each 
sample was conducted under three different heating rates - 2, 5, and 10 oC/min. The 
reproducible results indicate the melting temperature is independent of the heating rates 
within 2 – 10 oC/min.  
The crystal size distribution was measured using a Malvern Mastersizer 2000 with 
a Hydro 2000µP dispersion cell unit. Analytical hexane, in which propranolol 
hydrochloride is almost insoluble, was used as the liquid dispersion medium. The crystal 
morphology was investigated using a Jeol JSM-6700F Field Emission SEM. A small 
amount of samples were scattered on double-sided adhesive carbon tabs mounted on SEM 
stubs, and were coated with Au/Pd in a Cressington 208 sputter coater. 
8.3 Results and discussion 
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8.3.1 Semi-preparative HPLC separation of propranolol hydrochloride using 
Chiralcel OD-H column 
The loading capacity of propranolol hydrochloride on Chiralcel OD-H column 
(10mm ID x 250mm L) was determined by injecting different amount of sample onto the 
column. Propranolol hydrochloride shows almost baseline separation on Chiralcel OD-H 
at 8.95mg loading. As sample loading increased to up to 14.56mg, partial separation of 
propranolol hydrochloride was obtained as shown in Figure 8.3. Through semi-preparative 
chiral HPLC separation (14.56mg per analysis), we had isolated the R and S enantiomer 
from its racemate, by collecting at two different fractions at retention time, t =15-25 mins 
(fraction a) and at t =25-30 mins (fraction b) as shown in Figure 8.4. The enantiopurities 
of these two fractions were analysed on analytical column (Chiralcel OD-H, 4.6mm ID x 
250mm L) using hexane/isopropanol (80/20 v/v) as the mobile phase and flow rate of 
1.0ml/min (shown in Figure 8.5). From the obtained chromatographic data, fraction (a) 
consisted of R enantiomer with 36.7 % ee and fraction (b) consisted of S enantiomer with 
100% ee. Upon continuous HPLC separation using an autosampler and automated fraction 
collector, these two fractions could be accumulated until a certain volume (e.g. 1000ml) 




Figure 8.3 Partial separation of propranolol on Chiralcel OD-H semi-preparative HPLC 
column (dimension 250mm L x 10mm I.D) at different loadings (8.95mg and 14.56mg per 
injection) using 100% IPA as mobile phase, at 25oC column temperature, flow rate of 





Figure 8.4 Fraction collection under semi-preparative HPLC separation of propranolol on 
Chiralcel OD-H column (dimension 250mm L x 10.00 mm I.D.) under separation 
conditions: IPA (100%) at 25oC column temperature, flow rate of 1.0ml/min and UV-Vis 
detection at 254nm. Fraction (a) collected at retention time 15-25 minutes and fraction (b) 





Figure 8.5 Chromatogram of two fractions (a) and (b) obtained through semi-preparative 
HPLC separation of propranolol on Chiralcel OD-H analytical column (dimension 250mm 
L x 4.6 mm I.D.) under separation conditions: Hexane/IPA (80/20 v/v) at 25oC column 










8.3.2 Solubility and metastable zone width 
     As described in Chapter 5, the selection of a suitable solvent for an effective 
crystallization operation is crucial. A mixture of two or more solvents is sometimes found 
to possess the best properties for a particular crystallization purpose. It was found that the 
solubility of propranolol hydrochloride in methanol or water was too high. Thus the 
mixture of solvents was considered. The solubility of propranolol hydrochloride with 
different composition in the mixture of methanol and acetone was measured in my 
previous study (Wang et al, 2002). However, it was found that propranolol hydrochloride 
was easily decomposed in the presence of acetone at ambient temperature. In this study, 
the mixture of methanol and isopropanol was employed.  
    The solubilities and metastable zone widths of propranolol hydrochloride in the 
mixture of methanol and isopropanol were determined in Chapter 5. From the ternary 
phase diagram Figure 5.18, it can be seen that the eutectic composition is the one of the 
racemate, which is the most favorable situation for a racemic compound. The solubility of 
propranolol hydrochloride with different composition in the mixture of methanol and 
isopropanol (V:V =1:5) properly increases with temperature over the range of 12 – 35 oC. 
This suggests that the cooling crystallization for the chosen system is more favorable as 
temperature decreases. As illustrated by Wood (Collins et al., 1997), the difference of the 
saturation temperatures of (RS)- and (R)-propranolol hydrochloride at their respective 
concentrations is suitable for the cooling crystallization process.                
     The solubilities and supersolubilities of (R)- and (RS)-propranolol hydrochloride 
at cooling rate of 5 oC/h are shown in Figures 8.6. It was found that the MSZWs did not 
change obviously with the cooling rate at the range of 1 - 10 oC/h. These results show that 
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the characteristic of solubility and the widths of metastable zone over the experimental 
temperature range are favorable for direct crystallization process.   
 
 
Figure 8.6 Solubility and supersolubility of (R)- and (RS)-propranolol hydrochloride 
 
8.3.3 Progression of direct crystallization 
Four batches of direct crystallization of propranolol hydrochloride in mixture of 
methanol and isopropanol were carried out starting from the same solution containing 
36.7% ee (R)-enantiomer with four different modes, which are (a) Exp01: with seeding 

































-20 -10 0 10 20 30 40 
Temperature [oC]
 218
(c) Exp03: with seeding and final temperature at 18 oC; (d) Exp04: without seeding until 
nucleation occurred. 
As described in Figure 8.7, a saturated solution at 35 oC containing 36.7% ee (R)-
enantiomer is represented by point A. From the diagram of solubility and metastable zone 
widths of (R)- and (RS)-propranolol hydrochloride in Figure 8.6, the solution was 
saturated in the (R)-enantiomer at 30 oC represented by point B, and in the (RS)-
propranolol hydrochloride at 18 oC represented by point C. The solution was then seeded 
with (R)-enantiomer crystals and cooled to 23 oC, 20.5 oC and 18 oC, respectively.  It was 
found that at temperature greater than 18 oC, the product crystals were in the form of pure 
(R)-enantiomer, but at temperature lower than 18 oC, the product crystals were in the form 
of mixture of (R)- and (RS)-propranolol hydrochloride. This might imply that there is no 
selectivity of crystal growth of the pure enantiomer and racemate for a racemic compound 
when both (R) and (RS) reach supersaturation. It suggests that only the excess enantiomer 
can be crystallized out and no further resolution is attainable for a racemic compound. 
This is unlike preferential crystallization of a conglomerate, where the crystallization rates 
of two opposite enantiomers can be controlled to some extent and certain resolution can 
be achieved by carefully designed and controlled entrainment procedure. However, as 
mentioned before, as partially resolved solutions are readily obtained by other purification 
processes, when it is well designed and controlled, direct crystallization is a good way to 
get pure enantiomer. 
When the solution was cooled to 17 oC without seeding, the primary nucleation 
occurred after it exceeded the metastable zone of propranolol hydrochloride with initial 
composition of 36.7% ee, and the mixture crystals of (R)- and (RS)-propranolol 
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hydrochloride were always obtained. This again might be due to the crucial characteristic 
of a racemic compound – no selectivity of nucleation between the pure enantiomer and 
racemate for a racemic compound. The corresponding consequences of different cooling 
extent were reflected in the following product properties.  
 
                          Figure 8.7. Progression of direct crystallization 
8.3.4 Optical purity of final products 
The optical purity of the final crystal products were analyzed by means of HPLC 
method which was mentioned in Section 8.2. The chromatograms of the final crystal 
products are shown in Figures 8.8- 8.11. 
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Figure 8.8 Chromatogram of final crystal product obtained from exp01 on Chiralcel OD-
H analytical column (dimension 250mm L x 4.6 mm I.D.) under separation conditions: 
Hexane/IPA (80/20 v/v) at 25oC column temperature, flow rate of 1.0ml/min and UV-Vis 





Figure 8.9 Chromatogram of final crystal product obtained from exp02 on Chiralcel OD-
H analytical column (dimension 250mm L x 4.6 mm I.D.) under separation conditions: 
Hexane/IPA (80/20 v/v) at 25 oC column temperature, flow rate of 1.0ml/min and UV-Vis 








Figure 8.10 Chromatogram of final crystal product obtained from exp03 on Chiralcel OD-
H analytical column (dimension 250mm L x 4.6 mm I.D.) under separation conditions: 
Hexane/IPA (80/20 v/v) at 25oC column temperature, flow rate of 1.0ml/min and UV-Vis 
detection at 254nm.  
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Figure 8.11 Chromatogram of final crystal product obtained from exp04 on Chiralcel OD-
H analytical column (dimension 250mm L x 4.6 mm I.D.) under separation conditions: 
Hexane/IPA (80/20 v/v) at 25oC column temperature, flow rate of 1.0ml/min and UV-Vis 
detection at 254nm 
 
The optical purity of the final crystal products was also verified by means of DSC 
measurement. Prior to determining the optical purity of crystallization products by means 
of DSC, a calibration curve of melting temperature with enantiomeric excess (ee%) was 
constructed in Figure 8.12. The DSC thermograms of final crystal products obtained from 
the experiments at different temperature as well as the pure (R)- and (RS)-propranolol 
hydrochloride are shown in Figure 8.13.  
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Figure 8.12 Calibration curve of melting temperature with enantiomeric excess 
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Figure 8.13 DSC thermograms for final crystallization products and pure R- and RS-
propranolol hydrochloride 
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The optical purities of the final crystal products from the crystallization 
experiments, which were analyzed using the above-mentioned methods, are listed in Table 
8.1. 
                              Table 8.1. Final crystal products properties   
 
Figure 8.13 and Table 8.1 show that pure (R)-enantiomer crystal product was 
obtained from the seeding cooling crystallization experiments within certain safe limit. 
The crystallization of (RS)-propranolol was effectively inhibited by controlling the 
supersaturation of (R)- and (RS)-propranolol hydrochloride within the critical value.  
On the contrary, no optically pure crystal product was obtained from the non-
seeding crystallization experiment, and two peaks were obviously observed in the DSC 
thermograms shown as Figure 8.13. The crystal nucleation and growth of both pure 
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enantiomer and racemate must occur in this operation. That indicates primary nucleation 
of pure-enantiomer could induce nucleation of racemate (RS)-propranolol hydrochloride.  
 
8.3.5 Crystal morphology and size distribution   
The measurement of crystal size distribution (CSD) was described in Chapter 3. 
The CSDs of the product crystals obtained from the different cooling degree experiments 
are shown in Figure 8.14. The volume fraction of crystals was plotted versus their size 
(equivalent sphere diameter) in a semi-logarithmic diagram. From the distribution of 
exp_01, exp_02 and exp_03, it is observed, for the seeding crystallization experiments, 
the distribution of the product crystals was shifted to bigger size with the lower cooling 
degree. This indicates that crystal growth attained during the seeding cooling 
crystallization. For the non-seeding crystallization experiment exp_04, primary nucleation 
occurred, hence, the crystal size is obviously smaller. The properties of crystal shape and 
size were also reflected in the SEM images, shown in Figure 8.15.   
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Figure 8.15 SEM images of crystals produced from different conditions: (a) exp_01_with 







This Chapter performed an exploratory investigation to extend the application of 
direct crystallization to racemic compound coupling with chromatography. The partially 
resolved propranolol hydrochloride with 36.7% ee was obtained from HPLC with semi-
preparative column. Subsequently, the direct crystallization of propranolol hydrochloride 
with initial composition 36.7% ee was systematically studied in an automated reactor 
system. Based on the solubilities and MSZWs of (R)- and (RS)-propranolol 
hydrochloride, the direct crystallization progression was clearly illustrated under seeding 
and non-seeding processes. The optical purity of product crystals was accurately 
determined using HPLC and DSC methods. It was found that the direct crystallization was 
successfully applied to the enrichment of its partially resolved sample and optically pure 
crystal product could be obtained within certain safe supersaturation limit. There was no 
selectivity of crystal growth or nucleation between the pure enantiomer and its racemate 
when the solution reaches the temperature lower than the temperature of the 
supersaturated limit of the pure-enantiomer. The relative solubility and critical 
supersaturation control of the solution with respect to the pure enantiomer and racemate 








 The present work systematically studied the application of preferential 
crystallization in the optical resolution of chiral pharmaceutical intermediates from the 
system engineering perspective. In particular, the preferential crystallization of 4-hydroxy-
2-pyrrolidone in isopropanol, and the direct crystallization of propranolol hydrochloride in 
the mixture of methanol and isopropanol (Vol 1:5) were investigated from 
characterization, thermodynamics measurement and analysis, metastable zone width 
measurement and interpretation, crystal growth and nucleation kinetics estimation and 
process optimization and online monitoring. The results provided a systematic engineering 
approach to study preferential crystallization. Especially, the importance of critical 
supersaturation control and the integration of thermodynamics, crystallization kinetics and 
process modeling were proved essential to obtain pure enantiomer crystal products. 
In Chapter 4, three types of racemic crystals, namely racemic conglomerates, 
racemic compounds and pseudoracemates were identified with thermal analysis and 
structural characterizations. 4-hydroxy-2pyrrolidone and N-methylephedrine were 
classified as racemic conglomerate forming systems with a eutectic composition of a 
racemic mixture (R:S=50%:50%) using binary melting phase diagrams. Thermodynamic 
analysis showed positive values of the difference in the enthalpies of fusion (1600 and 
5100 J mol-1) of pure-enantiomer and racemic mixture and a typical values (close to ideal 
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Rln2) of entropies of mixing of the enantiomers in the liquid states. On the other hand, 
although propranolol hydrochloride showed similar characteristic of melting point phase 
diagram to that of a conglomerate forming system, the obviously negative value of the 
difference in the enthalpies of fusion of (S)- and (RS)-propranolol hydrochloride indicates 
it is a racemic compound favoring system. The close match of the FTIR, Raman spectra 
and the PXRD patterns of pure-enantiomer and of its corresponding racemic mixture for 
4-hydroxy-2-pyrrolidone and N-methylephedrine and the significant difference of the FT-
IR, Raman spectra, PXRD patterns and NMR spectra for propranolol hydrochloride 
confirmed the above claims. Thermal analysis indicates that atenolol is an ideal 
pseudoracemate forming system. 
In Chapter 5, the thermodynamic properties in solution were investigated using 
Lasentec FBRM and PVM for the above-mentioned four systems. Suitable solvents were 
firstly chosen and the solubilities, metastable zone widths and ternary phase diagrams at 
different enantiomer excess (ee) were subsequently measured.  In the aspect of solubility, 
4-hydroxy-2-pyrrolidone in isoprapanol and N-methylephedrine in the mixture of 
isopropanol and water (Vol 1:3) showed similar characteristics of higher solubility with 
lower ee. The racemic compound propranolol hydrochloride in the mixture of methanol 
and isopropanol (Vol = 1:5) also showed the similar solubility characteristics. However, 
their MSZW properties were found quite different. The metastable zone widths of both 
studied conglomerates 4-hydroxy-2-pyrrolidone and N-methylephedrine were independent 
of enantiomer excess, which is consistent with the characteristic of two enantiomers 
forming separate crystals in solution. On the other hand, for the racemic compound 
propranolol hydrochloride, the metastable zone widths of racemate and pure enatiomer 
were different. The properties of the evenly distributed molecules in the crystal lattice of a 
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racemic compound were contributed to this difference with nucleation theory. Three 
MSZW possibilities were raised for different solubility ratio of racemate to pure 
enantiomer for a racemic compound, where a cut value of 2 was highlighted.  
Furthermore, for the conglomerate 4-hydroxy-2-pyrrolidone, different orders of primary 
nucleation rate at different enantiomeric excess were found, which indicate there may be a 
critical supersaturation beyond which the nucleation of opposite isomer could occur. This 
appears to be the first detailed experimental investigation of metastable zone widths of 
different types of racemates in solution.  
In Chapter 6, the dynamic method was used to measure the crystal nucleation and 
growth kinetics of (R)-4-hydroxy-2-pyrrolidone and (S)-4-hydroxy-2-pyrrolidone in 
isopropanol. S-plane analysis was developed and applied to the crystallization kinetics 
parameters estimation and a more suitable transform s was found for the studied system. 
The regressed crystal nucleation and growth kinetics for both (R)- and (S)-enatiomers 
from each four batch measurements were pretty similar. No size dependent crystal growth 
was found and the crystal nucleation rate could be thought as temperature independent 
under the studied experimental conditions. 
In Chapter 7, the concept of critical supersaturation control was proposed for 
preferential crystallization. With combination of the thermodynamics properties and 
crystallization kinetics, a detailed mathematical modelling for batch crystallization was 
established and the orthogonal collocation method was employed to solve the population 
balance equation to predict the cooling profiles for the preferential crystallization of 4-
hydroxy-2-pyrrolidone in isopropanol. A simplified population balance model was found 
to be suitable for control the critical supersaturation for this system. A series of forced 
cooling and optimal operations of 4-hydroxy-2-pyrrolidone were experimentally studied 
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in the automated LabMax with online monitoring with FBRM and PVM. The in-situ 
monitoring shows that relatively high supersaturation of the target enantiomer induced 
spontaneous nucleation of the undesired enantiomer, which accordingly resulted in low 
optical purity and poor crystal size distribution. The proposed optimal temperature 
trajectory to control the critical supersaturation successfully inhibited the induced 
nucleation of the undesired enantiomer, and hence produced almost pure crystals with 
good habits. Further investigations under various supersaturations indicate that there could 
be an optimal supersaturation which would not lose optical purity. The importance and 
efficiency of critical supersaturation control was theoretically and experimentally proven. 
The integration of thermodynamics, crystallization kinetics and population balance 
modelling was proved essential and helpful to establish this control strategy.  
In Chapter 8, an exploratory investigation was carried out to extend the 
supersaturation control to the direct crystallization of racemic compound propranolol 
hydrochloride coupling with chromatography. The direct crystallization started with an 
initial composition of 36.7% ee which can be obtained from semi-preparative HPLC. The 
progression of direct crystallization with and without seeding was illustrated on the 
solubility and MSZW diagram. Optically pure crystal product could be obtained within 
certain carefully controlled supersaturation limit using partially chromatography resolved 
sample. No selective crystal nucleation and growth was found with respect to the pure 
enantiomer and its racemate when the solution passed the pure-enantiomer supersaturation 
limit.  
 
9.2 Suggestions for Future Work  
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The current optimal crystallization time might be relatively longer for industrial 
application, although it may be still worth have such an optimal operation to obtain the 
value-added optically pure pharmaceuticals.  As crystallization time is determined by 
system thermodynamics and crystallization kinetics, for other systems, the crystallization 
time could be as short as 1-2 hours. It would be attractive for industrial application to find 
such kind of systems. Furthermore, for the process scale-up, there could be more factors to 
investigate to determine the value of critical supersaturation.  
The development of process analytical technology (PAT) is very fast recently. This 
technique could be implemented with the current model-based critical supersaturation 
control from laboratory to large scale on chiral crystallization process. 
Although the systematic characterization of different racemic species has been 
studied, substantial investigation on the melting mechanism of N-methylephedrine during 
DSC measurement is needed. 
Although some exploratory work has been done for the characteristic of MSZWs 
for three different types of racemic species, in order to further confirm the general 
relationship of MSZWs with different racemic species, more detailed experimental 
measurements for many other chiral systems are needed. 
To obtain the optimal operating strategy for preferential crystallization, further 
research can be focused on the seeding programs, e.g. different seed size, seeding 
temperature.  
Further studies on mechanism of crystal nucleation and growth of pure enantiomer, 
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